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In this thesis I studied the localization and trafficking in living cells of the 
Extracellular Regulated Kinase signaling by making visible ERK1 and ERK2 with 
a fluorescent tag. This approach allowed to identify different dynamical properties 
of the two kinases, posing the bases for the understanding of the functional 
differences between ERK1 and ERK2. 
 The nucleo-cytoplasmic trafficking of tagged ERK1/2 has been measured by 
means of FRAP experiments. Surprisingly, I found that ERK1 shuttles at a much 
slower rate than ERK2. Moreover, I demonstrated that this difference is caused 
by an unique domain of ERK1 located at its N-terminus, since the progressive 
deletion of these residues converts the shuttling features of ERK1 into those of 
ERK2. Conversely, the fusion of this ERK1 sequence at the N-terminus of ERK2 
slows down its shuttling to a similar value found for ERK1 and, when fused to 
small cargos such as a GFP monomer, it is capable of hampering their shuttling 
too. In addition, I identified some crucial aminoacids at ERK1 N-terminus, 
responsible in large part of this phenotype. Finally, I have demonstrated that the 
speed of nucleo-cytoplasmic shuttling critically affects the ERK capability of 
activating downstream effectors.  
In conclusion, I propose a novel biochemical model, in which the regulation of 
nucleo-cytoplasmic trafficking  might provide a sensitive mechanisms through 
which cells modulate their response to extracellular stimulus. This mechanism 
significantly contributes to the differential ability of ERK1 and 2 to generate an 
overall signaling output. 
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WORKING HYPOTHESIS  
 
This work focused on dissecting protein dynamics inside a molecular pathway of 
crucial importance: the Extracellular Regulated Kinase (ERK) signaling, which is 
activated by a wide plethora of stimuli and is involved in almost every cellular 
process.  
Understanding the basic control mechanisms of a biological system like a 
molecular signaling cascade will help to develop new therapies, drugs and 
sensitive diagnostics tools.  
This work is characterized by a multidisciplinary approach, indispensable to 
unveil differences between the two kinases ERK1 and 2 which share a high 
sequence homology and the majority of the regulatory partners. The proteins of 
interest have been made visible by fusing them with fluorescent proteins. The 
resulting chimerical proteins were expressed in mammalian cells and were tested 
by experiments of live imaging. Furthermore, the functional consequences of the 







• Characterizing the biochemical-functional properties of GFP-ERK fusion 
proteins in order to validate them as investigation tools in living cells. 
• Deciphering nuclear translocation dynamics of ERK2, investigating the 
interplay between the activation and deactivation systems. 
• Measuring the nucleo-cytoplasmic shuttling of ERK1 and 2, by FRAP 
experiments. 
• Evaluating the effects of ERK trafficking on the signaling to the nucleus. 
The regulation of nuclear access constitutes a fundamental check point to 
control downstream effects. 
• Studying the capability of ERK1 N-terminus of influencing the trafficking 
across the nuclear barrier and the functional outputs. 
• Identification of specific residues at ERK1 N-terminus, which are 
responsible of the slower phenotype of nuclear shuttling. 
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SIGNIFICANCE OF THE WORK 
 
In this thesis the following results have been obtained: 
The mechanisms at the basis of ERK regulation have been better elucidated 
focusing on the spatio-temporal patterns of ERK phosphorylation and trafficking 
in living cells. In particular, I have found that there is a continuous counterbalance 
between the activation drive (MEK mediated) and the deactivation reactions (by 
Phosphatases). This is true also in basal conditions, given that a small 
percentage of MEK activity is still present. This push-pull mechanism is highly  
modulated in strength and over time, and is responsible for the on/off switching of 
the pathway. 
Furthermore, it has been measured the nucleo-cytoplasmic shuttling of ERK1 and 
2, by FRAP experiments, finding out that ERK1 and 2 drastically differ in their 
capability of crossing the nuclear envelope. Computational, biochemical and 
functional evidences proved that this trafficking difference causes ERK1 and 2 to 
have different signaling capabilities to the nucleus. Indeed, I demonstrated that 
the rate of nucleo-cytoplasmic shuttling is a crucial regulator of the signaling to 
the nucleus, representing a novel possible target for the molecular control of this 
pathway. 
Finally, it has been demonstrated that the difference in nuclear shuttling between 
ERK1 and 2 is caused by a short domain located at the N-terminus of ERK1. This 
region is necessary and sufficient to cause the differences of permeation and 
functional properties between ERK1 and 2. By directed mutagenesis some 
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Signal transduction: the keystone of living matter 
Why and how studying a molecular pathway? 
In biology, signal transduction refers to any process by which a cell converts an 
extra-cellular signal in a series of intracellular events leading to adaptive 
responses of the cell to the changing environment. This involves ordered 
sequences of biochemical reactions, carried out by enzymes and linked through 
second messengers or protein-protein interactions. Such processes are usually 
rapid, lasting on the order of milliseconds, as in the case of ion fluxes, to minutes 
for the activation of proteins and lipid-mediated kinase cascades. The main 
feature of most pathways is the capability of generating a “signal cascade”: 
indeed the number of proteins and other molecules participating in these events 
increases as the process goes on from the initial stimulus, providing amplification 
and the possibility of integrating different signals on common effectors. Each 
protein is committed to act in a well defined range of activities and it behaves like 
a fine sensor of the surrounding environment. All these components form highly 
interactive networks responsible of the first level of complexity in a living 
organism. The stunning perfection of the molecular orchestration inside a 
pathway is not only fascinating per se, but hides essential clues necessary to 
understand how a biological system works. Furthermore, understanding basic 
control mechanisms will help to develop new therapies, drugs and sensitive 
diagnostics tools.  
In this thesis I focused on dissecting protein dynamics inside a molecular 
pathway of crucial importance: the Extracellular Regulated Kinase (ERK) 
signaling. ERK pathway is activated by a wide plethora of stimuli, including 
growth factors, cytokines, integrins and hormones. It is involved in almost every 
cellular process like cell cycle, motility, differentiation, apoptosis and synaptic 
plasticity. Indeed, the ERK pathway represents a hot spot of investigation 
because of its large impact on widespread and serious diseases: for example, it 
has been reported that ERK1/2 activity is massively upregulated in several 
human cancers (Hoshino et al., 1999).  
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The basic assembly of the ERK pathway is a three-component module conserved 
in all eukaryotes, from yeast to humans. This module includes three serially 
linked kinases (Raf/MEK/ERK) of which ERK is the last effector.  
In mammals there are at least two “isoforms” for each level: Raf1, B-Raf and A-
Raf for the upstream form, MEK1 and MEK2 for the intermediate and ERK1 and 
ERK2 at the lower level. In this work I will investigate the differences between 
these two last proteins, that, although sharing many known features, they still 
hold some secrets.  
ERK1 and ERK2 have been considered as redundant isoforms for a long time, 
since they share the same regulatory machinery and targets. In addition, the 
identification of their individual role is complicated by technical difficulties in 
separating the action of each kinase. Given that ERK1 and 2 are characterized 
by a high degree of sequence homology (90% in humans), their existence raises 
the question of why they have been both conserved to date.  
 
Studying cellular processes in living cells 
Although biological processes and structures are dynamic in nature, most 
investigations into their mechanisms have been carried out in ex-vivo specimens 
using, for example, immunocytochemistry and biochemical assays. This 
incongruity has been imposed in large part by a lack of tool to analyze signal 
transduction in living cells. Recent developments in in vivo microscopy 
techniques and the discovery of the green fluorescent protein (GFP) and its 
spectral variants (Chalfie et al., 1994) have allowed the non destructive 
investigation of a wide range of dynamic processes in living cells [reviewed in 
(Lippincott-Schwartz et al., 2001; Misteli and Spector, 1997)]. In this work I took 
advantage of these new tools: ERK1 and 2 were made visible by fusion with 
fluorescent proteins. Then, the resulting chimeras were expressed in living cells 
to follow the dynamics of their movements between different compartments and 
their localization after specific stimuli. These experiments offered a different 
perspective on ERK function compared to the classic biochemical approach, and, 
as I will show, allowed to evidence differences between the two kinases ERK1 
and 2 that were, upon now, unsuspected.  
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In the following of this introductory chapter two main sections will be developed:  
 
° in the first part I will discuss the biological background of the proteins 
investigated; I will review the state of art of ERK biology specifically 
focusing on the molecular aspects concerning ERK targets, the regulatory 
mechanisms of the pathway and the communication between nucleus and 
cytoplasm.  
 
° in the second part I will introduce the multidisciplinary approach that 
characterizes this work, indispensable to unveil differences between the 
two kinases. I will illustrate potentialities and advantages of the imaging 
techniques used in tight conjunction with more classical molecular and 
biochemical methods. This kind of approach has made possible to unveil 










INTRODUCTION: Part 1 
 
The ERK1/2 cascade 
This pathway is one of the primordial signaling systems; it exists in all eukaryotes 
and controls fundamental cellular processes such as proliferation, differentiation, 
survival and apoptosis. The ERK cascade was originally discovered as a critical 
regulator of cell division and differentiation and this is the reason why it was firstly 
named Mitogen-Activated Protein Kinase (MAPK) cascade. As further details of 
this molecular signaling were worked out, it became clear that the ERK cascade 
is in fact a prototype for a family of signaling cascades that shares the motif of 
three serially linked kinases, which regulate each other by sequential 
phosphorylation. Thus, a revised nomenclature uses the term MAPK to refer to 
the entire superfamily of signaling cascades, comprising also SAPK/JNK (Stress-
Activated Protein Kinase/c-Jun NH2-terminal kinase)  and p38, and it specifies 
the prototype MAPK as ERK (Extracellular-Regulated Kinase). SAP/JNK and p38 
are principally activated by cellular stresses including osmotic shock, 
inflammatory cytokines, lipopolysaccharides (LPS) and ultraviolet light. 
Conversely ERK1/2 are primarily recruited by mitogens (such as polypeptide 
growth factors as well as insulin) and neurotrophins, but also by cytokines and 
hormones through Tyrosine Kinase Receptors (TKRs). Here I will focus on the 
dynamic regulation of the ERK1/2 pathway, activated by growth factors. The 
basic arrangement in the ERK pathway includes membrane receptors (principally 
TKRs) and a G-protein (Ras) which sits upstream of a core module consisting of 
a MAPK Kinase Kinase (Raf), that phosphorylates and activates a MAPK Kinase 





Schematic representation of the major components involved in ERK pathway (activated 

































                                               
Figure 2 
Tyrosine Kinase Receptors and their ligands 
The binding of specific extracellular signals with the extracellular domains of Tyrosine 
Kinase Receptors (TKR) activate the intracellular Tyrosine Kinase Domain (TKD). Before 
or after ligand binding, the dimerization of TKRs occurs. To activate a TKR the ligand 
usually has to bind simultaneously to two adjacent receptor chains. PDGF is a dimer and 
crosslinks two receptors together; EGF is monomeric and FGFs, also monomers, form 
multimers by binding to heparan sulfate proteoglycans. Once activated, the TKD transfers 
a phosphate group (autophosphorylation) from ATP to selected tyrosine side chains, both 
on the receptor protein itself and on intracellular signaling proteins, that subsequently 
binds to the phosphorylated receptor. Phosphorylation of Tyr within the Kinase Domain 
(KD) increases the kinase activity of the enzyme. Phosphorylation of Tyr residues outside 
the KD creates high affinity docking sites for the binding of scaffold proteins (with SH2, 
PTB and SH3 domains). 
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Upstream of ERK 
Tyrosine Kinase Receptors (TKRs) 
Membrane spanning cell surface receptors of the TKR family are endowed with 
intrinsic tyrosine kinase activity, catalyzing the transfer of the -phosphate of ATP 
to the hydroxyl groups of tyrosines on target proteins. All TKRs frequently contain 
a glycosylated extracellular ligand binding domain, connected to the cytoplasmic 
domain, which has a conserved Protein Tyrosine Kinase (PTK) core and 
regulatory regions that are subjected to autophosphorylation and phosphorylation 
by other kinases (Schlessinger, 2000a). Nearly all TKRs are monomers at the cell 
membrane, with ligand binding or ectopic overexpression resulting in receptor 
dimerization and tyrosine autophosphorylation in trans (Fig. 2). As the first TKR to 
be discovered (Downward et al., 1984), the epidermal growth factor receptor 
(EGF R, also known as ErbB1 from the v-erb-B transforming protein of an avian 
retrovirus) has helped to establish many of the principles of TKR functions 
(Schlessinger, 2002). 
Activating mutations and transforming overexpression, mimicking receptor 
oligomerization of EGFR and its fellow family members, have been implicated in 
numerous cancers, including mammary carcinomas, squamous carcinomas and 
glioblastomas (Blume-Jensen and Hunter, 2001). 
 
Scaffold proteins  
The EGF receptor contains at least nine tyrosine residues in its cytoplasmic 
domain capable of being phosphorylated, and seven of these are 
autophosphorylation sites (Levkowitz et al., 1999). The autophosphorylation of 
Tyr sites on EGFR and other TKRs provides a mechanism for the recognition of 
specific scaffold proteins and it represents a platform for the assembly of 
signaling complexes. Phosphorylated sites of EGFR are recognized and bound 
by Src Homology 2 (SH2) (Pelicci et al., 1992) and Phospho-Tyrosine Binding 
(PTB) domains (Schlessinger, 2000b). Shc can assist the binding of an other 
protein, the Growth factor receptor bound protein 2, Grb2  (Rojas et al., 1996), a 
cytosolic adaptor, containing a central SH2 domain flanked by two Src Homology 
3 (SH3) domains, that allows it to associate constitutively with the proline-rich 
regions of the nucleotide exchange factor Son of Sevenless (Sos) (Li et al., 
1993). The recruitment of Grb2 from the cytoplasm to the plasma membrane 
brings Sos near the membrane-bound Ras. Through guanine exchange, Sos 
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enhances GDP release and GTP binding to Ras, converting this GTPase into its 
active conformation. 
 
In a general view, it can be considered that the mammalian ERK pathway 
contains a central fifth-tiered module, which is strongly conserved and includes:  
• the GTPase protein Ras (H-Ras, K-Ras and N-Ras) and other still 
unknown kinases; 
• Raf (Raf-1, Raf A and Raf B); 
• MEK1 and 2; 
• ERK1 and 2; 
• RSK, MSK and MNK. 
 
In the following, I will describe features and functions of each components, 
particularly focusing on the isoforms which are principally involved in ERK1 and 2 
signaling (Raf1 and Raf-B, MEK1 and MEK2). 
 
Ras 
Ras is a notable member of the large family of GTPases, proteins that bind and 
hydrolyze GTP. First discovered as transforming oncogenes of murine sarcoma 
viruses (v-ras), three highly related 21 kDa mammalian proteins, Harvey-Ras (H-
Ras), Kirsten-Ras (K-Ras) and Neuroblastoma-Ras (N-Ras) have been identified 
(Bos, 1989). Ras family members are anchored to the cytoplasmic side of the 
plasma membrane by carboxyl-terminal farnesylation (post-translational 
modification by the attachment of an isoprenoid to the C-terminal cysteine 
residue). This localization to the inner leaflet brings Ras into close proximity with 
Sos, stimulating the exchange of GDP bound to Ras with GTP from the cytosol 
(Fig. 3). This exchange conformationally activates Ras, allowing it to interact with 
a number of downstream effectors (Avruch et al., 1994). Within the ERK signaling 
cascade, active Ras functions as an adaptor that binds to the effectors Raf 
kinases with high affinity, causing their translocation to the cell membrane, where 























It has been well established that specific alterations in members of the ras gene 
family can convert them into active oncogenes. These malignant transformations 
lead to a subversion of cellular pathways that regulate the proliferation, 
differentiation and survival of cells, resulting in altered cell growth (oncogenic 
transformation). In Ras family these alterations are either point mutations 
occurring in either codons 12, 13 or 61 or, alternatively, a 5- to 50-fold 
amplification of the wild-type gene resulting in Ras overexpression. 
Activating mutations of these Ras isoforms, which impair GTPase activity and 
stabilize the GTP bound state, are found in nearly one-third of all human cancers, 
making these oncoproteins among the most potent transforming polypeptides 
known (Seger and Krebs, 1995).  
The transformant properties of mutated Ras isoforms have been recently used to 
show that ERK1 and 2 differently transduce Ras-dependent cell signaling and 
proliferation (Vantaggiato et al., 2006). Ectopic expression of ERK1 but not of 






Ras functions as a switch, cycling in two 
distinctive conformational states: Active, when 
GTP is bound and Inactive when GDP is bound.  
Two classes of signaling proteins regulate Ras 
activity by influencing its transition: Guanine 
Nucleotide Exchange Factors (GEF) and 
GTPase-Activating Proteins (GAP). GEF 
stimulate the dissociation of GDP and the uptake 
of GTP, while GAP increase the rate of hydrolysis 
of bound GTP by Ras, inactivating Ras. 
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The linear module Raf-MEK-ERK 
This module is actually the central core module. Once activated, it accomplishes 
for the convergence of different up-stream stimuli, providing for a high degree of 
signal integration.  
 
Raf 
Raf is a Ser/Thr protein kinase, catalyzing the phosphorylation of hydroxyl groups 
on specific Ser and Thr residues (Chong et al., 2003). Like Ras, Raf was first 
discovered in the form of a mutant retroviral transforming agent, v-raf (Rapp et 
al., 1983). Mammals have 3 Raf proteins, ranging from 70 to 100 kDa in size: 
Raf-1, Raf-A and Raf-B.  
Raf-1 is ubiquitously expressed and studies on knockout mice indicated that Raf-
1 may serve a general role in tissue formation (Mikula et al., 2001). 
B-Raf is present in multiple isoforms and it is strongly expressed in fetal brain and 
adult cerebrum (Barnier et al., 1995) and it seems to fulfill more specialized 
duties (Wojnowski et al., 1997).  
Recruitment to the plasma membrane by GTP-bound Ras is the initial event in 
Raf activation. Different Ras isoforms appear to activate Raf with varying ability, 
despite binding in vitro with comparable affinity. For example, K-Ras both recruits 
Raf-1 to the plasma membrane more efficiently, and activates the recruited Raf-1 
more potently than H-Ras (Yan et al., 1998). It has also been suggested that Raf-
B is the primary target of oncogenic Ras isoforms (Marais et al., 1997). Activating 




Phosphorylated Raf activates MEK1 and MEK2 (Zheng and Guan, 1993). These 
kinases are about 45 kDa each and share 80% sequence identity. It is unclear 
why two MEKs exist, although conservation of both forms throughout eukaryotic 
species suggests non-redundant functions. Both MEKs are expressed 
ubiquitously in mammalian cells at micromolar levels, although some tissue-
specific variation has been noted (Brott et al., 1993). Raf family activation of 
MEK1 and MEK2 occurs through phosphorylation of two Ser found in the 
activation loop (Alessi et al., 1994). While Raf isoforms are enzymes of relatively 
low abundance, the high concentration of MEKs allows for amplification of 
signaling (Huang and Ferrell, 1996). MEK1 or MEK2 may activate ERK1 or 
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ERK2. At endogenous levels of expression, there is evidence for preferential 
coupling, which may depend on the upstream kinase or adapter proteins in 
addition to differences in their direct interactions. Several studies showed that 
Raf-1 complexes preferentially with MEK1 and ERK2 (Huang et al., 1993; Jelinek 
et al., 1994).  
MEK1 and MEK2 have distinct ways to contribute to the regulation of ERK activity 
and the mammalian cell cycle progression; MEK1 is required for Golgi 
fragmentation (Colanzi et al., 2000), whereas MEK2 is thought to be essential for 
progression through the G2/M checkpoint (Abbott and Holt, 1999). The 
phenotypes for loss of MEK1 versus loss of MEK2 have been studied in CT116 
cells, a colon cancer line with WT p53 (Ussar and Voss, 2004). Depletion of 
either MEK subtypes by RNA interference generated a unique phenotype. The 
MEK1 knockdown led to the induction of a senescence-like phenotype and 
permanent ablation of MEK1 resulted in reduced colony formation potential, 
indicating the importance of MEK1 for long term proliferation and survival. In 
contrast, MEK2 deficiency was accompanied by a massive induction of cyclin D 
expression and the centrosome over-amplification, inducing a delay in mitosis.  
Knockout studies have demonstrated that the inactivation of MEK1 gene leads to 
embryonic lethality, suggesting that MEK1 has a unique role during 
embryogenesis; while MEK2 is not necessary for the normal development of the 
embryo and its loss can be compensated by MEK1 (Belanger et al., 2003). All 
these experiments demonstrated that the two isoforms of MEK are not 




ERK was evidenced for the first time as a kinase protein phosphorylating the 
microtubule-associated-protein 2 (MAP2) in extracts of 3T3-L1 adipocytes 
(Sturgill and Ray, 1986). This polypeptide was identified to be the same found 
phosphorylated by many growth factors (Nakamura, 1983; Cooper, 1984; Cooper 
1985; Khono, 1985) and phorbol esters (Gilmore, 1983); these fidings reinforced 
the possibility that it might be an ubiquitous effector of mitogenic stimuli. This 
realization prompted the ridesignation of acronym “MAP” from “microtubule-
associated-protein” to “mitogen-activated-protein”. ERK genes were purified and 
cloned the beginning of the nineties’ (Boulton et al., 1991).  
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ERK1 and ERK2 are 44 and 42 kDa Ser/Thr kinases with 90% sequence identity 
in mammals. The two kinases are both expressed in most, if not all, mammalian 
tissues, with ERK2 levels generally higher than ERK1. Knockout studies in mice 
demonstrated that ERK2 may at least partially compensate for the other's loss, 
although ERK1 has been found to regulate specifically thymocyte maturation 
(Pages et al., 1999). Dual Thr and Tyr phosphorylations activate both ERK1 and 
2 at Thr202/Tyr204 for human ERK1 and at Thr185/Tyr187 for human ERK2. 
Unlike MEK, significant ERK activation requires phosphorylation at both sites, 
with Tyr phosphorylation preceding that of Thr (Ferrell and Bhatt, 1997).   
 
The regulation of ERK localization by activation and inactivation mechanisms 
In resting conditions ERK is mostly retained in the cytoplasm bound to MEK, 
which carries a Nuclear Export Signal, NES (Adachi et al., 1999; Rubinfeld et al., 
1999). Indeed, ERK does not display any localization sequence, and theoretically 
could be homogeneously distributed. MEK prevents basal levels of ERK from 
entering the nucleus in unstimulated cells. Only upon stimulation, the cascade 
activation propagates through the different components till ERK phosphorylation 
by MEK and the subsequent detachment of the two proteins. This event 
determines the massive translocation of ERK in the nucleus (Chen et al., 1992), 
















In resting conditions ERK1/2 are mostly retained in the cytoplasm by MEK, which 
carries a NES (Nuclear Export Signal). Upon stimulation of the pathway MEK 
doubly phosphorylates ERK1 and 2, which detach from their cytosolic anchor and 
accumulate in the nucleus. Besides, also MEK has been demonstrated to be able 
to cross the nuclear barrier, being continuosly exchanged between the cytoplasm 
and the nucleus (Fukuda et al., 1997; Jaaro et al., 1997; Tolwinski et al., 1999). 
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Also MEK1 can be continuosly exchanged between the nucleus and the 
cytoplasm, as demonstrated by several researchers (Fukuda et al., 1997; Jaaro 
et al., 1997; Tolwinski et al., 1999). However, the presence of the NES and the 
mantainance of its localization in the cytoplasm also after stimulation suggest that 
MEK has not any nuclear target. In conclusion, it is plausible that MEK principally 
acts as ERK1 and 2 activator, retaining them in the cytoplasm ready for 
sequential cycles of burst activity. 
Analyzing the control of ERK localization on multiple levels, it clearly emerges 
that there is a complex regulation operated by a network made of several 
components of the pathway. As already described, ERK activation is propelled by 
the Raf-MEK route and many feedbacks have been elucidated. For example, 
ERK has demonstrated to be able to phosphorylate Sos on multiple residues 
following growth factor stimulation (Waters et al., 1996). This phosphorylation 
destabilizes the Sos-Grb2 complex, eliminating Sos recruitment to the plasma 
membrane and interfering with Ras activation.  
To counterbalance the activation process and to restore the basal conditions, 
there are at least two major effectors responsible of the switch down of the 
signaling: phosphatases (either in part up regulated by ERK itself) and sprouty. 
Phosphatase action provides ERK dephosphorylation and makes possible 
to re-localize the kinase in the cytoplasm under MEK control. Because ERKs and 
other MAPKs require both Thr and Tyr phosphorylation for full activity, Dual 
Specificity Phosphatases (DSPs, more frequently called MKPs), that 
dephosphorylate both sites, are uniquely positioned to regulate MAPK signal 
transduction cascades. At least 9 MKPs have been identified in mammalian cells 
(Camps et al., 2000), but the MKPs more frequently associated with ERK 
inactivation include: MKP3, MKP4, and Phosphatase of Activated Cells 1 (PAC1). 
MKP3 is present in many tissues and is more specific for ERKs versus other 
MAPKs. MKP4, expressed in kidney, placenta and embryonic liver, strongly 
dephosphorylates ERKs, but it shows some reactivity with JNK and p38 as well. 
The hematopoietically expressed PAC1 also shows limited reactivity with JNK 
and p38 and it is transcriptionally upregulated by p53 (Yin et al., 2003). In 
addition to MKPs, the phosphatases PP2A and HePTP have been implicated in 
ERK2 dephosphorylation at Thr185 and Tyr187, respectively (Zhou et al., 2002).  
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ERKs are also capable to regulate negatively themselves by phosphorylating 
MKPs, reducing the degradation of these phosphatases through the ubiquitin-
directed proteasome complex (Brondello et al., 1999). 
Sprouty is an inhibitor of the ERK pathway that is phosphorylated on a 
tyrosine residue in response to growth factor stimulation and it acts as an inhibitor 
of ERK activation.  
Recently, it has been demonstrated that human Sprouty2 coimmunoprecipitates 
with protein phosphatase 2A (PP2A) in cells upon FGF receptor activation (Lao et 
al., 2007). c-Cbl and PP2A compete for binding on Sprouty2 and it can find at 
least two distinct pools of Sprouty2, one that binds PP2A and another that binds 
c-Cbl. c-Cbl binding likely targets Spry2 for ubiquitin-linked destruction, whereas 
the phosphatase binding and activity are necessary to dephosphorylate specific 
Ser/Thr residues. The resulting change in tertiary structure, following 
dephosphorylation, enables the binding with Grb2, a necessary step for Sprouty2 
to act as a Ras/ERK pathway inhibitor in FGF signaling. 
 
ERK and its targets 
ERK1 and ERK2 are proline-directed protein kinases which phosphorylate 
consensus P-X-S/T-P sequences in a large number of substrates throughout the 
cell, leading to diverse cellular outcomes. Docking sites present on physiological 
substrates confer additional specificity (Tanoue et al., 2000).  
To date, about 160 ERK substrates have been identified, including several  
transcription factors and immediate early gene products that facilitate the 
dramatic effects of ERK activation on gene expression and cell functions.  
The wide variety of incoming signals which conveys on the module Raf-MEK-
ERK is converted to a variety of actions owing to the phosphorylation of 
downstream effectors both in the cytoplasm and in the nucleus. This spatial 
segregation provides for diverse temporal profile of the following downstream 
effects. Indeed, the activation of cytoplasmic targets is responsible of acute 
effects: the major targets are represented by cytoskeleton proteins and other 
cofactors, which cooperatively act in migratory processes and outgrowth. 
Conversely, the translocation of activated ERK1/2 in the nucleus (Lenormand et 
al., 1993) is a necessary step for the long-term actions of the pathway on gene 
expression (Brunet et al., 1999), for morphological transformation of fibroblasts 
(Cowley et al., 1994) and for neurite extension in PC12 (Robinson et al., 1998). In 
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the following, I will explore some of the most significant targets for each category, 
in more details. 
Cytoplasmic Targets 
 
Ribosomal protein S6 Kinases (RSKs) 
ERK1 and ERK2 indirectly regulate transcription by phosphorylating RSKs, a 
family of broadly expressed Ser/Thr kinases activated in response to mitogenic 
stimuli, including growth factors and tumor-promoting phorbol esters (Chen et al., 
1991). RSK is phosphorylated in the cytoplasm and it shortly enters into the 
nucleus where it actually explicates its action on transcription factors. A highly 
conserved feature common to all RSK family members is the presence of tandem 
non-identical catalytic domains, involved in both exogenous phosphorylation and 
auto-activation (Dalby et al., 1998). These domains are activated in a sequential 
manner by a series of phosphorylation following the binding of active ERK1 or 
ERK2 to cytoplasmic RSK (Gavin and Nebreda, 1999). Active RSK plays a major 
role in transcriptional regulation, translocating to the nucleus and phosphorylating 
factors such as the product of proto-oncogene c-fos, serum response factor 
(SRF) and cyclic AMP response element-binding protein (CREB) (Chen et al., 
1993b; Xing et al., 1996). Although RSK1 was initially purified and named on the 
base of its ability to phosphorylate the ribosomal protein S6 in vitro, this 
translational component is apparently the physiological substrate for the p70 S6 
kinase, and not the RSKs (Chung et al., 1992).  
 
ERK-mediated cell migration 
I cannot get tired to outline the importance of spatial segregation; indeed, the 
intracellular and extracellular surface organization reflects a high degree of 
compartmentalization providing for precise and coordinated actions in response 
to exogenous signals. The targets herein discussed represent the major ERK-
mediated effectors involved in cellular response to migratory signals. These are 
typical examples of asymmetric stimuli, given that they are often characterized by 
a spatial gradients in the extracellular environment. Cells are able to sense well 
defined spatial oriented stimuli, that can cause migration of the cell towards or 
away from the active substance. This local activation on restricted areas of the 
cell surface is transduced intracellularly with the recruitment of specific proteins, 
which coordinate opposite actions in different region of the cell (e.g., elongation 
of phylopodia towards the direction of the migratory stimulus versus retraction in 
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the diametrically opposite region). This fine regulation provides for an efficient 
machinery able to respond to external agents with great flexibility and a short 
time lag. Molecules involved in this process and that are regulated by ERK are 
the following: 
Myosin light chain kinase (MLCK) phosphorylates myosin's regulatory light 
chain (and thus activates myosin) during nonmuscle cell contraction, cytokinesis, 
stress fiber formation and motility. Inhibition of the ERK pathway impairs MLCK 
and MLC phosphorylation and cell migration; expression of active MEK1 
promotes phosphorylation of MLCK and MLC and enhanced cell migration in 
COS-7, MCF-7 human breast cancer and HT1080 fibrosarcoma cells (Klemke et 
al., 1997). Moreover, ERK phosphorylates MLCK and causes some increase in 
MLCK activity (Klemke et al., 1997).  
Calpains are a family of Ca2+-activated proteolytic enzymes that are 
involved in cell migration (Dourdin et al., 2001; Huttenlocher et al., 1997). ERK 
phosphorylates m-calpain Ser50 both in vitro and in vivo (Glading et al., 2004) 
and this is required for adhesion turnover and cell migration because Ser50 
mutation inhibits cell migration (Glading et al., 2004). m-calpain also associates 
with the N-terminus of FAK upon Src activation (Carragher et al., 2003); the 
FAK–m-calpain interaction is involved in targeting m-calpain to focal adhesions, 
where calpain degrades cytoskeletal proteins and causes adhesion disassembly 
(Cuevas et al., 2003).  
Focal Adhesion Kinase (FAK) is a non-receptor protein tyrosine kinase that 
localizes at focal adhesions or focal contacts (Schaller, 2001). ERK 
phosphorylates FAK both in vitro and in vivo (Hunger-Glaser et al., 2003).  
Paxillin is constitutively associated with MEK and extracellular stimuli 
induce the  subsequent binding of active Raf and inactive ERK to paxillin, thus 
mediating ERK activation at focal complexes (Ishibe et al., 2003). The paxillin-
FAK interaction is also involved in ERK activation (Subauste et al., 2004). Liu et 
al. have shown that ERK phosphorylates paxillin both in vitro and in hepatocyte-
growth-factor-stimulated epithelial cells, and that paxillin phosphorylation in turn 
enhances paxillin-FAK association (Liu et al., 2002). However, Hunger-Glaser et 
al. have reported that ERK-mediated phosphorylation of FAK blocks the 
interaction of FAK with paxillin (Hunger-Glaser et al., 2003). These observations 
suggest that there might be a fine and complicated regulation of the FAK-paxillin 
complex, in which ERK might initially promote complex-assembly by 
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phosphorylation of paxillin and then promote disassembly by subsequent 
phosphorylation of FAK.  
Integrins: ERK might also participate in cell migration by suppressing the 
ability of integrins to bind to their extracellular matrix ligands. It is well known that 
dynamic integrin activation is required for cell migration (Huttenlocher et al., 
1996; Palecek et al., 1997) and that the Ras-Raf-MEK-ERK pathway regulates 
the affinity of integrins for their substrates (Chou et al., 2003; Hughes et al., 
1997), although the molecular mechanism remains to be elucidated. 
                                                                                                                                                 
Cytoskeleton regulation  
Microtubule associated protein 2 (MAP-2) was one of the first known substrates 
of ERK (Ray and Sturgill, 1987), this is the reason why it was also originally 
named Microtubule-Associated Protein-2 Kinase. MAPs are a group of proteins 
that stabilize microtubules, organize them into bundles, and connect them to 
membranes and intermediate filaments (Maccioni and Cambiazo, 1995). They 
are phosphorylated in response to cell stimulation and this inhibits their capacity 
to stabilize the microtubules (Jameson and Caplow, 1981). 
In proliferating cells evidences suggests that MAPK is involved in cytoskeletal 
regulation (Reszka et al., 1995). 
There is still no clear idea about the role of ERK in neurons; however several 
evidences pointed out to a regulational control of microtubule remodeling in 
axons. For example, Campenot chamber studies have shown that the ERK 
pathway is required for neurotrophin-induced axon assembly (Atwal et al., 2000), 
thus, application of pharmacological inhibitors of ERK to the side compartment 
blocks axon extension into the side chamber. Recent studies have also identified 
a potential downstream target of ERK, MAP-1b, reinforcing the idea of a link 
between ERK and axonal microtubule dynamics (Goold and Gordon-Weeks, 
2005). Furthermore, ERK inhibition in growing axons has been shown to induce 
actin depolymerization and growth cone collapse (Atwal et al., 2000).  
ERK signaling likely regulates actin filaments in the growth cone by using local 
protein translation, a mechanism that could ensure an efficient control of axon 
growth and guidance (Campbell and Holt, 2003). In support of this idea, 
increasing evidence shows that the synthesis of many cytoskeletal related 
proteins involved in axon growth and guidance is locally regulated in the axons; 
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e.g. mRNAs of b-actin (Bassell et al., 1998), the actin binding protein cofilin 
(Willis et al., 2005) and GAP43 (Smith et al., 2004). 
ERK has been also demonstrated to be capable of phosphorylating Ser-Pro and 
Thr-Pro motifs in tau proteins, a specific class of microtubule-associated proteins 
that are abundant in neurons in the central nervous system (Weingarten et al., 
1975), that have been found pathogenically hyperphosphorylated in Alzheimer 
disease (Anderton et al., 2001). 
Nuclear Targets 
 
ERK nuclear accumulation upon MEK-mediated phosphorylation is the crucial 
event to nuclear targeting: this provides a direct link between an extracellular 
signal, an internal signaling pathway and the genetic response. Even if ERK1/2 
do not directly interact with the final effectors responsible of the transcriptional 
regulation, they control many nuclear targets, influencing and coordinating their 
activity. These effects are responsible of long term actions, leading to functional 
changes on wider time scales and inducing deep transformations of the cellular 
morphology. Herein, I will present the most important targets localized in the 
nuclear compartment. 
 
The ETS transcription factor family 
Cumulative data have revealed that this family of transcription factors are down-
stream effectors of the Ras-MAPK signaling cascades (Wasylyk et al., 1998). The 
Ets family is defined by a conserved winged helix-turn-helix DNA binding domain 
(Papas et al., 1989; Wasylyk et al., 1998; Werner et al., 1995). Specific 
phosphorylation of Ets proteins greatly enhances their ability to activate 
transcription and regulate specific genes; this is achieved through interactions 
with other transcription factors on DNA.  
Two major groups within this family have been extensively studied, the Ets group, 
including Ets1, Ets2 and Pointed, and the ternary complex factors (TCFs) which 
includes Elk1, Sap1a, Sap1b, Fli1 and Net (Fig. 5). The first group of Ets family 
members has a single MAPK phosphorylation site located near the pointed 
domain (Brunner et al., 1994; Wasylyk et al., 1997). TCFs, on the other hand, 
contain a transactivation domain that can be phosphorylated on multiple serine 
and threonine residues (Hipskind et al., 1994; Treisman, 1994). Phosphorylation 
generally enhances their ability to activate transcription by binding to specific 
sequences termed Ras-Responsive Elements (RREs) and Serum Response 
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Elements (SREs) present in the promoters of many immediate early response 





The major members of ETS family.  
These transcription factors are characterized by the presence of the ETS 
DNA-binding domain and sequence conservation, within this domain 
alone is sufficient to classify ETS-domain proteins into subfamilies. Elk-1 
is recruited to the SRE (Serum Response Factor) by a combination of 
protein-DNA and protein-protein interactions.  
 
 
Elk1 represents the founding member of the TCF subfamily; it is directly 
phosphorylated by ERK1 and ERK2 at multiple sites (Marais et al., 1993), 
presenting two different domains acting as MAP kinase docking sites, the D-
domain (Jacobs et al., 1999; Yang et al., 1998) and the FxF motif (Jacobs et al., 
1999). Elk1 forms a complex with the Serum-Response Factor (SRF) and it 
recognizes the regulatory sequence SREs. Elk1 phosphorylation both enhances 
Elk1 recruitment to DNA (either in ternary complexes or autonomously) and 
potentiates its transcriptional activation activity. ERK-mediated Elk1 
phosphorylation is also thought to promote the formation of quaternary 
complexes containing two Elk1 molecules (Gille et al., 1996).  
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There are several indications that Elk1 might have a role in neurons, indeed, Elk1 
is expressed in neuronal cell types in the rat brain, and becomes phosphorylated 
in response to the activation of glutamate receptors (Sgambato et al., 1998).   
Upon activation, Elk1 binds to the promoters of many immediate early genes, e.g. 
c-fos, egr-1, egr-2, nur77, pip92, b-actin, vinculin and jun-B (Wasylyk et al., 
1997), however, the full spectrum of TCF target genes it is still not known.  
Elk1 is not the unique ERK target belonging to the TCF family, Sap1 and Sap2 
have been shown to be phosphorylated by ERKs (Price et al., 1995).  
The TCFs are direct targets also of other MAP kinases, like JNK (c-Jun N-
terminal kinase) and p38 cascades (Cohen, 1997; Robinson and Cobb, 1997). In 
contrast with the ERK cascade, which is activated by growth factors and 
mitogens, the JNK and p38 cascades respond to cytokines and stress stimuli.  
 
The AP-1 (activating protein-1) transcription factor family 
The activation of AP-1 family of transcription factors is one of the earliest nuclear 
event induced by growth factors that stimulates extracellular signal-regulated 
kinases (Karin, 1996). The AP-1 family consists of several bZIP (basic region 
leucine zipper) domain proteins, like Jun, Fos, ATF1 (Activating Transcription 
Factor 1), which all have to dimerize before they can bind to AP-1 DNA 
sequences, in order to regulate the gene expression of their DNA target sites 
(Fig. 6). Indeed, structural and functional analysis of c-Fos have revealed that it 
heterodimerizes with c-Jun and binds DNA through its bZIP DNA binding domain  
(Halazonetis et al., 1988; Kouzarides and Ziff, 1988; Nakabeppu et al., 1988; 






Structure of the c-fos/c-
jun/DNA complex 
PONDR® predicted disorder 
and order are represented 
respectively by the red and 
the blue ribbons.  
(Molecular Kinetics, Inc., 
Washington State University)  
 
 
The levels of expression and activities of these proteins are regulated by a variety 
of extracellular stimuli. They are thought to function in nuclear signal transduction 
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processes in many different cell types. The role of Fos and Jun in gene 
transcription is complex and may be regulated in several ways including 
association with different dimerization partners, interactions with other 
transcription factors, effects on DNA topology, phosphorylation and finally, 
reduction/oxidation of a conserved cysteine residue in the DNA-binding domain. 
In the case of c-Fos, activation of ERKs leads to the coordinated stimulation of c-
fos expression by acting on transcription factors bound at the c-fos promoter 
(Treisman, 1994; Whitmarsh et al., 1995); ERK also induces the post-
translational modification of c-Fos by the direct phosphorylation of the c-Fos 
Carboxy-terminal Transactivation Domain (TAD) (Chen et al., 1993a; Murphy et 
al., 2002), thereby enhancing c-Fos transcriptional activity (Monje et al., 2003). 
However, the precise mechanism by which phosphorylation by ERKs alters the 
function of these transcription factors remains not fully understood. For example, 
reversible phosphorylation may result in changes in the stability, the nuclear 
localization, the rate of binding to target DNA sequences, and/or the positive or 
negative modulation of the transactivating activity of these transcription factors 
(Hill and Treisman, 1995). In the latter case, it is possible that the 
phosphorylation of specific residues may favor the interaction with other 
transcription factors or with the transcriptional initiation complex, either directly or 
through the recruitment of co-activators. In this regard, it has been shown that c-
Fos interacts with the TATA box binding protein (Metz et al., 1994) and the 
transcriptional activator cAMP-responsive element binding protein (Bannister and 
Kouzarides, 1995).  
 
Mitogen and Stress-activated Kinase (MSK) 
MSK1 is localized in the nucleus and, as RSK, it catalyzes the phosphorylation of 
CREB at Ser133, indirectly linking ERK activity to the control of gene expression 
(Deak et al., 1998). MSK1 and the closely related MSK2 can mediate the stress-
induced phosphorylation of CREB, because they are also activated in cells by 
SAPK2/p38 (Deak et al., 1998). In addition, the overexpression of MSK2 
stimulates CREB-dependent reporter gene transcription in transfected cells 
(Pierrat et al., 1998). Finally, using knockout mice, MSKs were also found to 
phosphorylate histone H3 and the high-mobility-group protein HMG-14, 
facilitating the rapid induction of immediate early genes following mitogenic 
stimulation (Soloaga et al., 2003). 
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Duration, magnitude and compartmentalization of ERK response  
The serially linked members of the ERK pathway provide not only for signal 
amplification, but, even more importantly, for additional regulatory interfaces that 
allow the specificity, duration and amplitude of activity to be precisely tuned. 
Despite having enjoyed a decade in the limelight of scientific investigation, which 
led to reveal a plethora of new insights into the circuitry of signaling pathways in 
general, this cascade still holds many secrets. These pertain mainly to how 
specific biological responses are encoded by spatial and temporal changes in the 
activity and sub-cellular distribution of the pathway components and how these 
fluctuations are orchestrated at the molecular level. The complexity of ERK 
signaling does not lie only in the enormous number of partners involved or in the 
variety of stimuli by which ERK can be activated; there are also other 
sophisticated levels of control represented by the duration, the magnitude and 
the subcellular compartmentalization of ERK activation/inactivation mechanisms. 
Accumulating evidences have demonstrated that differences in the duration, 
magnitude and subcellular compartmentalization of ERK activity determine 
signaling specificity. For example, ERK activation can elicit opposite outcomes 
depending on the situation: cell proliferation versus cell-cycle arrest, cell survival 
versus cell death, and so on. This cannot be fully explained by cell type 
specificity, because ERK activation has distinct outcomes even in the same cell 
type (Schaeffer and Weber, 1999; Tan and Kim, 1999).  
In the following, I will separately present the most important determinants of the 
temporal pattern of ERK activation (paragraph “Duration”) and of the spatial 




Treatment of PC12 cells with nerve growth factor (NGF) induces sustained 
activation of ERK and causes their differentiation into sympathetic-like neurons, 
which is characterized by neurite outgrowth. By contrast, epidermal growth factor 
(EGF) stimulates transient ERK activation and causes cell proliferation (Gotoh et 
al., 1990; Marshall, 1995); furthermore, when the EGF receptor (EGF-R) is 
overexpressed in PC12 cells, ERK activity becomes sustained and the cells 
undergo differentiation in response to EGF (Traverse et al., 1994). The duration 
of ERK activity therefore appears to determine PC12 cell fate.  
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The ERK-signal-duration affects different cellular responses also in other cell 
types. Sustained, but not transient, activation of ERK is required for quiescent 
fibroblasts to begin to proliferate (Balmanno and Cook, 1999; Dobrowolski et al., 
1994). When quiescent fibroblasts are treated with thrombin or platelet-derived 
growth factor (PDGF), they display sustained ERK activation and enter S phase. 
By contrast, thrombin-mimicking peptide (TMP) or EGF stimulate transient ERK 
activation and cannot induce the onset of S phase (Murphy et al., 2002; Vouret-
Craviari et al., 1993). Indeed, blocking ERK activity with a specific MEK inhibitor, 
even several hours after growth factor stimulation, effectively blocks S phase 
entry (Weber et al., 1997). Murphy et al. have provided clues for understanding 
how sustained ERK activation causes fibroblast proliferation (Murphy et al., 
2004). Whereas both transient and sustained activation of ERK induce 
transcription of immediate early genes (e.i. Fos, Jun, Myc, Egr1), only sustained 
ERK activation causes phosphorylation and stabilization of the proteins they 
encode. Because most immediate early genes encode transcriptional factors, 
they should in turn change expression levels of other genes crucial for cell 
proliferation. In fact, the mRNA and protein levels of cyclin D1 (a transcriptional 
target of the Fos-Jun complex and important for S-phase entry) are both elevated 
and maintained by sustained ERK activation (Weber et al., 1997).  
 
What causes the difference in the duration of the ERK signal? Several 
determinant have been evidenced, herein I will discuss the principal positive 
regulators. 
Ras and Rap1. In PC12 both EGF and NGF induce transient Ras activation but 
NGF stimulation also leads to sustained Rap1 activation (York et al., 1998). 
Recently, a combination of computational simulations and experimental validation 
has provided a more detailed analysis of Ras and Rap1 dynamics (Sasagawa et 
al., 2005). 
PKC. It stimulates ERK activation through activation of Raf. ERKs activate 
cytosolic phospholipase A2 (cPLA2), and the arachidonic acid produced by 
cPLA2 activates PKC. Inhibition of PKC signaling has no effect on initial ERK 
activation, but blocks sustained ERK activation. 
Growth factor receptor. The dynamics of the activation of TRK receptors might 
contribute to the different effects on the duration of ERK activity (Di Fiore and Gill, 
1999). Upon EGF stimulation, the EGF-R undergoes rapid internalization 
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followed by degradation, which terminates ERK activation and thus makes it 
transient.  
I can conclude that the duration and extent of ERK activation is the results of the 
balance between activating processes, as described before, and inactivating 
reactions directly carried out by phosphatases (ERK dephosphorylation) or 
indirectly by sprouty, which sequesters Grb2, impairing full activation of Ras 
cascade and, consequentially, ERK recruitment (as described in the paragraph 
“The regulation of ERK intracellular localization by activation and inactivation 
mechanisms”). 
 
Magnitude and compartmentalization 
In addition to the simple linear Ras–Raf–MEK–ERK module, all of these core 
signaling proteins have additional means of regulation. The enormous potential 
for convergence and divergence of signals onto and from the Ras–Raf–MEK–
ERK pathway raises the question of how specificity is achieved, and the answer 
lies partially in scaffold proteins, molecules that tether signaling proteins in the 
vicinity of one another.  
Recent studies have revealed scaffolding as a mechanism that helps the ERK 
cascade to transduce signals with both high efficiency and specificity. Scaffold 
proteins could play an important role in the regulation of the magnitude of ERK 
activity and they physically segregate ERK in specific loci of the intra-cellular 
environment. Experiments in mammals have focused on two scaffolding proteins: 
Kinase Suppressor of Ras (KSR) and MEK Partner 1 (MP1). KSR1 translocates 
to the plasma membrane on receptor activation, localizing MEK and activated Raf 
at the plasma membrane and providing a docking platform for ERK. This 
facilitates the sequential phosphorylation events needed for ERK activation, after 
which ERK dissociates from the complex to bind substrates in the cytoplasm 
and/or nucleus (Kolch, 2005; Nguyen et al., 2002). Experiments with KSR-
deficient mice indicate that KSR is not absolutely required, but it enhances 
signaling from Ras (Nguyen et al., 2002).  
The specialized adapter protein MP1 tethers MEK with ERK and seems to favor 
the activation of ERK1 over ERK2, linking exclusively MEK1 with ERK1 
(Schaeffer et al., 1998). The physiological significance of this differential 
activation is not understood, but reduction of MP1 using RNA interference results 
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in defective ERK signal transduction with a decreased ERK activation in 
response to growth factor stimulation (Teis et al., 2002). 
 
Modeling: a bridge between biochemistry and computation 
In silico modeling represents an important tool of investigation and I firmly believe 
that, in order to maximize its efficacy, there should be a tight integration between 
models and experimental data. This approach can provide not only the validation 
or refusal of the hypothesis formulated to explain the observed phenomena, but it 
also helps to guide the design of new experiments. In this perspective, data 
coming from experiments must be quantitatively analyzed, in order to get specific 
parameters that can be used as input data for the computational model. This 
method allows to reduce the number of freedom degrees assumed for a certain 
model and it might represent a far more powerful tool, compared to only 
computational simulations.  
ERK signaling has been object of investigation of several scientists, particularly 
concerning the dynamics controlling the signaling network at the basis of ERK-
dependent functional outputs.  
Bhalla et al. have conducted computational simulations and they reported that 
sustained ERK activation in fibroblasts is brought by a positive feedback loop 
between ERK and protein kinase C (PKC) signaling (Bhalla and Iyengar, 1999; 
Bhalla et al., 2002). 
Sasagawa and coworkers have developed a simulation model of ERK signaling 
by constraining in silico dynamics on experimental data from living cells. In 
particular, they correlated the temporal pattern of ERK activation of two stimuli 
(EGF and NGF) with different outputs, and they demonstrated the involvement of 
Ras and Rap1 dynamics in the specification of PC12 fate. In particular, Ras and 
Rap1 capture the temporal rate of the stimuli presentation and the concentration 
of growth factors and then, they encode these physical properties into transient 
and sustained ERK activation (Sasagawa et al., 2005). 
In this work, I took advantage of this integrated approach by modeling our 
experimental data in order to quantitatively estimate the effects of ERK nuclear 
inactivation and trafficking speed on the nuclear ERK phosphorylation. I tested 
the hypothesis that the relevant differences observed between the two kinases 
could be explained with a basic assumption of an equilibrium between the 
different states in which ERKs can exist. 
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In conclusion, ERK activity is the result of the synergy of several control 
mechanisms and regulatory feedbacks that are continuously modulated and that 
can operate differently in different cellular compartments. The resulting “average” 
state of ERK activity, that is seen by the nuclear targets and that is crucial for 
determining cell fate, is due to the integration of these processes.  
 
Nucleo-cytoplasmic shuttling of ERK 
A hallmark of eukaryotic cells is their separation into compartments, which are 
surrounded by membranes, impermeable to macromolecules, so specific 
transport systems have evolved to allow protein to be exchanged between 
different compartments.  
For specific molecular components it is essential to move towards a particular 
compartment (e.i., RNAs once translated in the nucleus must move to the 
cytoplasm, chromatin remodeling proteins have to localize in the nucleus, etc…). 
The directionality of this process is provided by the presence of specific tags, 
which specifies the compartment of destination. The transport of the cargo 
presenting such special signals is mediated by specific transporters energy-
dependent, like the importins and karyopherins (see later).  
Nevertheless, there are proteins that are able to continuously move back and 
forth between the nucleus and the cytoplasm without the help of any carrier and 
in an independent-energy manner; these proteins are key factors in conveying 
information on nuclear and cytoplasmic activities within the cell. One of these is 
ERK; it notifies the nucleus of biochemical events upstream its activation which 
occurs in the cytoplasm. Then, the biochemical information coded in the ERK 
activation state is transduced in the regulation of gene expression.  
In this work I investigated the exchange of ERK1 and 2 across the nuclear 
membrane in different conditions of pathway activation. In the following chapter, I 
will present the main features of the trafficking through the nuclear barrier. In 
particular, I will describe the complex structure which characterizes nucleoporins 
and the main routes followed by most cargos, paying particular attention to the 
anomalous transport system (not completely elucidated yet) which is responsible 
of ERK delivery.  
 
Nuclear Pore Complexes: the gatekeepers of the nuclear entry 
The spatial separation of transcription and translation provides eukaryotes a 
powerful mechanisms for controlling gene expression, but also necessitates 
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selective transport between the nuclear and cytoplasmic compartments to 
maintain the distinctive composition of each.  
There are several nuclear transport pathways, each of which delivers a specific 
range of macromolecules either into or out of the nucleus (Moore, 1998; Peters, 
2005; Wente, 2000). Most pathways use a homologous family of carrier 
molecules collectively called -karyopherins, with import carriers called importins 
and export carriers called exportins. Many proteins are imported using importin- 
(often using importin- as an adaptor), although some are imported using other 
importins, such as transportin; many proteins are exported using the export 
carrier CRM1, whereas pre-microRNA and tRNA are exported by exportin-5 and 
exportin-t (all of which are importin- homologues). In each pathway, cargo 
proteins (macromolecules that are greater than ~40 kD) usually present short 
Nuclear Localization Signal (NLS) sequence motifs or Nuclear Export Signals 
(NES), being actively transported, respectively, in or out of the nucleus, using 
soluble transport factors or carrier molecules that cycle between the cytoplasm 
and nucleus (Sorokin et al., 2007).  
Trafficking across the nucleus occurs by transiting through the NPCs, huge 
macromolecular assemblies that perforate the nuclear envelope and form the 
conduit for the bidirectional exchange of molecules between the cytoplasm and 
nucleus through a central channel that has a limiting diameter of ~25–30 nm 
(Beck et al., 2004). NPCs are constructed from multiple copies of ~30 different 
proteins collectively called nucleoporins; these frequently contain FG sequence 
repeats, large regions consisting of tandem repeats based on highly conserved 
cores, containing one or two phenylalanines linked by hydrophilic spacers of 
variable sequence, but rich in charged and polar residues (Doye and Hurt, 1997; 













of the nuclear pore 
complex.  
FG repeat regions have 
been found on the inner 
and outer surface and 
inside the pore channel. 
 
 
The two most common cores are GLFG or FxFG (where x is usually serine, 
glycine or alanine), and some nucleoporins contain over 20 copies of these 
repeats. FG repeat regions of nucleoporins may not have a large amount of 
regular structure in solution and so may be very flexible (Bayliss, R 2000 Cell). 
Nucleoporin FG repeats appear to be directly involved in nuclear trafficking 
(Bayliss et al., 2000). Complementary postembedding studies, by using 
antibodies that label FxFG repeats indicate that FG nucleoporins, are found in the 
central channel as well as on both faces of NPCs (Grote et al., 1995) (Fig. 7). 
Recently, quantitative measurements, by using cell-free nuclei reconstituted in 
Xenopus egg extract, showed that nuclear accumulation follows first-order 
kinetics and reaches steady state with a Michaelis–Menten function (Kopito and 
Elbaum, 2007). This saturation suggests that receptor-mediated translocation 
across the nuclear pore occurs bidirectionally. A far-reaching consequence is that 
the nuclear localization signal dictates the fate of a protein population rather than 
that of the individual molecules that bear it, which remain free to shuttle back and 
forth. This implies an open communication between the nucleus and cytoplasm 
and an ubiquitous mechanism for signaling in both directions. 
Concerning ERKs shuttling across the nuclear barrier, it has to be considered 
that ERK does not display any obvious sequence corresponding to known NLS or 
NES sequences (Whitehurst et al., 2002). It seems to enter the nucleus by a 
carrier-independent mechanism (Adachi et al., 1999) and might therefore be 
ferried across the nuclear membrane (Whitehurst et al., 2004) by virtue of binding 
to other proteins such as the phosphatases MKP-3 (Camps et al., 1998), MEK 
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(Adachi et al., 2000; Burack and Shaw, 2005; Fukuda et al., 1997) or the 
phosphoprotein enriched in astrocytes, PEA-15 (Formstecher et al., 2001). 
Nevertheless, PEA-15, in contrast to MEK and MKP-3, would retain ERK2 in the 
cytoplasm in the active state, so it not only impairs nuclear signaling, but it also 
favors ERK signaling to cytoplasmic targets (Formstecher et al., 2001; Whitehurst 
et al., 2004). Recently, it has been identified a 3 aminoacid region (SPS), which 
when phosphorylated allows the interaction with importin7 (Chuderland et al., 
2008). Interestingly, this site has been found also in other proteins which were 
thought to cross the nuclear envelope without the help of any carriers (Xu et al., 
2003; Xu et al., 2000), like SMAD 3 (Chuderland et al., 2008). Furthermore it has 
been demonstrated that ERK can directly interact with NUP214/CAN and 
NUP153 (Matsubayashi et al., 2001; Whitehurst et al., 2002). Again, the 
interaction interface was mapped to the FG-repeats of NUP214/CAN and 
NUP153, although the exact ERK2 domain that is involved in such interaction 
remains undefined (Matsubayashi et al., 2001; Whitehurst et al., 2002). Only 
recently, using import reconstitution assays, Yazicioglu et al. have examined a 
group of ERK2 mutants defective in known protein interactions to determine 
structural properties of ERK2 that contribute to its nuclear entry. Several ERK2 
mutants defective in interactions with FxF motifs displayed slowed rates of 
nuclear import and also showed reduced binding to a recombinant C-terminal 
fragment of nucleoporin 153 which is rich in FxF motifs (Yazicioglu et al., 2007). 
These results further support the idea that direct interactions with nucleoporins 
are involved in ERK2 nuclear entry and that multiple events contribute to the 
ligand dependent relocalization of this protein kinase. 
ERK1 and ERK2: the “different twins” 
ERK1 and 2 share approximately 90% of aminoacid identity; they are activated 
by the same stimuli and are believed to bear similar substrate recognition 
properties and subcellular localization (Boulton et al., 1991; Seger and Krebs, 
1995). Although it has been assumed that ERK1 and 2 were functionally 
equivalent, recent studies have shown critical functional differences between 
these two proteins. While the genetic ablation of ERK2 in mice results in 
embryonic lethality, loss of ERK1 only causes deficits in tymocyte maturation 
and, surprisingly, leads to a dramatic enhancement of striatum-dependent long-
term memory (Mazzucchelli et al., 2002; Pages et al., 1999). Significant 
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differences between the two kinases also appear in the control of cell growth, at 
least in cultured fibroblasts (Vantaggiato et al., 2006). Only very recently 
knockdown mice have been generated in which ERK2 expression was partially 
(20-40%) reduced; these mutants showed a deficit in long-term memory in 
classical fear conditioning, whereas short-term memory was normal (Satoh et al., 
2007).  
Combining together all these data, it is getting clear that the two kinases have 
only partially overlapping roles, and that they might undergo differential 
regulation. However, it has not yet emerged a clear molecular mechanism at the 
basis of these differences.  
Since the long term effects of ERK action depends on the biochemical 
communication to the nucleus, I wondered whether some of the differences 
between ERK1 and 2 might originate in different trafficking properties. To this 
effect I resorted to imaging-based techniques to study trafficking across the 
nuclear envelope of the two kinases. I  corroborated the imaging data with the 
help of classical biochemistry methods and in silico models. By using “dynamics 
techniques” it has been possible to unmask “dynamic properties” of fundamental 
importance to understand ERK functions and differences.  
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INTRODUCTION: Part 2 
Dissecting a pathway: techniques to investigate molecular mechanisms 
Every biological system is well described using a fundamental keyword: 
“dynamics”; communication is strictly and “dynamically” controlled at each level 
(molecule, cell, tissue and finally the entire body) and the regulation of each 
component is “dynamic” so that the system can answer quickly to different 
external agents. 
I developed my study at the cellular level, investigating kinetics and relationship 
between cardinal proteins acting in several primary processes. There is no doubt 
that the best way to study a living system is to investigate the internal 
mechanisms without perturbing their homeostasis. This approach is nowadays 
possible and reliable, because of great improvements in molecular biology 
techniques and in the latest sophisticated technologies of living cell imaging.  
The behavior of a molecule can be followed along time and space: the temporal 
scale plays a pivotal role in the hierarchy of molecular events and, on the other 
side, cells are strictly structured in ordered compartments that efficiently 
communicate together. Many processes take place in specific areas and only 
recruitment of critical proteins in specific loci are successful in determining a 
cascade activation. 
I adopted fluorescence-based imaging techniques that allow to collect data with 
high spatial and temporal resolution in a living system. This would be impossible 
to achieve by using classical methods of investigation only (western blot, 
immunocytochemistry, etc…), that, although providing precious information about 
the state of chemical modifications or about the selective discrimination of 
molecules, cannot follow in real time and in physiological conditions what it is 
happening inside a cell. All the experiments in the present study have been 
conducted in living cells transfected with a plasmid carrying the cDNA of the 
protein of interest, tagged with a gene encoding a fluorescent protein belonging 
to the GFP family (Green Fluorescent Protein). This approach permits to visualize 
the fluorescent probes localization in real time.  
In the following, I will discuss features and potentialities of imaging techniques in 
more detail, specifically, I will address: 
° the generation of fluorescent fusion proteins and their validation; 
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° the tracking of protein movements and their relationship with the protein 
biochemistry; 
° the measure of Fluorescence Recovery After Photobleaching (FRAP) to 
study protein trafficking inside or between different intracellular 
compartments. 
 
Generation of fusion proteins and their validation  
The fine tuning of geography, movement and chemistry gives proteins their 
extraordinary capability of virtually regulating all dynamic process in living cells. It 
is required making the proteins visible, in order to unveil how they move. The 
discovery and development of Green Fluorescent Protein (GFP) from the jellyfish 
Aequorea victoria (Fig. 8) have revolutionized our ability to study protein 
localization, dynamics and interactions in living cells (Tsien, 1998).  
The chromophore (Fig. 9) is composed by an amino-acid triplet, Ser-Tyr-Gly, that 
undergoes a chemical rearrangement to form a fluorophore (Heim et al., 1994) in 
two steps reaction (cyclization and oxidation).    
Advances in GFP biology, most notably the molecular engineering of the GFP-
coding sequence, have resulted in optimized expression of GFP in different cell 
types, as well as the generation of GFP variants, with more favorable spectral 
properties including increased brightness and relative resistance to the effects of 
pH variation on fluorescence and photo-stability (Fig. 10). In addition, new 
fluorescent proteins have been discovered that are excited at longer 
wavelengths, like the Red Fluorescent Protein (DsRed), derived from the sea 
anemone Discosoma striata, increasing the current availability of fluorescent 
protein variants (Fig. 10). 
Any fragment of cDNA, codifying for a specific protein or small parts of it, can be 
cloned in frame with the cDNA of a fluorescent protein and introduced into a 
suitable vector. Once created, the recombinant plasmid is transfected into cells, 
so they can produce by themselves the fusion protein that accumulates in 
different compartments according to the specification of functional domains. GFP 
fusion proteins have been used to address a wide range of questions in individual 
cells, as well as in tissues of a particular organism. 
The resulting chimera often retains parent-protein targeting and functions when 
expressed in cells (Tsien, 1998) and therefore it can be used as a fluorescent 









Tridimentional structure of the GFP. 

























Cerulean (Rizzo et al., 2004, Nat. Biotech.)
greatly improved quantum yield;
higher extinction coefficient; 
fluorescence lifetime fit by a single 
exponential 2.5-fold brighter than ECFP. 
Venus (Nagai et al., 2002, Nat. Biotechnol.)
improved speed and efficiency of maturation
increased resistance to environment (Cl-)
Citrine (Griesbeck et al.; 2001, JBC)
indifference to chloride;
twice the photostability of previous YFPs;






(Shaner et al., 2004)
More complete maturation
More tolerant to N-term. Fusion





Representation of the most common fluorescent proteins 
The reported proteins emitting from blue to yellow (EBFP, CFP, YFP and their 
optimized variants) have been obtained by mutagenesis of the GFP codifying gene 
(from the jellyfish Aequorea victoria); the red-shifted variants have been obtained 
from DsRed (from the Reef coral Discosoma striata). Numerous other variants have 




Of course, every new fusion protein has to be validated in order to demonstrate 
that it behaves like the corresponding endogenous protein. The following 
fundamental aspects have to be taken into account: 
1. The fluorescent tag must not interfeare with the protein operations. It is 
important to make sure that fusion proteins correctly undergo to the same post-
traduction modifications of the corresponding endogenous forms. Furthermore, in 
case of tagged enzymes, control experiments are required to test that the 
addiction of an exogenous protein (GFP) does not interfere with their catalytic 
activity. Virtually GFP can be tagged to any protein either N- or C-terminally. This 
is due to the fact that both termini of GFP are rather flexible on the surface of the 
beta-barrel, so that both the structure of GFP and of the protein of interest are not 
significantly distorted. Notwithstanding this, it is of crucial importance controlling 
by specific biochemical tests, whether proper post-translation modifications can 
occur once the chimera is expressed in a cellular system.  
2. It is essential that the concentration of the chimera is as low as possible in 
order to preserve the physiological conditions and the endogenous homeostatic 
mechanisms. As I will show in the following, it is impossible to underevaluate the 
importance of this condition, since excessive overexpression of the fusion protein 
can cause an unbalancing of the pathway, leading to pathological or artificial 
conditions. For example, the localization of the fusion protein MP1 (MEK binding 
Partner1), GFP-tagged, reveals a strong dependency on over-expression, as 
shown in further details in Box 2.  
To overcome the problem of overexpression there are at least two other 
methods. In the following, related benefits and drawbacks are reported:  
Co-expression of the main regulatory components of the protein of interest.  
This approach has been applied by Burack et al. in a live cell imaging study; 





A) A cell overexpressing only ERK-YFP: the 
protein is mostly localized in the nucleus, despite 
that the cell has been starved.  
B) The cotransfection of MEK-CFP and ERK2-
YFP rescues the ectopic localization of ERK, 
causing its exclusion from the nucleus. Both 
images were collected in the YFP channel, so 
only the signal of ERK localization is visualized.  




Cotransfecting both the binding partners it is possible to restore the stoichiometric 
balance between MEK and ERK, and now the correct localization is achieved. 
However, this approach causes the overexpression of both proteins and this 
condition can influence other molecular equilibria through the pathway. 
Silencing of the endogenous form and replacing it with the fusion protein.  
This can be achieved in culture cells, by siRNA technology, while in primary cells 
(derived from a fresh tissue) the generation of transgenic animals is required.  
 
Tracking protein movements 
Protein localization following exogenous stimuli or modifications of cellular shape, 
can be recorded with time lapse imaging techniques, which consist in collecting a 
long series of images of cells, at predetermined time intervals, while a certain 
process is occurring. 
There is a great variability in the duration of cellular processes (milliseconds, 
minutes, hours to days); for example cell division occurs every 24 hr, while 
changes in ions concentration can occur as rapidly as few seconds. For these 
reasons, it is very important to know the right time scale of a certain process, in 
order to collect pictures of all the fundamental phases (see Box 3).  
Initially, imaging recordings were done using photographic films and these 
movies were instrumental in demonstrating the dramatic behavior of cell motility. 
Over the last 25 years, cell biology has benefited from improvements in electronic 
imaging technologies that have largely replaced film recordings. Computer-based 
digital image-capture systems have revolutionized the study of the dynamic 
events of cell biology with their high quantum efficiency, low-noise characteristics 
and ease of use.  
Working with imaging techniques, many technical requirements and strategies for 
maintaining cell viability during imaging have to be considered. Tight control of 
the culture environment is one of the most critical factors in successful live-cell 
imaging experiments. Aspects of the environment that are readily manipulated 
include the physical parameters of the chamber in which the cells (especially 
from mammals) are grown and imaged: temperature (cellular functions are 
exquisitely sensitive to temperature), atmospheric conditions (gas mixture and 
humidity), nutritional supplements, growth medium buffering (pH) and osmolarity 
of the culture medium. Specific chambers providing the control of the main 
environmental parameters are now available. Furthermore, time-lapse imaging 
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can be compromised by several artifacts that can affect the focus, like minute 
changes in temperature of the microscope (avoided by using thermostatic 
chambers) or cell motility and bulging. 
Finally, an other important parameter to take into account is the illumination-
caused photobleaching and phototoxicity, which can constrain time-lapse imaging 
because of cell damage. Indeed, repeated illumination, even at low intensity, 
induces the production of reactive oxygen compounds, derived from the 
excitation of the fluorescent probes imaged; so economizing light exposure would 
be preferable to reduce the photo-damage. The resultant image sequence 
portrays the true nature of cellular processes and makes it much easier to grasp 
the dynamics of these events. But the sequences produced are not just pretty 
pictures; they provide a wealth of analytical informations that can be readily used 
to conduct image analysis. The acquired images return a wide variety of 
informations about motility, morphology or distribution of intracellular 
components, unmasking how the system reacts. In a fluorescence-based system, 
the change of the chimera localization in response to stimuli or drugs is the final 
read out about what it is going on, that can be quantified by using image analysis 
software.  
 
“Sliding molecules”: measuring protein movements with FRAP 
Fluorescence Recovery After Photobleaching (FRAP) was developed over 30 
years ago (Peters et al., 1974) as a tool to study the molecular mobility in several 
media, including aqueous solutions, gels and living cells. In cell biology, FRAP 
was originally used to study membrane diffusion of lipids and proteins coupled to 
fluorophores (Axelrod et al., 1976; Edidin et al., 1976). In conjunction with GFP 
tagging of intracellular proteins, the development of confocal laser scanning 
microscopes (CLSMs) provided scientists with an excellent standard tool to 
perform FRAP experiments. GFP fusion proteins are ideal to use in FRAP studies 
because they can be bleached with low degree of damage to the cell (Lippincott 
et al., 1999). This is presumably because the compact barrel-like structure of 
GFP shields the external environment from the damaging effects that are caused 
by reactive intermediates generated by photobleaching (Prendergast, 1999; Yang 
et al., 1996).  
In a typical FRAP experiment a region of the cell is briefly illuminated with a laser 
beam at high-intensity, with a wavelength near the excitation peak of the 
expressed fluorescent protein. Consequently, most of the fluorophores inside this 
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region irreversibly loose their fluorescence, a phenomenon known as 
photobleaching. As fluorescent proteins are attached to molecules that move in 
and out of the bleached region, fluorescence inside this zone increases and 
eventually equilibrium is reached (Fig. 12).  
 




Cell photobleached in a small region of the cytoplasm; the 
fluorescence recovers from not photobleached nearby regions. 
 
 
The analysis of the temporal sequence returs a plot of the recovery kinetics 
displaying fluorescence changes in the bleached regions of the cell over time 
(Fig. 13). From this plot a number of parameters can be directly extracted, that 
describe the kinetics of fluorescence equilibration. They 
 can be extrapolated “descriptive” parameters, not directly linked to a model, but 






Profile of the fluorescence 
recovery after photobleaching 
Schematic representation of 
the typical fluorescence 
recovery of the region that 
has been photobleached. By 
fitting with an exponential 
curve it is possible to estimate 





A typical FRAP curve provides useful informations about molecular mobility, 
codified by the Mobile Fraction, Mf, and the Diffusion coefficient, D. The Mobile 
 46 
fraction is the fraction of the total amount of protein that can be exchanged 
between the bleached area and the nearby regions. It is determined by 
calculating the ratio of the final to the initial fluorescence intensity in the bleached 
region, corrected for the amount of fluorescence lost during photobleaching 
(Swaminathan et al., 1997) (Eqn. 1). 
 











A Mf less than 100% indicates that some fluorescent molecules might form 
immobile aggregates, or the protein is confined to a compartment and cannot 
contribute to fluorescence recovery in a separate disconnected compartment 
(Edidin, 1992; Edidin et al., 1994; Feder et al., 1996). In other words, there is a 
fraction of the entire pool of the protein of interest (Immobile Fraction= 1-Mf) 
which is partially or permanently immobilized, along the time window explored or 
that it interacts with other components and has a very high dissociation constant. 
Alternatively, non-diffusion factors, such as diffusion barriers or discontinuities 
within the structure where a protein localizes, might be responsible for the 
reduced mobility (Ellenberg et al., 1997; Feder et al., 1996), this latter condition is 
common for proteins localized in internal compartments that are disconnected 
from other structures (for example, endosomes and lysosomes). 
The diffusion constant, D, provides a measure of the rate of protein movement in 
absence of flow or active transport (Lippincott–Schwartz et al., 1999; Axelrod et 
al., 1976;  White et al., 1999). The theoretical D for a protein principally depends 
on its size and cellular environment, and reflects the mean squared displacement 
that a protein explores through a random walk over time. D has units of area per 
time (m2 s-1). The “effective” diffusion constant for a particle in a free volume is 
described by the Stokes–Einstein formula (Eqn. 2): 
 







where D is the diffusion constant, T is the absolute temperature,  is the viscosity 
of the solution, k is the Boltzmann constant and R is the hydrodynamic radius of 
the particle. 
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Because absolute temperature is usually constant within cells, the most important 
factors underlying D are the size of a protein (or radius) and the viscosity of the 
medium within which it is diffusing. For a soluble spherical protein, an eight-fold 
increase in molecular weight will lead to a two-fold decrease in D. The recovery 
of relative fluorescence intensity within the bleached region is plotted as a 
function of time and fitted with various equations from which it is possible to 
estimate a time constant value (τ), which is indirectly related with the effective D. 
For example, when a small spot or narrow strip is bleached, simple equations can 
be used to estimate D, such as the equation by Axelrod and colleagues (Axelrod 
et al., 1976; Ellenberg et al., 1997; Sciaky et al., 1997) (Eqn. 3): 
 




γωτ =  
 
where  is the width of the bleach,  is a correction factor for the amount of 
bleaching (a weak function of the beam shape and of the bleach depth) and D is 
the diffusion time. This formula assumes unrestricted two-dimensional diffusion 
into a circular bleached area without recovery from above and below the focal 
plane, so it is valid only for diffusion in membranes. Formulas based on 
unrestricted diffusion in a free volume are used for characterizing protein diffusion 
in the cytoplasm. 
Even though viscosity and size are key factors underlying the diffusion rate of a 
protein, other factors also have a role in determining protein diffusion rates inside 
cells. Deviations from the theoretical value can provide useful information about 
the environment of the protein. For example, a D significantly lower than a 
predicted value (indicating slower diffusion) suggests that a fluorescent protein 
could be incorporated into an aggregate or a large complex, because D is 
inversely proportional to protein size. Alternatively, the environment of a protein 
could be notably more viscous than expected, or the protein could be interacting 
transiently with large or fixed molecules. By contrast, if D is significantly higher 
than predicted (indicating faster diffusion), the protein might be showing non-
diffusive behavior such as flow or directed movement by motor proteins, or the 
viscosity of the environment might be decreased.  
Soluble GFP in the cytoplasm, the mitochondrial matrix and nucleus diffuse three 
to four times more slowly than GFP in water, indicating that these environments 
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are more viscous than water (Partikian et al., 1998; Swaminathan et al., 1997); 
despite this, inert molecules such as GFP can cross the nuclear pores rapidly 
(Swaminathan et al., 1997). The high mobility of small solute molecules in the 
cytoplasm and nucleus is likely to be important for coordinating the complex 
regulatory pathways that operate in these environments. Diffusion of GFP within 
the ER lumen revealed it to diffuse three- to six-fold slower than GFP in the 
cytoplasm, so the ER lumen seems more viscous than the cytoplasm (Dayel et 
al., 1999). The abundance of protein-folding machinery and branched 
carbohydrate side-chains on proteins in the ER lumen could explain why its 
viscosity is greater than that of the cytoplasm. The apparent mobility of several 
nucleoplasmic GFP fusion proteins is surprisingly low. For example, the diffusion 
coefficients of GFP fused to the high mobility group SF2/ASF (Partikian et al., 
1998) or fibrillarin, that have been measured by FRAP experiments, were 
extremely low, D= 0.24–0.53 m2 s–1 (Kruhlak et al., 2000; Phair and Misteli, 
2000). As these proteins have been shown to associate rapidly with larger 
steady-state structures in the nucleus (splicing factor complexes and the 
nucleolus), one explanation for their low D is that recovery reflects two 
processes: diffusion and binding/release from an immobile substrate (Kruhlak et 
al., 2000; Phair and Misteli, 2000). 
Differences between theoretical and effective D values for a protein can also 
arise from unusual cellular geometry. Equations of D for a protein in a membrane 
or a free volume usually assume that the spatial distribution of fluorescence in the 
cell is uniform (Axelrod et al., 1976). However, GFP fusion proteins are not often 
distributed homogeneously within the cell, as occurs when complex three-
dimensional structures, like the endoplasmic reticulum (ER) and Golgi, are 
labeled (Cole et al., 1996; Edidin, 1992). Relating the diffusive spread of 
fluorescence through such structures to an idealized planar membrane or volume 
has required the development of theoretical models and simulation programs that 
take topology into account. More sophisticated equations and modeling are also 
required for analyzing FRAP experiments in which there are several diffusing 
species or when recovery occurs by more than one process (for example, when 
diffusion and binding/release from a substrate occur). Anomalous diffusion and 
flow-based processes can also contribute to recovery in FRAP experiments; the 
shape of the recovery curve is no longer characteristic of simple diffusion under 
these conditions.  
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Changes in the mobility of GFP fusion proteins observed under different 
conditions can provide insight into how a protein changes its association with 
other proteins.  
Given that there are many ways to interpret different D and Mf or If values, it is 
important to combine FRAP measures with biochemistry and cell biology data to 




































ERK1b It is an alternatively spliced form of ERK1 with a 26 aminoacids 
insertion between residues 340 and 341 of ERK1a (MW 46 kDa), 
whose kinetics of activation was similar to that of ERK1 and ERK2 
in most cell lines and conditions, but showed higher fold activation 
in response to osmotic shock and epidermal growth factor 
treatments of Ras-transformed cells. Despite the uniform pattern 
of expression of ERK1 and ERK2, ERK1b seem to be present 
only in certain tissues, especially abundant in the rat and human 
heart. ERK1b seems to not interact with MEK1 and to be the 
major ERK isoform that responds to exogenous stimulation in 
Ras-transformed cells probably due to its differential regulation by 
MEK (Yung et al., 2000). 
 
 
ERK1c It is an other alternatively spliced form of ERK1 playing a role in 
Golgi functions (Shaul and Seger, 2006). There are evidences 
pointing out at ERK1c involvement in cell cycle regulation via 
modulation of Golgi fragmentation. Although ERK1 was activated 
in mitosis as well, it could not replace ERK1c in regulating Golgi 
fragmentation. Thus, ERK1c extends the specificity of the Ras-
MEK cascade by activating ERK1/2-independent processes. 
 
 
ERK3 It is a protein of 62 kDa in size with a C-terminal domain that 
extends 180 amino acids beyond the conserved core of ERK 
family protein kinases and it is ubiquitously expressed in a variety 
of cell lines and tissues (Zhu et al., 1994). ERK3 does not 
phosphorylate typical MAP kinase substrates, indicating that it has 
distinct functions. It has been shown that ERK3 specifically 
interacts with the MAPK-activated protein kinase 5 (MK5 or 
PRAK) in vitro and in vivo (Schumacher et al., 2004). Complex 
formation between ERK3 and MK5 results in phosphorylation and 
activation of MK5, concomitant stabilization of ERK3, and the 
nuclear exclusion of both proteins. 
 
 
ERK4 It is most closely related to ERK3 displaying 62% overall 
aminoacid sequence identity and 73% within the predicted kinase 
domain. Both kinases do not contain the highly conserved 
activation loop motif TXY, substituted by a single phospho-
acceptor site within an S-E-G motif; they both carry long C-
terminal extensions (Kant et al., 2006). MK5 has been evidenced 
to interact also with ERK4 (Aberg et al., 2006) however unlike 
ERK3, ERK4 is a stable protein, and its half-life is not modified by 





ERK5 It is twice the size of other MAPKs (Lee et al., 1995; Zhou et al., 
1995). The amino-terminal half contains the kinase domain (TEY 
activation motif), whereas the carboxy-terminal half is unique. 
ERK5 has nuclear localizing activity in its C-terminal region (Yan 
et al., 2001), owing to a bipartite nuclear localization signal 
(Kondoh et al., 2006). In addition, ERK5 has nuclear export 
activity (Buschbeck and Ullrich, 2005; Raviv et al., 2004), even if a 
NES in ERK5 has not been identified so far. ERK5 is activated by 
several extracellular stimuli, such as stress stimuli and growth 
factors, and it has an important role in several cellular responses 
including cell proliferation and differentiation. Upon stimulation, 
MEK5 phosphorylates and activates ERK5, and then the activated 
ERK5 phosphorylates substrates including myocyte enhancer 
factor 2 (Kato et al., 1997). ERK5, as well as ERK1/2, can also 
induce immediate early genes, such as c-Fos and c-Jun 
(Kamakura et al., 1999; Kato et al., 1997). Recent genetic studies 
have demonstrated that ERK5 is essential for cardiovascular 
development and neural differentiation. The C-terminal region of 
ERK5 has transcriptional activation activity (Akaike et al., 2004; 
Kasler et al., 2000; Terasawa et al., 2003); this region is required 
for the maximum activation of MEF2, peroxisome proliferator 
activated receptor 1 (PPAR 1) and members of the AP1 family, 
like c-fos and Fra1. 
 
ERK6 It is a 45 kDa protein which is highly expressed in human skeletal 
muscle and appears to function as a signal transducer during 
differentiation of myoblasts to myotubes (Lechner et al., 1996). In 
addition it has been observed that levels of mRNA transcript and 
protein abundance for ERK6 are increased during the 
differentiation of 2 rodent myoblast cell lines in culture, in contrast 
to the expression of ERK1 and ERK2 whose expression does not 
change during myogenesis. These results delineate a distinct 
pattern of ERK6 expression in mature skeletal muscle cells and 
suggest a specific role for ERK6 in muscle development or muscle 
function (Tortorella et al., 2003). 
 
ERK7 It is a 61 kDa protein that shares approximately 40% homology  
with ERK1 and ERK2, but nether MEK1 nor MEK2 phosphorylate 
ERK7. Kinase phosphorylating ERK7 have not been identified to 
date. Instead, ERK7 seems to be constitutively active due to 
autophosphorylation. It is known ERK7 phosphorylates the 
transcription factor c-Fos and c-Myc and there are some 
evidences it also phosphorylates the oestrogen receptor- 
(Bogoyevitch and Court, 2004; Henrich et al., 2003). 
 
ERK8 It presents 69% overall homology with ERK7. Serum is the only 
stimulus identified that seems to activate ERK8, through the Src-





BOX 2: MEK binding Partner 1 
 
MP1 is a scaffold protein of about 13 kDa (Schaeffer et al., 1998), that 
has been identified specifically to bind MEK1 and ERK1, but not ERK2, 
presumably facilitating their activation. Signaling pathways in eukaryotic 
cells are often controlled by the formation of specific signaling complexes, 
which are coordinated by scaffold and adaptor proteins. 
I fused MP1 either at the N- than at the C-terminal of EYFP; then I 










I noticed that the localization of MP1-YFP was strictly dependent on the 
concentration of the fusion protein. Indeed, only at very low levels of 
expression I could detect MP1 on the surface of small round shaped 
organelles, which actually reflects its putative involvement in endosome 
signaling. But, as MP1-YFP concentration increases, I can detect the 
protein diffused all over the cellular compartments, resulting in an 
impairment of the correct localization (see Fig. Box 2.2).   
Figure Box 2.2 
NIH 3T3 cells transfected with MP1-EYFP. The first image has been 
acquired at a 4-fold laser intensity; the fluorescent signal results very dim 
and with a low signal to noise ratio. These acquisition parameters are 
required for the detection of cells with the correct MP1 localization, but 
they are inappropriate to conduct prolonged live imaging. 
 
        
This phenomenon probably reflects the fact that there is a limited 
number of binding sites on the membrane of the endosome 
structures, that once saturated cannot retain anymore the protein in 
place,  thus leading to its ectopic delocalization. 
 
 
                                     Concentration 
Figure Box 2.1 
Schematic representation of 
the fusion of MP1 at both 




BOX 3: Long Term Time Lapse  
 
Visualizing chromatin rearrangement in living cells 
Time lapse recording can be used to visualize many kind of cellular and 
molecular processes: here, as an example, I show a recording covering a 
time window of 12 hrs. Specifically, fibroblast were transfected with a 
fluorescent probe for MeCP2 (Methyl CpG–binding protein), a protein 
involved in the transcriptional regulation and epigenetic mechanisms.  
Epigenetics refers to changes in gene expression (e.g. methylation) that are 
stable between cell divisions, and sometimes between generations, but do 
not involve changes in the underlying DNA sequence of the organism.  
MeCP2 is a X-linked gene coding for a protein functioning as a 
transcriptional repressor. It is an abundant component of pericentric 
heterochromatin and its mutations or duplications are present in around 
80% of patients with a neurological disorder known as Rett Syndrome. 
MeCP2  can recognize with high affinity methylated sites on the chromatin, 
because of the presence of a specific recognition domain, the Methyl 
Binding Site. MeCP2 action depends critically on its binding to chromatin, 
indeed the crucial event at the basis of its action is represented by its 
binding to CpG methylated chromatin.  
To study the chromatin rearrangement mediated by MeCP2, the cDNA 
sequence of MeCP2 wt was fused in frame to GFP (Fig. Box 3.1) and then 
















Figure Box 3.1 
Wild type MeCP2 fused with GFP  
WT: Wild Type, MBD: Methyl Binding Domain; TRD: Transcription Repression 




By using long term time lapse, it has been obtained for the first time a direct 
demonstration of the dynamics of chromatin clustering caused by the 
expression of MeCP2, in living transfected cells. This experimental 
approach (Fig. Box 3.2) allows to demonstrate that chromocenters 
clustering proceeded in parallel with the increase of protein concentration 
and that this process invariably involved nearby chromocenters connected 
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(Marchi et al., Epigentics, 2007) 
 
Figure Box 3.2 
Time-lapse imaging of the effects of GFP-MeCP2 expression on chromatin 
structure. 
On the top, time lapse sequence of the nucleus of two NIH3T3 cells transfected 
with GFP-MeCP2. Imaging begun 7 hours after transfection and the cells were 
followed for 13 hours. At the beginning of the imaging session cell 2 is barely visible 
in the first frame of the sequence. As time passes by, the expression of GFP-
MeCP2 increased in both cells. At the bottom it is represented a magnification of 
half nucleus of cell 1, enumerating the different chromocenters present and their 
successively clustering. The graph shows the relationship between the increasing 
concentration of MeCP2 in the nucleus (the concentration increases as time passes 
by after transfection) and the  number of chromocenters and the nuclear size as 
functions of time. During the interval covered by the time-lapse imaging the 






All the experiments in the present study have been conducted in living cells 
minimally perturbed by employing very low level of fusion protein expression; the 
concentration was estimated by comparing the fluorescence of the cells with 
artificial micelles loaded with known concentrations of EGFP (see Methods). This 
approach avoids altering the relative abundance of the chimera compared with 
the endogenous forms and the upstream and downstream elements.  
I generated both the N- and C-terminals fusion proteins for every ERK fusion 
protein tested. The most important experiments were repeated with both the 
configurations with similar results.  
Herein, I will present data concerning the dynamical regulation and functional-
structural differences between the two kinases ERK1 and ERK2. 
 
The ERK1/2 Cascade 
The ERK pathway is very complex and includes many components that integrate 
an enormous variety of stimuli at different levels; I principally focused on: 
• Characterizing biochemical-functional properties of ERK fused to a 
fluorescent protein. 
• Deciphering nuclear translocation dynamics of ERK2, investigating the 
interplay between the activation and deactivation systems; 
• Studying the trafficking rate of the kinases ERK1 and ERK2 through the 
nuclear membrane; 
• Evaluating the effects of ERK trafficking on the signaling to the nucleus; 
• Studying the capability of ERK1 N-terminus of influencing the trafficking 
across the nuclear barrier and the functional outputs. 
Fluorescent probe validation 
 
Checking for correct post-translational modifications 
I fused ERK1 and ERK2 with a fluorescent tag (EGFP) and I transfected the 
plasmid carrying the resultant cDNA in NIH-3T3 cells; then I tested the chimeras 
with a western blot assay to check if they retained the correct size and whether 
they can be correctly phosphorylated (Fig. 14).     
 




















A) Immunoblotting with antibody against GFP displays a band at about 71 kDa in cells 
transfected with an ERK1-GFP vector, a band of 69 kDa in cells transfected with an 
ERK2-GFP vector and a band at 27 kDa in cells transfected with GFP only. 
B) Immunoblotting with an antibody against phosphorylated ERK demonstrates that the 
phospho-specific antibody recognized both the wild type ERK1/2 doublet, respectively 44 
and 42 kDa, and the fusion proteins after stimulation with 10% serum. Experimental 
conditions: Starv: starved, cells kept for 24 hr in 1% serum; Ser: serum, starved cells 
were stimulated for 15 min with 10% serum. 
 
 
Immunoblotting demonstrates that the pERK antibody recognized both the wild 
type ERK1/2 doublet and the fusion proteins after stimulation with 10% serum at 
the expected molecular weight, so the two chimeras can undergo to the same 
post-translational modification as the endogenous forms do, once expressed in a 
cellular system.  
 
Testing the catalytic activity 
Another important issue to be considered is whether the fusion proteins retain 
their catalytic activity on specific substrates. I performed a second in vitro 
biochemical assay to verify the capability of phosphorylating downstream targets. 
I did not address this issue directly on cells, otherwise the test would be 
influenced by the endogenous form, making impossible to reveal the contribution 
coming only from the chimera. For this reason, I have isolated the fusion proteins 
by immunoprecipitation from transfected cells, previously stimulated with serum, 
in order to select a high percentage of activated protein; then I assayed the 
capacity of phosphorylating the purified substrate Myelin Binding Protein (MBP), 
a well known ERK target. Finally, I detected the signal coming from 
phosphorylated MBP, by staining with an anti-pMBP antibody, as shown in figure 
15. 
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Cells were transfected with a vector carrying respectively ERK1-GFP and 
ERK2-GFP; then they were stimulated with 10% of serum for 10 min and 
afterward immunoprecipitated with an anti-GFP antibody. Samples were 
therefore let to react in vitro with the substrate MBP. Finally, they were 
immunoblotted with an anti-phoshoMBP. Both lanes display a strong signal 




The presence of the band at 21 kDa, corresponding to the phosphorylated form 
of MBP, demonstrated that the two chimeras were able to catalyze the 
phosphorylation of the MBP. These results show that the two fusion proteins are 
catalytically active, notwithstanding the presence of GFP. 
 
Chimera localization and expression level 
In resting conditions ERK predominantly localized in the cytoplasm, since it is 
retained by MEK which carries a NES (Adachi et.al., J Cell Biol. 2000). The 
presence of a stimulus (e.g. FGF, serum…) in the external environment induces 
receptor activation and it starts the signaling of Ras, finally switching on ERK 
phosphorylation. The next fundamental step is ERK translocation in the nucleus 
where the two kinases activate specific targets committed to regulate gene 
transcription.  
Immunocytochemistry staining revealed that stimulation for 15 min with FGF 
caused an increase in the phospho-ERK signal and the nuclear localization of the 
fusion protein (respectively, in red and green in Fig. 16), this means that  the 
chimera can be activated by the signal transduction elicited in cells by external 








Subcellular localization of ERK2-GFP 
In starved cells ERK2-GFP (green) was mostly excluded from the nucleus and the 
pERK signal (red) was very low. Conversely, upon stimulation with FGF, ERK2-GFP 
mainly accumulated in the nucleus, colocalizing with a strong pERK signal, which 
indicates that ERKs have been phosphorylated. I stained the nuclei with the DNA stain 
Hoechst 33342 (blue; 10 min in 1 g/ml solution). Cells were imaged by combining 1- 
and 2-photon excitation: ERK2-GFP and pERK fluorescences were excited at visible 
wavelengths (respectively, 488 and 543 nm), whereas Hoechst was excited at 870 nm 















































of ERK2-GFP CI 
Distribution of the 
cumulative probability of 
the Concentration Index 
measured in cells 
transfected with ERK2-
GFP and imaged after 
starvation (red curve) or 
after stimulation with 10% 
serum (P0.001, 
Kolmogorov-Smirnov 
test). Similar results were 
hold for ERK1. 
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In figure 17 I presented a quantification of ERK nuclear accumulation in terms of 
cumulative probability (the integral to the probability distribution); this method is 
very effective in displaying the differences between two populations, regardless 
of their normality (Fig.  17). On the horizontal axis it is reported the value of the 
Concentration Index (CI), which is a measure of the level of nuclear accumulation 
of the protein, defined as the ratio between the mean fluorescence of nucleus  
and cytoplasm (see Methods). 
As I have already reported in the introductory chapter, it is essential to work with 
a low concentration of exogenous protein in order to minimize the perturbation of 
the endogenous homeostatic mechanisms. Indeed, high amount of expressed 
ERK-GFP could result in an anomalous accumulation into the nucleus, even in 
absence of any stimulus. This effect is saturable and it is due to the disruption of 
the relative ratios between MEK and ERK (Fukuda et al., 1997; Lenormand et al., 
1993; Rubinfeld et al., 1999). In previous studies this problem was either ignored 
(Ando et al., 2004) or overcome by co-expressing MEK1 to rescue this 
unbalancing (Burack and Shaw, 2005; Horgan and Stork,  2003). Rather than 
ignoring the problem or introducing a second exogenous protein, I opted for a 
different strategy. I chose to determine an upper limit for the concentration of 
ERK-GFP that is low enough to be compatible with the normal cell physiology, 
but that it is  sufficient to allow confocal imaging. 
To estimate ERK-GFP concentration I compared the fluorescence of the cells 
with the  fluorescence of artificial cells loaded with known concentrations of 
EGFP. In this way I can verify whether the abundance of expressed chimera 
influences its relative distribution  between the nucleus and the cytoplasm. I 
quantified ERK localization by means of the Concentration Index. Figure 18 
shows that cells with higher concentrations of  ERK-GFP exhibited a pronounced 
nuclear localization of the chimera. This distribution is not due to ERK activation 
since cells have been starved for 24 hr before imaging, but it depends only from 
the threshold saturation of the cytosolic anchor. This plot allows to estimate the 
upper limit of ERK-GFP expression which is compatible with a physiological  


































The graph shows the relationship between the transfection level in terms of [ERK2-GFP] 
(fluorescence averaged on the entire cell) and the nuclear localization of starved cells, 
measured by the Concentration Index. The dotted line indicates the upper level of 
expression that I accepted in my experiments (150 nM). To extend the measures on two 
decades I used varying laser power according to the best imaging conditions for each 
cell: data were pooled together after normalization to reference imaging conditions. The 




These data demonstrate that ERK-GFP localization was normal up to about 150 
nM and  that nuclear accumulation saturated at concentration larger than 1.5 µM 
(Fig. 18). In about 80% of the cells included in this study the concentration of 
ERK-GFP was 100 nM. Additionally, I have excluded cells that, notwithstanding 
the low fluorescence, exhibited visible nuclear accumulation in the starved state.  
 
   
 Resolving spatiotemporal dynamics of the ERK activation/inactivation  
 
Notwithstanding the centrality of the process of ERK translocation, most of the 
dynamical details of this event are still unknown. I focused on the kinase ERK2 
and I tried to elucidate various aspects of the translocation event analyzing the 
contribution of the different counterparts in a living system with the application of 
specific inhibitors. 
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ERK2 in action: the nuclear translocation 
I evaluated nuclear translocation properties recording several groups of cells 
transfected with ERK2-GFP and following their distribution after stimulation, 




































ERK2-GFP translocates in living cells after stimulation.  
A) In cells stimulated with 20% serum translocation can be discerned as early as about 4 
min from stimulation; the process reached the maximum peak in about 10 min.  
Bar 20 µm.  
B) Cumulative time courses of the translocation index of cells stimulated with FGF4 (80 
ng/ml, blue, n=9) or with serum (10%, green, n=15). The vertical bars are representative 




After an initial latency, ERK2-GFP rapidly concentrated into the nucleus reaching 
90% of response within about 9 minutes from the onset of stimulation. I 
presented these data plotting the normalized CI in function of time. The 
translocation of the N- and C-terminal fusion proteins followed a similar time 
course excluding a dependency from allosteric influence of the GFP on specific 
ERK domains. I confirmed the generality of the result presented before finding 
similar translocation behaviors in other cellular types. In particular I tested NIH L1 








Demonstration of the 
nuclear accumulation 
of ERK2-GFP in two 
additional cell types.  
A) NIH L1 
preadipocytes were 
starved for 24 hr in 1% 
serum before 
stimulation with 10% 
serum. Bar, 20 m. 
NIH-L1 preadipocytes 
were cultured 
according to ATCC 
protocols. In both 
panels time 0 indicates 
the beginning of 
stimulation. 
B) Primary fibroblasts 
were starved 24 hr 
prior to the experiment 
and stimulation with 
FGF4. Primary 
fibroblasts were 
dissociated from the 
tail of an adult mouse 
and transfected at 
passage 3. Both cell 
types were transfected 
and imaged as 
described for NIH-3T3. 
 
 
Then I compared the responses induced by FGF and different concentrations of 
serum in NIH 3T3: initially, serum and FGF4 produced similar responses 
activating a monotonically increasing translocation; after 20 min from the 
stimulus, the serum-induced response declined gradually, while FGF4 caused 







































































A)-B) Series of images representing cells at three different times during the experiment, 
respectively with serum (A) and FGF stimulation (B). Bar, 20 m. 
C) Cumulative time courses of ERK2-GFP nuclear accumulation, in terms of CI, after 
stimulation with two different doses of serum (green, 10%, n=7; yellow, 1%, n=8) and 














































A) Cells have been stimulated with FGF4 (80 ng/ml) for only 4 min. The fusion protein 
exhibited a transient translocation. Bar 10 µm.  
B) Cumulative time course after 4 min of stimulation (red trace, n=15) compared with 
the kinetic of the response to a stationary stimulus (blue trace). The vertical bars are 
representative of the standard error during imaging. 
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Interestingly, 1% serum gave a  response of smaller amplitude respect to the 
maximum stimulation obtained with 10% serum; this might reflect the smaller 
amount of ERK which is recruited for translocation. I have also looked into the 
temporal fidelity of ERK nuclear accumulation following the stimulus temporal 
profile, by treating the cells with a brief presentation of FGF4. Cells were 
stimulated with FGF for only 4 minutes, washing away the stimulus from the 
recording chamber afterwards (Fig. 22). 
Initially, ERK2-GFP concentration in the nucleus increased like it happened with 
the response to a stationary stimulus; however soon after peak the CI declined 
exponentially, almost to baseline level. Notice that the presence of the stimulus is 
not simultaneous to the response, suggesting that the delay observed is required 
to start up the pathway machinery and to transduce the activation signal in the 
ERK-specific output. Besides, this experiment demonstrated that a continuous 
stimulation is a necessary condition to sustain ERK translocation. 
 
MEK and Phosphatases: the hero and the villain? 
Activators and deactivators rigorously play their roles in the plot of ERK life; they 
simultaneously and continuously act to settle ERK fate. During time lapse 
recordings I applied selective drugs that selectively affect either the activation or 
the inactivation pathway. This approach represents a powerful method of 
investigation: it makes possible to dissect the underneath dynamics between 
these regulatory proteins (Fig. 23) and to measure separately their activities.       













In resting condition ERKs are retained by MEK in the cytoplasm; once the pathway is 
activated, MEK doubly phosphorylates ERK1 in Thr203/Tyr205 and ERK2 in 
Thr183/Tyr185 (Mus musculus). ERKs translocate into the nucleus where they can act on 
their substrates. In the nucleus ERKs can only be dephosphorylated by nuclear 
phosphatases. As I will show later on, ERKs can bidirectionally pass the nuclear barrier in 
both states: phosphorylated or dephosphorylated. 
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In starved cells the upstream pathway would not necessarily be totally 
deactivated: ERK might be regulated by the dynamic equilibrium of a moderate 
basal activity of the Ras-MEK1-ERK1/2 module with competing phosphatases. 
The rational of this basal under-threshold activity of MEK is the maintenance of 
the pathway in a state ready to quickly answer to changes coming from the 
extracellular environment. 
This putative basal activity should be revealed by the blockage of 
dephosphorylation. Indeed, in resting conditions the majority of ERK molecules 
are bound to MEK in the cytoplasm, so whether MEK basal activation was 
present, I should observe a progressive accumulation of ERK in the nucleus upon 
administration of the phosphatase inhibitor. Indeed, upon perfusion of starved 
cells with 1 mM of sodium-orthovanadate, ERK2-GFP began to accumulate in the 
nucleus within few minutes (Fig. 24).  
The accumulation of ERK2-GFP in the nucleus gradually increased throughout 
the duration of the imaging period (up to 1 hour). This demonstrates that even 
after 24 hours of serum deprivation, the ERK1/2 pathway is undergoing some 
basal activation that in normal conditions is equilibrated by a corresponding level 












































Treatment with the phosphatase inhibitor Sodium Orthovanadate caused gradual nuclear 
translocation.  
A) Cells expressing ERK2-GFP before orthovanadate treatment (1 mM), 30 and 50 min 
afterwards. Calibration bar 20 m. 
B) Starved cells were treated with the phosphatase inhibitor at time 0.  
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This nuclear accumulation occurs in parallel with ERK activation, as 










































Inhibition of phosphatase causes ERK phosphorylation and translocation.  
A) Immunocytochemistry with the pERK antibody conducted on starved cells 
treated with sodium orthovanadate (1 mM) for 40 min before fixation. 
Representative images of pERK distribution in starved cells and during 
treatment with phosphatase inhibitor are shown. Bar 20 µm.  




Interestingly, the nuclear accumulation caused by the phosphatase inhibitor (Fig. 
24) is much slower than the change observed after stimulation, as indicated by 
the time constants of the two processes (= 26 min, after phosphatase inhibitor 
treatment, and = 3.3 min after FGF stimulation). This slow kinetics is likely to 
reflect the fact that MEK basal activity is much smaller than after activation. 
However, it is not possible to overstretch this interpretation because the speed of 
permeation of the inhibitor in living cells is unknown. 
The experiment upon presented outlines an essential feature of the MEK-ERK 
system: the push-pull regulation by activating and inactivating mechanisms 
operating also at a basal level of  activity. If a similar dynamical equilibrium 
between phosphorylation and dephosphorylation holds also after activation by 
extracellular stimuli, it would be expected that the sustained nuclear accumulation 
caused by FGF4 would require continuous activation of the MEK1-ERK pathway. 
To shed light on this issue, I treated the cells expressing ERK2-GFP with U0126, 
after 15 min of stimulation with FGF4 (Fig. 26): this caused the immediate 
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decrease of ERK-GFP concentration in the nucleus. The speed of this process 
(=3 min, see Fig. 27) showed that U0126 diffused rapidly in the intracellular 
medium and that its effect was very fast. It appears evident that the drug 
permeation is not a rate limiting factor: U0126 seems to be able to cross the 








































ERK2 activation and consequent translocation required continuous activation 
of the MEK-ERK pathway.  
A) Cells were treated initially with FGF and 15 min later, with 20 µM U0126. 
Blockage of MEK caused the rapid loss of nuclear fluorescence. Bar 20 µm.  
B) Averaged time course.  
 
 
ERK activation and localization are determined by the balance between two 
competitive reactions: phosphorylation and de-phosphorylation. Phosphatase 
activity converts ERK in an inactivated state by dephosphorylation and during the 
steady-state phase of ERK response, this process is balanced by the 
phosphorylation operated by MEK. In the experiment shown in figure 26 the 
addition of the MEK inhibitor, U0126, impairs the steady state equilibrium causing 
ERK2-GFP outflux from the nucleus. 
To allow a better comparison of the time course of all the processes that have 
been described so far, the change of CI in response to the different treatments 
has been normalized between 0 and 1 and it is displayed in figure 27. Time 0 
corresponds to the beginning of treatment of naïve cells with FGF4 or 
orthovanadate and of FGF-treated cells with U0126. The continuous lines are 
exponential fits to the experimental data: the time constant of the loss of ERK 
concentration from the nucleus is 3.0±0.13 min (R2=0.99, blue curve), similar to 
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the FGF-induced response (=3.3±0.12 min, R2=0.99, green curve). In 
comparison, the rate of nuclear accumulation induced by the block of 
phosphatases in starved cells is much lower (=26±0.48 min, R2=0.98, red 
curve), suggesting that upon stimulation the rate of ERK2 phosphorylation 
increased by almost a factor of ten. The latency of the effect of U0126 is virtually 
zero, demonstrating that imported ERK2 is rapidly dephosphorylated and 
exported from the nucleus. In normal conditions the response to FGF4 is seen as 
ERK2 sustained translocation because of the influx of phosphorylated ERK2; the 
ihibition of MEK1 bloks this continuous influx and unveils the inactivation process, 
especially in the nucleus.  
 
 
































Comparison of the time course of ERK2-GFP translocation in response to FGF, 
FGF4+U0126 and orthovanadate. 
Traces have been normalized from 0 to 1, with 0 indicating the CI at the time of 
administration of the specific compound and 1 indicating the asymptotic value of the 
exponential fits. The decline of Concentration Index caused by U0126 (empty circles) 
has been inverted for a better comparison with the other data. The continuous lines are 
exponential fits to the top 80% of the data points. 
 
 
Summarizing these last experiments, I have shown that by disrupting the steady-
state balance between the activator MEK and the inactivators Phosphatases, I 
obtained the following results: 
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° MEK inhibition caused a net ERK outflux from the nucleus originated by 
phosphatase activity, that was balanced no more, demonstrating that 
phosphatases continuously counteract ERK activation;  
° Phosphatase inhibition caused ERK accumulation into the nucleus; this 
demonstrates that in starved conditions phosphatase activity is required to 
counteract basal activation of the Ras-ERK module. 
 
Whether these considerations were true, I would expect that even at the 
maximum of ERK translocation, a fraction of dephosphorylated ERK is still 
present, due to the continuous activity of phosphatases. The continuous 
operation of phosphatases implies that, after stimulation, nuclear ERK is only 
partially phosphorylated and the residual inactive ERK should be revealed by 
blocking phosphatase activity, after having strongly stimulated the pathway. Cells 
expressing ERK2-GFP were treated with FGF and, within about ten minutes, 
ERK accumulated in the nucleus; at this time I added the phosphatase inhibitor 
and in response nuclear ERK2 equilibrated at a higher steady-state level (Fig. 
15). This treatment unmasked a small but significative fraction of ERK not 
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FGF4 alone was not sufficient to cause maximal translocation. 
A) ERK2-GFP distribution before in starved condition (baseline), after 15 min from the 
FGF administration and in co-presence of orthovanadate and FGF (30 min). Bar 20 µm 
B) Cells were treated initially with FGF4 and with orthovanadate 15 min later, which 




This experiment demonstrates that nuclear ERK is only partially phosphorylated 
during steady stimulation with FGF. Comparing the results shown in figure 24 and 
28, it is interesting to notice that ERK nuclear accumulation following 
orthovanadate addition in resting cells (Fig. 24) is slower respect to what I 
obtained in activated cells (Fig. 28). Exponential fit gave respectively the 
following time constants: 26 min versus 4 min. This striking difference permits to 
exclude the hypothesis that the slow rate of ERK nuclear accumulation in starved 
cells is due to an intrinsic difficulty of the drug to penetrate cells, but it rather 
seems to reflect a real kinetic property of the occurring process.  
 
 
ERK1 and ERK2: focus on nucleo-cytoplasmic shuttling properties  
 
Do ERK1 and ERK2 display different temporal patterns of localization? 
It is well established that ERK1 and ERK2 are activated by the same upstream 
kinase MEK and, in accordance, they share the putative recognition regions. 
Indeed ERK2-GFP and ERK1-GFP translocated to the nucleus with the same 
kinetics upon stimulation with FGF4 (Fig. 29 A,B). Specific residues at the C-
terminal segment of ERK have been proposed to play a key role in the docking to 
substrates and phosphatases, as well as to MEK1/2 (Rubinfeld et al., 1999; 
Tanoue et al., 2000; Xu and Goldfarb, 2001). Furthermore, phosphatases seem 
to interact with both ERK1 and ERK2 (Pulido et al., 1998; Tanoue and Nishida, 
2002); so I can suppose that phosphatases react with the two kinases with the 
same affinity.  
Even if these considerations suggest an identical regulation for ERK1 and 2, I 
was curious to see whether I might detect some difference in the dynamics of the 
activation/inactivation processes. To this effect, I repeated the FGF-U0126 
experiment shown above (Fig. 26) with ERK1-GFP. Surprisingly, this experiment 
revealed a dramatic difference between ERK1 and 2. 
As it can be noticed from figure 29, upon FGF administration both kinases 
translocated with identical kinetics (Fig. 29 A,B), reaching the peak within 15 
minutes. After blockage of MEK activity with the U0126, the behaviuor of ERK1 
and 2 drastically diverged: the loss of ERK1 from the nucleus was much slower 
than ERK2 ( = 9.3±1.3 min for ERK1-GFP versus  = 3.0±0.1 min for ERK2-








































































































ERK activation required continuous activation of MEK-ERK pathway. 
A-C) Selected frames displaying ERK1 and 2 localization at the time points 
indicated by the red arrow heads in panel B-D  Bars 20 µm in all panels. 
B) Cumulative nuclear translocations of ERK1 (green, n=18) and ERK2 
(magenta, n=12). 
D) Cells were treated initially with FGF and 15 min later with 20 µM U0126. 
Blockage of MEK caused nuclear fluorescence loss with different kinetics for 
ERK1 (pink, n=9) and ERK2 (green, n=10); the averaged time courses are 






This phenomenon underlines again the dynamic regulation of ERK localization 
and, more interestingly, it suggests that, although the two kinases share common 
partners and undergo to the same regulatory mechanisms, there might be crucial 
differences in the true nature of these proteins that have been overlooked until 
now.  
Looking in more details at the particular experimental conditions, I can draw 
some considerations in order to clarify the real meaning of these results. ERK 
activation is continuously counteracted by phosphatases, which operate both in 
the nucleus and in the cytoplasm. In the condition of maximal stimulation (at the 
peak of the nuclear accumulation after FGF addition), phosphatases dispose of a 
high abundance of substrate (p-ERK) in the nucleus, so they begin to 
dephosphorylate ERK immediately. After MEK blockage, the predominant 
contribution to the net ERK efflux across the nucleoporins is likely to be 
constituted by dephosphorylated ERK. A simple explanation of the differences 
observed between ERK1 and ERK2 might be due to a different capability of 
crossing the nuclear membrane. Following this idea, figure 29 C,D would suggest 
that in the dephosphorylated state ERK1 crosses the nuclear membrane more 
slowly than ERK2. In order to clarify this aspect I designed specific experiments 
of photobleaching to study the trafficking across the nuclear barrier of ERK1 and 
2. 
 
Nucleo-cytoplasm exchange of ERK1 and ERK2 
To study ERK trafficking across the nuclear barrier, I measured the recovery of 
ERK-GFP fluorescence after photobleaching of the nucleus. Given that photo-
bleaching is irreversible, any recovery of nuclear fluorescence must be due to the 
influx of unbleached ERK-GFP from the cytoplasm. Since the protein 
concentration in the nucleus is left unaffected by photobleaching, this influx is in 
equilibrium with an equal efflux of bleached chimera and the time constant of the 
recovery is inversely proportional to the permeability through the nuclear 
membrane. 
The shuttling must be fast enough to replenish a pool of nuclear pERK that is 
dephosphorylated and exchanged with the cytosol through a process with 
3 
min. I can compute two important parameters from nuclear FRAP experiments: 
the speed of protein exchange between the two compartments and the fraction of 
immobilized protein inside the nucleus. Cells transfected with ERK1-GFP or 
ERK2-GFP have been photobleached for few seconds in the nucleus, then the 
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recovery of fluorescence has been imaged until equilibrium is re-established. The 
traces of the recovery were fitted with remarkable accuracy by a single 
exponential in all measured cells; therefore, the process can be described by its 
time constant τ and asymptotic value. τ is related to the speed of protein shuttling 
across the membrane, and the asymptotic value can be used to calculate the 
immobile fraction (see Methods). I measured the shuttling time constant of ERK1 
and 2 in two fundamental conditions: starved and after stimulation with FGF.  
Figure 30 shows that ERK2-GFP is continuously exchanged between nucleus 
and cytoplasm and that the turnover accelerated after activation, as 
demonstrated by the time course of the fluorescence recovery before and after 
stimulation. 
I repeated the FRAP measure on ERK1-GFP expressing cells. The fluorescence 
recovery of the two kinases exhibited strikingly different values of τ (Fig. 31), in 
particular ERK1 was remarkably slower respect to ERK2, both in starved 
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ERK2-GFP continuously shuttles through the nuclear membrane.  
A) Images of two cells recorded during a nuclear FRAP experiment in starved 
conditions (upper sequence) and 30 min after stimulation with FGF4 (80 ng/ml). Bar 10 
µm.  
B) Time course of the recovery of the nuclear fluorescence in the cell indicated by the 
red arrow in A. Stimulation caused a faster turnover of ERK2-GFP through the nuclear 
membrane since the time constant of the fluorescence recovery decreased from 144 s 
down to 69 s. A similar effect occurred to the upper cell in A (starved τ=236 s; FGF4 
τ=84 s). The exponential fit of the fluorescence recovery (continuous lines) is used to 
compute time constants.  
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Comparison of the nucleo-cytoplasmic shuttling of ERK1 and 2 in starved conditions.  
A) Series of images collected during the nuclear fluorescence recovery of a cell 
transfected with ERK1-GFP (at the top) and ERK2-GFP (at the bottom). ERK1 
fluorescence recovered more slowly than ERK2, indicating a slower turnover of ERK1 
across the nuclear membrane.  
Calibration bar 10 µm.  
B) Time course of the fluorescence recovery of the cells showed in A. Data points were 
well fitted by single exponentials with respectively the following time constants (τ) of 





Since ERK1 is heavier than ERK2 I felt necessary to wonder whether the 
difference in shuttling speed might be simply due to their different size, which 
obviously affects permeation though the nuclear pore. For this reason, I studied 
the trafficking of two molecules of different molecular weight undergoing passive 
diffusion: a GFP monomer and a dimer GFP-GFP (54 kDa), which serve as 
control of size-limit. The monomer shuttled very rapidly with a rate slightly faster 
than activated ERK2-GFP (respectively 58 s ± 5 s versus  84 s ± 5 s; Fig 32), in 
spite of the fact that ERK2-GFP is far heavier (69 kDa ERK2-GFP vs. 27 kDa 
GFP). Interestingly, the dimer GFP-GFP was much slower if compared with all 
the other proteins (1360 s ± 171 s vs. 654 s ± 43 s of ERK1-GFP and 267 s ± 26 
s of ERK2-GFP, both in in starved cells; Fig. 32), even if it is sensibly smaller that 
both ERK1-GFP and ERK2-GFP. This demonstrates that ERKs-GFP must diffuse 








































Figure 32  
Mean time constants 
of ERK1 and 2 GFP-
tagged, GFP alone 
and double GFP 
nucleo-cytoplasmic 
shuttling.  
The time constant is 
not proportional to the 
increasing molecular 
weight as 
demonstrated by the τ 
obtained with the 
double GFP (in black, 
54 kDa against 69 kDa 
of ERK2, in red, and 
71 kDa of ERK1, in 
green). Although GFP-
GFP has a slightly 
smaller molecular 







Since the time course of the fluorescence recovery was rather variable between 
different cells, I thought necessary to perform the FRAP experiments in the same 










































































Scatter diagram correlating the time constant of the recovery and Concentration Index  
The two panels show the measures performed for ERK1-GFP and ERK2-GFP. A similar 
accelerating trend clearly emerged in all of the paired cells considered.  
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I wondered about the possible cause of the striking difference between the 
nucleo-cytoplasmic exchange of ERK1 and ERK2. Since they share all the major 
regulatory components (see Box 7), I hypothesized that the secret should be hold 
somewhere in the protein structure. For this reason I compared the primary 
aligned sequences (Fig. 34) in order to identify some crucial region or single 
residues which could be responsible of such behavior.  
 
 
ERK1 N-terminus: a key domain for understanding functional differences 
between ERK1 and ERK2? 
 
Comparison of the sequences of ERK1 and ERK2  
The two kinases have been considered for a long time simply as isoforms, which 
undergo to the same regulatory mechanisms and that are responsible for the 
same biological outputs. Nevertheless, the high degree of evolutionary 
conservation through a widespread phylogenic scale rises some doubts about 
their interchangeability: why evolutionary driving force should have maintained 
two almost indistinguishable isoforms? Which would be the real advantage of 
that? Actually several evidences have recently come to light that pointed out to 
relevant differences between the two kinases (see introductory chapter). Suffice 
to say that, while the ERK2 knockout is lethal at very early stages of the 
development, the ERK1 knockout is perfectly vital, exhibiting only some deficits in 
tymocyte maturation and, surprisingly, small but striking differences at the level of 
the nervous system (Mazzucchelli et al., 2002; Pages et al., 1999). In the 
previous pages I have reported a surprising difference between ERK1 and ERK2 
at a completely different level. I decided next to investigate which domains of 
ERK1 and ERK2 might be responsible for the trafficking differences that I have 
just described. Comparing the aligned amino acidic sequences (Fig. 34), it can be 
noticed that there are several isolated differences (darker colored characters in 
figure 34) distributed all over the two proteins. None of these residues are located 
in mapped functional domains (Box 7). The major difference resides in the N-
terminus of ERK1, which contains a region completely absent in ERK2. I sought a 
way to ascertain whether this region holds a key for the understanding of the 














Erk1 MAAAAAAPG GGGGEPRGTAGVVPVVPGEV EVVKGQPFDV
Erk2 MAAAAAAGP                      EMVRGQVFDV
 
Figure 34 
Aligned primary amino acidic sequences of the two kinases (Mus musculus).  
Bold represent different residues. Underlined residues have been demonstrated for ERK2 




I chose the strategy of deleting portions of ERK1 N-terminus and consequently 
verifying whether these changes alter the trafficking properties of the modified 
ERK1-GFP. To implement this idea, I have analyzed the N-terminus of ERK1 in 
more details identifying three regions (Fig. 35): 
1. aa 1-9, an alanine enriched cap in common with ERK2 (region 1, blue box); 
2. aa 10-29, an unique sequence present only in ERK1 (region 2, red box); 
3. aa 30-39, a homologous, but not exactly identical, domain respect to ERK2 
(region 3, green box). 
 
Erk1 MAAAAAAPG GGGGEPRGTAGVVPVVPGEV EVVKGQPFDV
Erk2 MAAAAAAGP                      EMVRGQVFDV                                              
Putative SH3 domain




Comparison between the N-terminal of ERK1 and ERK2  (Mus musculus). 
Dotted lines indicate different aminoacids. The domain PVVP in region 2 has been 
identified as a putative SH3 domain interaction sites with the SH3-Hunter web server 
(Ferraro et al., 2007). 
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Such organization does not pretend to formally classify functional domains, but it 
only represents a simple way to dissect ERK1 N-terminus in distinct 
compartments to clarify the involvement of each one in ERK1 shuttling.  
I opportunely designed, different transgenes selectively deleting one or more of 
the domains displayed in figure 35; then I tested the resulting truncated derivative 
by measuring the shuttling rate through the nuclear envelope, both in starved 
condition and upon stimulation with FGF4 (Fig. 36).   
Surprisingly, the deletion of the entire N-terminus of ERK1 (in the deleted 
proteins E1	7-39 or E1	39) converts the characteristic slow phenotype in a faster 
one (very similar to ERK2), suggesting that the N-terminus is able, per se, to slow 
down the permeation through the nuclear envelope. This observation suggests 
that the difference in shuttling is due to the N-terminus, so, in the following 
experiments, I focused only on this region.  
Interestingly, the partial deletion in E1	26 showed an intermediate result. In 
contrast, the deletion of the poly-A sequence (aa 1-7) did not alter trafficking (not 
shown); this is in accordance with previously results which showed that the 
deletion of ERK2 N-terminal from Ala3 to Ala7 did not impair the interaction with 
MEK, the protein localization and the kinase activity (Eblen et al., 2001). These 
data encouraged us to attempt the opposite approach: would it be possible to 
transform the shuttling properties of ERK2 to ERK1 by fusing the N-terminus of 
ERK1 to ERK2? To answer to this question I opportunely fused the N-terminus of 















GEV  EVVKGQPFDV  GPRYTQLQYIG…
GPRYTQLQYIG…
MAAAAAAPG                                   GPRYTQLQYIG…
MAAAAAAPG GGGGEPRGTAGVVPVVPGEV  EVVKGQPFDV  GPRYTQLQYIG…



















































ERK1 N-terminus is responsible for slowing down the nucleo-cytoplasmic 
shuttling.  
A) ERK1 wild type (from Mus musculus) contains a series of aminoacids at 
its N-terminus which are not present in ERK2. I produced fusions with GFP of 
three different deletions of ERK1, as indicated in the diagram.  
B) The time constant of the nucleo-cytoplasmic shuttling of ERK1 mutants is 



































MAAAAAAPG GGGGEPRGTAGVVPVVPGEV  EVVKGQPFDV  GPRYTNLSYIG…
MAAAAAAPG GGGGEPRGTAGVVPVVPGEV  EVVKGQPFDV  GPRYTQLQYIG…











































Fusion of ERK2-GFP with the N-terminal of ERK1 (39E2).  
A) Alignment of the N-terminus of ERK1, ERK2 and 39 E2.  
B) The domain added at the ERK2 N-terminus considerably decreases the 
speed of nucleo-cytoplasmic turnover both in the starved (t-test E1 vs. 	39E2, 





As predicted, the shuttling rate across the nuclear membrane of the new fusion 
protein changed accordingly: the trafficking of 	39E2 was much slower than ERK2 
wt (Fig. 37 B).  
In conclusion, I can propose some considerations about the specific role of each 
of the three regions of ERK1 N-terminus:  
° The alanine rich cap (1-9 aa) does not seem to play any role in controlling the 
shuttling rate given that its absence did not change the trafficking (E1	7-39 
and E1	39 showed indistinguishable results). This suggest that the region 1 
(in particular aa 1-7) is not involved in the passage across the nuclear barrier. 
° Conversely, the protein lacking aa 1-26 (E1	26) gave an intermediate results 
between ERK1 wt and ERK2 wt. This deleted protein completely lacks the 
region 1 (that I demonstrated not being involved in the shuttling) and almost 
the entire region 2 (aa 10-26 respect to 10-29); consequently I can conclude 
that region 2 seems to be heavily involved in this phenomenon, although not 
uniquely responsible. 
° E1	39 lacks the entire N-terminus (all the regions: 1, 2 and 3) and only in this 
condition the slow phenotype of ERK1 shuttling can be completely reverted 
into the ERK2. I can conclude that also region n.3 (aa 30-39) contributes to 
slow down the rate of trafficking. 
In the following I will investigate in more details the involvement of each region, 
by directly fusing fragments of the ERK1 N-terminus to GFP and studying their 
behavior in terms of nuclear shuttling. 
 
 
ERK1 N-terminus: specific functional domain or steric hyndrance for nuclear 
access? 
I demonstrated that ERK1 N-terminus influences the kinetics of nuclear shuttling 
as a sufficient and necessary condition; but I did not provide any possible 
explanation concerning the involved mechanisms.  
The slowing down of ERK1 shuttling rate could be explained by hypothesizing 
that the folding of the N-terminus masks the sites on ERK structure which are 
responsible of the interaction with nucleoporins, thus impairing ERK1 capability of 
passing through the pores. In other words, the slower trafficking would be not 
caused by specific interactions of the N-terminus, but it would simply be an 
indirect effect caused by its steric hindrance. To test this hypothesis I decided to 
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directly fuse GFP with ERK1 N-terminus (Fig. 25) and to measure the velocity of 
nucleo-cytoplasm exchange by FRAP experiments.  
First of all I produced a series of N-terminus fragment fused to GFP, including 





































































































A) Alignment of ERK1 N-terminus of different lengths fused to the GFP, the GFP alone 
and a random sequence of comparable length, fused to GFP, in order to exclude that 
results would simply be affected by the heavier molecular weight. 
B) All the ERK1 N-terminal proteins showed an unquestionable slower behavior 
compared to the controls.  
GFP-	N1-39 and 	N1-39-GFP were not significantly different, so I pooled together all the 
relative data. GFP-	N1-27 showed an intermediate time constant, significantly different 




These data clearly show that ERK1 N-terminus is able per se to slow down the 
speed of exchange across the nuclear envelope (Fig. 38 B) and this property is 
not related with its size, since a protein obtained by fusing GFP with a random 
sequence of similar lengt to the N-terminus (GFP-Mock) behaves exactly like 
GFP. In addition, I can exclude that this terminal region would mask some critical 
sites on the ERK ternary structure responsible of the interaction with 
nucleoporins, indeed, this peptide succeeded in slowing down also the GFP. 
A second interesting aspect clearly emerges from these results: the two truncated 
domains fused to GFP (GFP-	N1-39  and  GFP-	N1-27) decreased the shuttling 
rates to a different extent. Specifically, GFP-	N1-27 was faster than GFP-	N1-39, 
but it resulted  significantly different from the GFP and the random sequence. 
These data confirm that the “slow” phenotype is due to the combination of at least 
two factors, one connected with the region 2 (aa 9-29) and the other one related 
to region 3 (aa 30-39). I believe that the slow rate of trafficking could be due to 
protein-protein interactions mediated by specific domains of ERK1 N-terminus. I 
decided to investigate which aminoacids confer such phenotype, generating a 
series of mutagenized derivatives of region 2 and 3 of ERK1 N-terminus. I tested 
the following two non exclusive hypothesis:  
1. In region 2, the sequence presents a putative SH3 domain recognition site. It 
can be supposed that the PVVP site might interact specifically with a SH3 binding 
partner and that this interaction might be somehow responsible for the slower 
permeation. To verify the importance of this particular site, I generated a series of 
mutations targeted to one or both the prolines (the SH3 recognition site is a 
proline-rich sequence with the basic motif PxxP) and a deletion of the whole 
region PVVP (Fig. 39).  
2. In region 3 of ERK1 there are only three different aminoacids respect to the 
homologous region of ERK2 (Fig. 39). I mutated V31 and K33 converting them in 
alanine (aminoacid with a very small lateral chain and characterized by low 




Erk2 MAAAAAAGP              ---- EMVRGQVFDV…








Mutagenized ERK1 N-terminus  
Figure displays the wild type N-terminus of ERK1 and ERK2 evidencing the putative SH3 
interactor site and the two different aminoacids: V31 and K33. 
Mutagenized sites are reported in the magnification under the sequences; aminoacids 







The same design of mutagenesis was applied both to the N-terminus of ERK1 
fused to the GFP (GFP-	N1-39) and to the entire wild type ERK1 fused to GFP. 
In order to verify and/or exclude some of the upon presented hypothesis I tested 
all the new mutants by measuring the time constant of shuttling trough the 
nuclear envelop (Fig. 40). In the following, I will first present the data from GFP-

























MAAAAAAPGGGGGEPRGTAGVV  PVVP GEVEVVKGQPFDV
MAAAAAAPGGGGGEPRGTAGVV  AVVP  GEVEVVKGQPFDV
AVVA  
- - - -































































































































A) Aminoacidic composition of the mutagenized ERK1 N-terminus. All the mutants have 
been fused either to the N- or C- terminus of GFP, obtaining identical results. 
B) Cumulative data of nucleo-cytoplasm shuttling of mutants. 
All the cells have been measured in starved conditions. Only the mutant N-V31A-K33A 
showed a faster shuttling respect to the control (p=0.02). There were not significative 






The modification of the putative SH3 interacting site did not give any different 
result compared to the control, in any kind of rearrangement of the target 
sequence. This suggests that, even if some interacting sequence might exist, it 
does not interfere with the nuclear trafficking. Conversely, the neutralization of 
V31 and K33 conferred a strikingly faster rate of exchange. This is quite surprising 
given that, although ERK1 and ERK2 show different aminoacids in position 31 
and 33 these residues can be classified as belonging to the same chemical 
category. Indeed, ERK1 has a valine instead of a methionine in position 31, both 
non polar aminoacids, and a lysine instead of an arginine in 33, both positively 
charged. I converted the valine and the lysine in alanine, a very small non polar 
aminoacid, because alanine has not a large lateral chain so its insertion 
presumably does not overstretch or distort the entire structure. In addition, its low 
reactivity should not influence neighboring residues.  
The conversion of V31 and K33 in alanine sensibly affects the nuclear turnover of 
ERK1 N-terminus leading to a faster rate of exchange across the nucleus respect 
to the control (Fig. 40; p=0.02), even if this modification is not sufficient to obtain 
a GFP-like behavior. This probably means that V31 and K33 are determinant for 
slowing down the passage though the nuclear pores, but not uniquely 
responsible. This is consistent with the data shown before (Fig. 36), thus 
confirming the presence of some kind of cooperation with the upstream residues 
of the region 2.  
I can hypothesize that the entire N-terminal peptide undergoes to a specific 
folding, which takes in proximity the aminoacids V31 and K33 (region 3) with the 
residues of region 2, creating a ternary complex which is responsible for the 
effect I observed. As a further control, I mutagenized also the entire ERK1, in the 
same way as it has be done for the isolated N-terminus (Fig. 41). As all the 
manipulation on PVVP site gave identical results and they did not differ from the 
control. In contrast, the neutralization of V31 and K33 confirmed the result of a 











MAAAAAAPGGGGGEPRGTAGVV  PVVP GEVEVVKGQPFDV …
MAAAAAAPGGGGGEPRGTAGVV  AVVP  GEVEVVKGQPFDV …
AVVA      
- - - -
MAAAAAAPGGGGGEPRGTAGVV  PVVP  GEVEAVAGQPFDV …
















































































































A) Aminoacidic composition of the mutagenized N-terminal portions of 
ERK1. 
All the mutants have been fused either to the N- or C- terminus of GFP, 
obtaining identical results. 
B) Cumulative data of the shuttling time constants. Only the mutant E1-
V31A-K33A showed a faster shuttling respect to the control (p<0.05). There 
were not differences between all the modified E1-terminus at the PVVP, so 
I pooled together all the data. Comparing  E1-V31A-K33A and the modified 









Effects of the shuttling rate on ERK phosphorylation: a quantitative model 
What are the functional consequences of the slower trafficking of ERK1? Since 
ERKs are activated in the cytoplasm but are continuously inactivated in the 
nucleus, the pool of nuclear phospho-ERK needs to be continuously replenished 
from the cytoplasm in order to maintain a sustained nuclear phosphorylation level 
(Costa et al., 2006; Volmat et al., 2001). The low nuclear permeation of ERK1 
suggests that during steady stimulation and translocation, a large fraction of 
nuclear ERK1 is inactivated and is therefore unable to exert downstream effects. 
This qualitative observation was modeled in order to quantitatively estimate the 
effects of nuclear inactivation and trafficking speed on the nuclear ERK 
phosphorylation. The basic assumption of the model considers an equilibrium 
among 4 different states regulated by first order kinetics as detailed in the 










where pERK and ERK indicate the concentration of the phosphorylated and not-
phosphorylated pools, respectively, either in the cytoplasm (Cyt) or in the nucleus 
(Nuc). When the cells are at steady state, either before stimulation or at the 
plateau of the translocation response, the net flux across the nuclear membrane 
is zero.  
The following parameters were included in the model: 
° rate constants  and , from the time constant of recovery of FRAP 
experiments. Since the FRAP experiments suggest that nucleoporins 
provide for a bidirectional passage of molecules, the same rate to the 
influx and efflux was assigned;  
° phosphorylation rates in the cytoplasm  and in the nucleus ; 
° dephosphorylation rate in the cytoplasm  ’ (in the nucleus it has been 
assumed that the dephosphorylation rate 











It has been developed a simulator that computes the temporal evolution of the 
system under arbitrary changes of the parameters of the state population (see 
Methods).  
Initially, the imaging data reported in figure 26, on cells transfected with ERK2-
GFP, were fitted with the model in order to estimate the rate of 
dephosphorylation. To this effect I have modeled the data obtained in a recently 
published experiment (Costa et al, 2006). Here, cells were treated with FGF for 
15 min, until the translocation response reached the plateau level. At this point 
the MEK inhibitor U0126 was administered, causing the rapid inactivation of ERK 
with the consequent loss of ERK2-GFP from the nucleus. During inhibition, the 
phosphorylation rates tend to 0 and I can fit the model prediction of the actual 
time course of protein localization to obtain an estimate of the de-phosphorylation 
rates in nucleus and cytoplasm. As shown in figure 29 A, the model fitted the data 
with great accuracy and provided that γ' 
  0.003 corresponding to t=170 s. Then, 
I used the model to predict the outcome of an identical experiment performed 
with the ERK1 fusion protein. In this new computation I used the de-
phosphorylation rate I just estimated and I inserted the translocation rates  and 
 measured in the FRAP experiments with the ERK1-GFP construct. This time 
lapse experiment showed that ERK1 was retained in the nucleus for a much 
longer time than ERK2, and the modeling suggest that this is due to the lower 
rate of the ERK1 shuttling, that is especially slow for the non-phosphorylated 
protein. Next, I used the model to compute the percentage of activated ERK in 
the nucleus for ERK1, ERK2 and for proteins with varying shuttling rates. As it is 
shown in figure 42 B nuclear phosphorylation decreased in parallel with 
decreasing speed of nucleo-cytoplasmic shuttling. This indicates that even if 
ERK1 and ERK2 are subjected to identical rates of activation and inactivation, 














































































































































Computational estimate of the functional consequences of the different shuttling rates of 
ERK1 and E2. 
A) By fitting the time course of the decay of nuclear ERK2-GFP in cells stimulated with 
FGF for 15 min and afterward treated with U0126 (empty red diamonds) with the model 
output (continuous red line), we could estimate the dephosphorylation rate. This estimate 
was included in the model together with the shuttling rates measured for ERK1 to predict 
the outcome of this experiment practiced on the cells transfected with ERK1-GFP. The 
model prediction (green line) describes with great accuracy the experimental points (filled 
green symbols).  
B) The model was used to compute the phosphorylation in the nucleus as a function of 
the shuttling speed. The empty symbols represent the result of a single simulation run 
and the filled symbols are the averages of each group. The phosphorylation level has 
been normalized to ERK2, therefore the computation shows that the total level of 
phosphorylation of ERK1 is only about half of ERK2. The numbers under each set of data 
points are the time constants (in seconds) of nuclear shuttling in the starved (above) and 




The results of both the imaging experiments and the simulations suggested that 
in stimulated cells the fraction of phosphorylated ERK1 is smaller than the 
fraction of activated ERK2. To verify this idea I studied the intensity/response 
relationship in cells treated with four increasing concentrations of serum (1%, 2%, 
5% and 10%) for 15 min (Fig. 43). The gels have been blotted and probed with 
the phospho-specific ERK antibody and then analyzed with a phospho-imager to 
ensure linearity. The relative phosphorylation was evaluated by measuring the 
pERK1 and pERK2 signals and by computing the ratio pERK2/pERK1. If the two 
kinases were following the same activation profile I should expect that the ratio of 
activation would remain constant. On the contrary, I found that at low serum 
doses, ERK2 activation is larger than ERK1 indicating a better sensitivity (Fig. 43 
A). According to our model this difference may largely be dependent on the 
action of nuclear phosphatases that affect more ERK1 because of its longer 
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retention time in the nucleus. If this were true, one could expect that the inhibition 
of phosphatases should attenuate the difference in activation between ERK1 and 
2. 
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Comparison between the activation of ERK1 and ERK2.  
A) NIH 3T3 cells have been starved for 24 hr before treatment for 15 min with increasing 
concentrations of serum, as indicated. The densitometric analysis of the gel blotted with 
the phospho-specific antibody has been performed with a linear imager to quantify the 
intensity of the phospho-ERK1 and 2 signals. From each experiment I computed the 
ratio pERK2/pERK1 which is a measure of the relative activation of the two kinases. The 
graphs shows that ERK1 activation lags behind ERK2.  
B) Effects of phosphatase inhibition on the relative activations of ERK1 and ERK2. Cells 
have been starved for 24 hr before a 30 min treatment with serum 10% and/or a cocktail 
of phosphatase inhibitors. Inhibition of phosphatases in presence of serum caused a 
further increase of phosphorylation compared to serum only. This increase was larger 




This idea was tested by assaying ERK1 and 2 activation by immunoblotting. Cells 
were harvested in either starved conditions or after 30 min in 20% serum, in 
presence or in absence of a cocktail of phosphatase inhibitors (cocktail 1 and 2  
cat. n. respectively P2850 and P5726, Sigma). As predicted, figure 43 B shows 
that the inhibition of phosphatases decreased the difference between ERK1 and 
2, indicating that in normal conditions ERK1 is more subjected to the action of 
phosphatases than ERK2.  
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In conclusion, these data suggest that: 
1) ERK1 activation lags behind ERK2, as demonstrated by the lower 
response of ERK1 to non saturating stimuli. 
2) This differential activation of ERK1 is reduced after inhibition of 
phosphatases. 
 
Toward a functional interpretation  
These conclusions are fully compatible with the theory that a prime reason for the 
functional differences between ERK1 and 2 is the slower trafficking of ERK1 that 
makes it more vulnerable to phosphatase inhibition in the nucleus and 
contributes to make ERK1 less competent than ERK2 in activating the 
downstream nuclear targets. It is now important to understand which are the 
functional implications for cells.  
Since  there is roughly a 1 to 1 relationship between the abundances of ERK1/2 
and MEK, it is expected that during activation ERK1 and 2 compete for the 
upstream partner MEK. Therefore, I can expect that in conditions of strong 
activation, when the rate of the reaction ERK>>MEK>>pERK is very fast, the 
overexpression of ERK1 would act as an inhibitor of the pathway, while the 
overexpression of ERK2 would facilitate signaling to the nucleus. Viceversa, 
overexpressing the swapped proteins (E1	7-39 and 	39E2) it would revert the 
corresponding effects. To fully demonstrate this idea is necessary to devise 
experiments useful to evaluate the cellular response to ERK activity in cell 
systems overexpressing ERK1 and ERK2 or the swapped E1	7-39 and 	39E2. 
One possible strategy is offered by the experimental approach followed by 
Vantaggiato and colleagues (Vantaggiato et al., 2006): the colony formation 
assay in NIH 3T3 cells. 
A collaboration was started with their laboratory staff in order to verify this 
hypothesis (see Box 8). The colony growth experiments with cells expressing the 
construct generated by myself, were performed in Milan. I think it is fitting to 
mention the result of these experiments because they nicely close the deductive 
process I followed during this study. The results of these experiments are 





BOX  4: Correlation between the time constant and the 
concentration of ERK2-GFP 
 
ERK seems to directly interact with components of the nucleoporin 
complex that are enriched in FG repetitions and that are known to be 
involved in facilitated diffusion (Whitehurst et al., 2002; Matsubayashi et 
al., 2001). Given that nucleoporins and the FG sites are present in a 
limited number, the facilitated diffusion process should be affected by 
saturation, depending of the overall amount of cargo to be transported. I 
performed some experiments to evaluate the degree of correlation 
between the time constant and the concentration of ERK2-GFP. Such 
correlation appeared to be almost completely absent in the concentration 









































































Figure Box 4.1 
A) For weakly expressing cells (150 nM), the rate of ERK2-GFP exchange is 
independent on the concentration of the chimera. The panel shows typical 
recordings from starved cells: fluorescence was converted in average nuclear 
concentration of ERK2-GFP according to the calibration (see Methods). 
Logarithmic plot exponentials of similar  are parallel.  
B) The time constant of the recovery is independent on the average 


























































































































Figure Box 4.2 
Averaged  of recovery for starved cells (red 
symbols) or after stimulation (45 minutes: green; 
3 hours: dark green). Starved over-expressing 
are represented in magenta. Time constants 
have been measured in cells transfected with 








However, the situation changed in cells strongly overexpressing ERK2-
GFP. I found that the turnover was significantly slower (Fig. Box 4.2), 
indicating saturation of the machinery presiding at nuclear import and 
export. These data stress the importance of operating on cells with 













BOX  5:  ERK2 immobile fraction in the nucleus 
 
 
The asymptotic value of the recovery would be equal to 1 if the pool of 
nuclear protein was completely exchangeable with the cytoplasm, and it 
would be less than 1 in presence of a fraction of protein immobilized in 
the nucleus. The IF in over-expressing cells was zero (IF=0.01, 
P0.001; Fig. Box 5.2), indicating that ERK2-GFP accumulation was not 
because of immobilization in the nucleus. This is demonstrated also by 
the detection of a low signal of pERK in the nucleus (Fig. Box 5.2). 
 
Starved cells expressing ERK2-GFP showed a small IF, significantly 
different from zero (4%) (p0.0001, t-test); after 45 minutes from the 
administration of the stimulus the IF increased to 12%; finally, after 3 
hours I evidenced a decrease to 5% (Fig. Box 5.2). 
 
The IF measured in the nucleus simply evaluated the pool of nuclear 
ERK that is not available to be exchanged with the cytoplasm. 
Presumably, this is due to the binding of ERK with some nuclear 
component which impairs its capability to cross the nuclear membrane. 
This explanation is also supported by the fact that I cannot detect any 
loss of fluorescence localized in the bleached region. Indeed, even if the 
bleach is performed in a small central region of the nucleus (see 
Methods, for more details), 5 s after bleach we observe that the loss of 
fluorescence is distributed rather uniformly through the entire nucleus, 
suggesting that ERK can freely move in the nuclear volume. 
 
It is interesting to notice that the IF in overexpressing cells is close to 
zero, in contrast to the IF (5%) detected in starved cells at lower levels 
of expression. This demonstrates that immobilization occurs on a limited 



























Figure Box 5.1 
Starved cells with a high expression of ERK2-
GFP exhibited strong nuclear localization of the 
chimera (green). In contrast, the pERK immuno-
histochemistry  (red, anti-pERK) did not show 
neither an appreciable phosphorylation nor 
nuclear accumulation. This indicates that 
nuclear accumulation in overexpressing cells 

































































































































Figure Box 5.2 
Cumulative data for Immobile Fraction (IF) 
from FRAP experiments. 
Averaged IF for starved cells (red 
symbols) or after stimulation (45 minutes, 
green; 3 hours dark green); black symbols 
represent over-expressing cells measured 






BOX 6:  Mechanism at the basis of ERK2-GFP nuclear accumulation 
 
 
Inactive wild-type ERK is bound to MEK1 and the presence of a 
canonical NES in MEK has suggested that MEK might serve as an export 
shuttle for ERK (Fukuda et al., 1997). This suggestion is partially based 
on experiments using Leptomycin B treatment, which causes nuclear 
accumulation of both MEK and ERK (Adachi et al., 2000; Yao et al., 
2001).  This mechanism also operates on the ERK2-GFP chimera as 
demonstrated by the onset of a gradual accumulation of ERK2-GFP in 
the nucleus during treatment with the inhibitor leptomycin B (Kudo et al., 
1999) (Fig. Box 6.1 A,B).  
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Figure Box 6.1 






A) Imaging of a NIH3T3 cell after starvation in 1% serum and during treatment 
with the CRM1 blocker leptomycin B (5 ng/ml). Bar 20 µm. 
B) Time course of the translocation index averaged on 7 cells. Leptomycin 
caused a gradual accumulation of ERK2-GFP beginning after about 20 min from 
treatment onset.   
C) Combined effect of Leptomycin, FGF and U0126 measured in 12 cells. 
Starved cells were pre-treated with leptomycin, then was added FGF4 and finally 
U0126 as indicated by the bars. The red curve is an exponential fit used to 
evaluate the rate of loss of nuclear ERK2-GFP (=4.47±0.20 min, R2=0.98) 
during inhibition of the ERK pathway and CRM1-mediated export. 
 
 
Thus, the cytosolic localization of ERK in starved cells is because of the 
efflux mediated by CRM1. Although it is well established that CRM1 is 
required for the depletion of ERK from the nucleus in starved cells, 
nothing is known about its role in controlling ERK efflux after stimulation. I 
tested this by pre-treating cells with leptomycin, followed by treatment 
with FGF and U0126 (Fig. Box 6.1C).  
If CRM1-mediated export was the main vehicle of ERK export in activated 
cells I should observe an inhibition of the response to U126. By contrast, I 
observed that treatment with U0126 caused an immediate reduction in 
the nuclear concentration of ERK2-GFP, even if CRM1 export is ihibited.  
Although this process might be slightly slower than observed in control 
conditions (=4.47 min vs. 3.0 minutes in control, as from Fig. 29 D), 
these data suggest that a large fraction of ERK2 exit occurs because of 
bidirectional facilitated diffusion across the nucleoporins independently of 
CRM1. This is in accordance with FRET studies (Burack and Shaw, 
2005) on the binding between ERK and MEK. In this work ERK was 
fused to YFP and MEK to CFP; when ERK and MEK are bound together 
the two fluorescent proteins get near to each other and a FRET signal 
can be detected; while when ERK detaches from MEK, such signal is 
lost. No FRET effects were detected between MEK and ERK in the 
nucleus and ERK did not accumulate in the nucleus after energy 
depletion (the NES-dependent export requires energy); all these data 
suggest that the MEK/CRM1 system does not mainly contribute to the 
export of ERK from the nucleus.  
Furthermore, the special role of CRM1-mediated export is that it can 
operate against a gradient. When ERK2 is strongly overexpressed there 
is a sizable fraction of ERK2 not bound to MEK1 and that is therefore 
unable to be exported by CRM1. In these conditions ERK2 accumulates 
in the nucleus and this requires that either its influx occurs against a 
gradient or that its mobility once in the nucleus is reduced.  
The mobility of ERK2-GFP can be also measured by FRAP 
experiments. Here, I verified whether the effective diffusion coefficient 
(Deff) of ERK2-GFP depends on its phosphorylation state, since this 
would influence the activity-dependent translocation process. I have 
studied ERK2-GFP mobility by bleaching a small spot of the nucleus 
with a brief laser pulse (250 milliseconds) and imaging the recovery 
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Figure Box 6.2 
Reduced mobility of ERK2-GFP in the nucleus.  
A) Imaging of a cell before and after the photobleaching of a small area of the 
nucleus (dotted circle in the magnified image in B) and at the indicated time 
during recovery. B) False colour representation of the difference with the last 
frame of the sequence. Bar 10 µm. C) Difference between the pre-bleach 
image and the last image of the recovery sequence (36s). The signal in the 
nucleus indicates that the pre-bleach fluorescence is still recovering: this 
requires the slower equilibration through the nuclear envelope. D) Time course 
of the normalized fluorescence recovery in the nuclei of starved (red) and 
stimulated (green) cells. GFP recovery is shown in light blue. Estimate of the 
asymptotic value reached by the recovery showed the presence of a small, but 
significative (p0.0001) immobile fraction (% of total normalized fluorescence: 
3.3±0.6 starved, 3.2±0.7 FGF). E) ERK activation caused a considerable 
decrease of the recovery speed. The data in E have been normalized to allow 
a better comparison of the time course, and have been fitted with an 
approximate solution of the diffusion equation (continuous lines). F) Computed 






This technique is a very effective tool for measuring the diffusion of 
nuclear protein and it does not inflict any damage on the analyzed cells 
(Koster et al., 2005; Phair and Misteli, 2000). 
The rate of fluorescence recovery is correlated with the mobility of the 
fluorescent reporter, with a faster time course being associated with a 
larger diffusion coefficient (Carrero et al., 2003; Lippincott-Schwartz et al., 
2001).  
The qualitative inspection of the fluorescence recovery indicates that 
ERK is substantially less mobile than GFP (Fig. Box 6.2 D,E): the result 
differs from previous studies (Burack and Shaw, 2005). Indeed, the 
recovery of GFP fluorescence is almost completed during the time 
elapsed from the end of photobleaching to the beginning of imaging (0.71 
s). At the same time point the bleaching of ERK2-GFP is still very 
pronounced, demonstrating a much slower diffusion. Cell stimulation 
caused a clear decrease in ERK2-GFP mobility, as shown in Fig. Box 6.2 
E by the comparison between the normalized recovery of starved and 
stimulated cells.  
I have estimated ERK2-GFP Deff by fitting the recovery with an 
approximate solution of the diffusion equation (continuous lines) (Feder et 
al., 1996). The diffusion coefficient of ERK2-GFP is well within the 
methodology sensitivity and was found to decrease by a factor of two 
upon stimulation (from 3.1 µm2/s to 1.6 µm2/s, Fig. Box 6.2 F).  
The small residual recovery of GFP only allowed a rough estimate of a 
lower limit for GFP diffusion coefficient (
15 µm2/s), which is consistent 
with published values (DGFP>20 µm2/s) (Chen et al., 2002).  
The meaning of the IF measured in this experiment is different from the 
IF found in the whole-nucleus experiment. The IF observed in the whole-
nucleus photobleaching measures the fraction of ERK that is unable to 
leave the nucleus, but which is not necessarily immobile within the 
nucleus. For example, this could be caused by the formation of large 
complexes to which the membrane is impermeable. By contrast, the spot 
FRAP experiments measure the fraction that is truly immobilized. These 
data are consistent because the IF measured in the spot experiments 
must be  to the IF measured in the whole-nucleus experiments (starved 
IFWholeNuc=4.0%, IFSpot=3.3%; FGF IFWholeNuc=12%, IFSpot=3.2%).  
The slow diffusion of ERK2 in the nucleus is probably because of the 
phosphorylation-dependent binding of ERK2 to sites of low mobility. 
Since these sites would be saturated by elevated concentrations of 
ERK2, I should expect that in strongly overexpressing cells most ERK2-
GFP would diffuse freely. Since the temporal resolution of the previous 
assay was insufficient to measure the fluorescence recovery of freely 
diffusing molecules, I employed a different technique based on the line 
scan of the cell (Fig. Box 6.3). 
In this experiment I bleached a thin stripe centred on the nucleus for 300 
ms and I imaged the recovery process at high speed. These measures 
confirmed that ERK- GFP is much slower than GFP alone; in contrast to 
our data, earlier experiments did not find any difference between the 
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Figure Box 6.3 
High speed FRAP measures 
A) The cell is repeatedly imaged along the dotted line at high frequency (400 Hz). 
Bleaching is performed along a strip covering the nucleus for 300 ms. 
Fluorescence is corrected for background and divided by the cytoplasm 
fluorescence to compensate for imaging bleaching.  
B) Recovery of fluorescence for the same cell before (red) and after stimulation 
with FGF4. Fluorescence has been normalized to the pre-bleach value.  
C) Cumulative results. At this temporal resolution the recovery of GFP (starved 
cells) is clearly discernible and it almost overlaps with the recovery of ERK2-GFP 
measured in strongly over expressing cells (blue, stimulation did not cause any 
change). Photobleaching in low-expressing cells is larger and the recovery is 
slower, indicating lower mobility, which is dependent on ERK activation. 
 
 
I believe that the cause of such difference resides in the experimental 
conditions used to measure the mobility by FRAP, indeed, those 
experiments were performed in strongly overexpressing cells (the right 
balance between MEK and ERK were rescued only coexpressing both the 
two fusion proteins), and therefore the impeded mobility of ERK2 was 
hidden by the saturation of the binding sites. 
 Accordingly, I have demonstrated that the fluorescence recovery of ERK2-
GFP in strongly overexpressing cells almost overlaps with the recovery of 
GFP alone (Fig. Box 6.3C), confirming that the reduced mobility of ERK2 in 
the nucleus occurs because of the operation of saturable mechanisms. I 
have failed to see any phosphorylation-dependent change in mobility in 
these cells. Since the saturation of MEK1 causes a certain amount of 
nuclear translocation in overexpressing cells, the low-mobility sites in the 
nucleus must saturate at a higher concentration of ERK2 than MEK1.  
Once again, this fact highlights the importance of operating on cells 





BOX 7:  Mapped domains of ERK  
 
 
Here I show some of the most relevant domains of ERK. The primary 
sequences of ERK1 and ERK2 are displayed after alignment (ERK1 in 
the first line and ERK2 in the second line); bold characters on ERK1 
sequence represent the divergences from ERK2 sequence. As it can be 
seen, the most important domains are almost perfectly conserved 




ERK2 	19-25 can be phosphoryated, but has little kinase activity and is unable to bind MEK 
(Eblen et al.; MCB, 2001)
Thr157-Thr158: ED domain.
It regulates and contributes to
the specificity of target protein
binding
(Tanoue et al.; Embo, 2001)
MAAAAAAGP                      E MVRGQVFDVG PRYTNLSYIG
EGAYGMVCSA YDNLNKVRVA IKKISPFEHQ TYCQRTLREI KILLRFRHEN 
IIGINDIIRA PTIEQMKDVY IVQDLMETDL YKLLKTQHLS NDHICYFLYQ
ILRGLKYIHS ANVLHRDLKP SNLLLNTTCD LKICDFGLAR VADPDHDHTG 
FLTEYVATRW YRAPEIMLNS KGYTKSIDIW SVGCILAEML SNRPIFPGKH 
YLDQLNHILG ILGSPSQEDL NCIINLKARN YLLSLPHKNK VPWNRFLPNA 
DSKALDLLDK MLTFNPHKRI EVEQALAHPY LEQYYDPSDE PIAEAPFKFD 
MELDDLPKEK LKELIFEETA RFQPGYRS
MAAAAAAPGG GGGEPRGTAG VVPVVPGEVE VVKGQPFDVG PRYTQLQYIG
EGAYGMVSSA YDHVRKTRVA IKKISPFEHQ TYCQRTLREI QILLGFRHEN 
VIGIRDILRA PTLEAMRDVY IVQDLMETDL YKLLKSQQLS NDHICYFLYQ 
ILRGLKYIHS ANVLHRDLKP SNLLINTTCD LKICDFGLAR IADPEHDHTG 
FLTEYVATRW YRAPEIMLNS KGYTKSIDIW SVGCILAEML SNRPIFPGKH 
YLDQLNHILG ILGSPSQEDL NCIINMKARN YLQSLPSKTK VAWAKLFPKS










173-181 no role in ERK2 
phosphorylation and activation; 
responsible for the 
detachment from MEK1
(Wolf et al.; JBC, 2001)
173-175 negative regulators of
phosphatase action on ERK2, 
(Bendetz-Nezer et al.; JBC, 
2007)
299-313: sequences necessary
for passive diffusion through
the nucleus
(Shibayane et al.; JBC, 2002)
Leu333-336-34: involved in ERK dimerization
(Wolf et al.; JBC, 2001)
312-320: necessary to bind




(Tanoue et al.; Nature cell
biology 2000)
Ser244-Pro245-Ser246: the phosphorylation of one of both Ser is
necessary for ERK nuclear translocation mediated by importin7














Recently it has been demonstrated that ablation of ERK1 in mouse 
embryo fibroblasts and NIH 3T3 cells, by gene targeting and RNA 
interference, results in an enhancement of ERK2-dependent signaling 
and in a significant growth advantage. By contrast, knockdown of ERK2 
almost completely abolishes normal and Ras-dependent cell proliferation 
(Vantaggiato et al., 2006). Besides, ectopic expression of ERK1 but not 
of ERK2 inhibits oncogenic Ras-mediated proliferation in NIH 3T3 cells 
and it is sufficient to attenuate Ras-dependent tumor formation in nude 
mice (Vantaggiato et al., 2006). Since these phenotypes are 
independent of the kinase activity of ERK1 (expression of a catalytically 
inactive form of ERK1 is equally effective) I hypothesized a relationship 
between the functional effect on cell growth and the shuttling properties I 
found out.  
 
I demonstrated the changes of nucleo-cytoplasmic exchange are 
controlled by the N-terminus of ERK1, so I asked whether the deletion of 
this domain, by providing ERK1 with a faster turnover (E1	39), would 
also convert ERK1 in a kinase functionally similar to ERK2. If our 
prediction was right, I would also expect the reverse, i.e. a conversion of 
ERK2 mutant with a slow turnover (	39E2) into an ERK1-like molecule. 
This hypothesis was challenged with a colony formation experiment in 
collaboration with Brambilla’s groups in Milan, who tested these ERK 
mutants for their effect on Ras-dependent cell growth (Fig.  Box 8.1). 
NIH 3T3 cells have been transfected with ERK1, ERK2, E1	39 or 	39E2 
(fused to GFP) alone or each one co-transfected with a constitutive 
activated form of Ras (Q61L), in order to test a system that is maximally 
stimulated; then the number of colony formed under each condition 
were quantified, by using a parameter directly proportional to the growth 
capability, so, indirectly, to the success in activating nuclear substrates 
and induce the cell cycle progression. 
 
The N-terminus deletion of ERK1 (E1	39) failed to inhibit the 
proliferation caused by oncogenic Ras expression; in contrast, the 
fusion of the N-terminus of ERK1 with ERK2 (	39E2) results in a protein 

















































































Figure Box 8.1 
Number of colonies counted after transfection with the specified vector, 
normalized to the colonies transfected with the empty vector. Expression 
of constitutively active H-Ras Q61L causes a large increase in 
proliferation that is inhibited by co-expressing ERK1, but not by ERK2. 
The mutant of ERK1 characterized by fast shuttling (E1∆39) did not 
prevent H-Ras Q61L-induced proliferation behaving similarly to ERK2. In 



















Use of fluorescent probes to study cellular processes in living cells 
 
The approach of making proteins visible to study their involvement in intracellular 
events belongs to a complex inter-disciplinary field, which includes expertise in 
molecular biology, fluorescence-based microscopy and, eventually, 
computational modeling. This method of investigation can be applied to the study 
of every cellular process and provides the possibility to follow in real time what is 
happening inside a living cell.  
I studied the dynamical aspects of the ERK pathway and I compared the behavior 
between ERK1 and 2, by expressing GFP-tagged ERK1 or ERK2 in cells and 
then following their localization and trafficking between different intracellular 
compartments. 
In this paragraph I want to discuss the major characteristics of this approach for 
the study of ERK dynamics. 
This method requires preliminary controls to validate the new fusion proteins. 
Notwithstanding the fact that this point is not always properly covered in the 
published literature, I deemed necessary to address two major aspects: A) the 
biochemical characterization and B) the control of the concentration level of the 
fusion protein. 
A) At the basis of this method there is the assumption that the fusion protein 
should mimic the endogenous form, indeed only in this case it would be possible 
to get information about the real behavior of the wild type protein. In order to 
verify the fidelity of the chimera, it is essential to demonstrate that the fusion 
protein can undergo to the same post-translational modifications of the wild type 
protein. Furthermore, in case of an active molecule, it has to be proved also that 
they are catalytically active and can recognize their substrates.  
Upon activation of the Ras module, ERKs are doubly phosphorylated by MEK 
and in turn phosphorylate their targets in the nucleus and in the cytoplasm. I 
demonstrated that GFP-tagged ERK1 and 2 can be correctly phosphorylated 
upon FGF stimulation (Fig. 14) and that they can properly phosphorylate a well 
known ERK target as MBP (Fig. 15). These assays are fundamental to exclude 
possible interference due to the proximity of the fused GFP. Indeed, the 
fluorescent tag could disturb or modify the structural properties of the protein of 
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interest, leading, for example, to their ectopic localization or impairing their 
capability of interacting with other important partners of the pathway.  
Given that the ERK phosphorylation assay was performed in vitro, it cannot 
account for the intracellular localization of the chimeras; for this reason, I 
confirmed the result by immunocytochemistry experiments (Fig. 16). The chimera 
localization perfectly reflected the state of activation/inactivation of ERKs, 
demonstrating that ERK changes in localization are effectively promoted by 
phosphorylation of the fusion proteins. Specifically, cytoplasmic localization of the 
chimera is associated with a low level of phospho-ERK signal (in red, Fig. 16), 
while in stimulated condition nuclear accumulation of ERK-GFP (in green, Fig.16) 
colocalizes with a high pERK signal in the nucleus. All these results 
demonstrated that the two fusion proteins are functional: they can mimic the 
biochemical features of the corresponding wild types and they can be correctly 
controlled by the pathway, once expressed in living cells. 
B) The second important issue to take into account is the level of 
expression in cells; the overexpression has two main effects on the pathway: the 
alteration of the stoichiometric ratio with binding partners and/or a possible 
saturation of binding sites.  
I selectively studied cells with very low levels of expression that were compatible 
with a normal ERK localization in nucleus and cytoplasm. The expression level 
was evaluated by measuring the fluorescence of the chimera after a calibration 
performed on micelles, loaded with known amounts of recombinant GFP (see 
Methods). Successively, I correlated the concentration with a parameter 
estimating the distribution of the protein between nucleus and cytoplasm in 
resting conditions.  
Figure 17 shows that the increase of ERK concentration causes the ectopic 
accumulation of the protein in the nucleus. This was due to the alteration of the 
stoichiometric balance with endogenous MEK, as it has been already 
demonstrated by several laboratories (Burack and Shaw, 2005; Stork and 
Schmitt, 2002). This experiment was instrumental to identify an upper limit for the 
concentration of ERK-GFP (150 nM) that was low enough to be compatible with 
normal localization, but sufficiently high to allow confocal imaging. 
The overexpression of GFP-tagged ERK can heavily affect the evaluation of 
important cellular processes. For example, Burack et al. used live cell imaging to 
examine the interaction between CFP-MEK and YFP-ERK by means of FRET 
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effect (Burack and Shaw, 2005). In this experiment, they rescued the 
stoichiometric unbalance between MEK and ERK, by introducing large amounts 
of both proteins. Although this procedure might address the unbalance between 
ERK and MEK, it does not fix the unbalance with other binding partners. Indeed, I 
have demonstrated that the strong overexpression of ERK2-GFP considerably 
slowed down trafficking (Fig. Box 4.2), indicating the saturation of the machinery 
presiding at nuclear import and export. This interference of the trafficking 
mechanisms, due to the overexpression, might explain why Burack and 
colleagues did not observe the dependency of ERK turnover on its 
phosphorylation, in contrast with what I and others have found (Ando et al., 2004; 
Costa et al., 2006).   
The majority of the cells included in my study showed a concentration of ERK-
GFP less than 100 nM and since ERK levels in mammalian cells have been 
estimated to be in the 1-3 µM range (Ferrell and Bhatt, 1997; Whitehurst et al., 
2002), ERK-GFP was much less abundant than the endogenous protein with 
consequently minimal perturbation of the biological homeostasis.  
 
Dynamics of ERK activation/deactivation  
The ERK1/2 pathway integrates various cytosolic signals depending on the 
cellular context (Bhalla and Iyengar, 1999; Chuderland and Seger, 2005). This 
plethora of incoming signals is converted to a variety of actions, owing to the 
phosphorylation of downstream effectors both in the cytoplasm and in the 
nucleus.  
The translocation of ERK within the cell represents one level at which the 
specificity of ERK signaling pathway might be regulated. In particular, 
cytoplasmic-to-nuclear movement of ERK has been suggested to be important for 
the long-term consequences of ERK activation in multiple cellular processes, 
such as cell growth, differentiation and neuronal plasticity (Marshall, 1995).  
In this work I studied ERK translocation process under different aspects, paying 
particular attention to the regulatory mechanisms that control the on/off switching 
of the cascade and measuring the temporal pattern of ERK localization.  
I followed ERK nuclear translocation, after serum or FGF stimulation, with time 
lapse recordings, capturing all the crucial phases of the processes and 
measuring their temporal profiles. Nuclear accumulation is biphasic: the latency 
phase of approximately 2 min is followed by a rapid accumulation of the protein 
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(Fig 19). The observed time lag correlates with recent data which showed that 
ERK2 unbinds from MEK1 within 90 s from the stimulus onset (Burack and Shaw, 
2005). Afterwards, nuclear accumulation follows a sigmoidal rising phase that 
concludes in a plateau in about 15 min.  
The general characteristics of this process are highly conserved in different 
replicating cell lines (L1 3T3 and primary mouse fibroblasts; Fig. 20), even if the 
timing is variable. 
Interestingly, at longer times (more than 15-20 min from stimulation) different 
stimuli led to diverse responses. A continuous stimulation with FGF gave a 
sustained nuclear accumulation of ERK, while serum provoked a transient 
maximal accumulation, which soon after declined and stabilized on a lower 
plateau (Fig. 21). This difference probably reflects the high variety in composition 
of serum, which contains many active molecules, and some of these may 
influence phosphatase activity or other molecules responsible of the negative 
feedback mechanisms which switch off ERK activation.  
The steady response to a constant stimulus is potentially capable of controlling 
gene expression with noteworthy rapidity; for example, the transcriptional effects 
of activated ERK on MKP expression can already be detected 15-30 min after 
stimulation (Bhalla et al., 2002). This regulatory mechanism implies that, in the 
appropriate context, the degree of ERK activation and its translocation might 
follow complex temporal patterns with a bandwidth of few minutes and that ERK 
might undergo burst-like episodes of activation lasting 15-20 minutes.  
Conversely, I showed that a brief presentation of FGF, lasting 4 min, caused only 
transient ERK nuclear translocation, which would not be sufficient to maintain a 
steady state activation of nuclear targets (Fig. 22). Indeed, it has been 
demonstrated that sustained, but not transient, activation of ERK is required for 
quiescent fibroblasts to begin to proliferate (Balmanno and Cook, 1999; 
Dobrowolski et al., 1994) Furthermore, whereas both transient and sustained 
activation of ERK induce transcription of immediate early genes (e.i. Fos, Jun, 
Myc, Egr1), only sustained ERK activation causes phosphorylation and 
stabilization of the proteins they encode (Murphy et al., 2004; Murphy et al., 
2002). 
In the FGF pulse experiment there is another level of complexity: the 
internalization of the growth factor inside the cell (Wiedlocha and Sorensen, 
2004) and the consequent persistency of the active signaling complex 
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FGF/receptor/scaffold-proteins/ERK module. This could lead to prolonged 
activation of the pathway, which depends no more on the presence of the signal 
in the extracellular environment. In conclusion, these observations suggest that 
there might be a minimal temporal window to start and establish the molecular 
mechanisms necessary to maintain ERK signaling over long time periods.  
The temporal pattern of ERK phosphorylation and translocation is finely tuned; if 
a certain threshold of ERK activation is overcome, mechanisms like stabilization 
of early genes products, auto-catalytical activation and positive feedback events 
are favored, and all of them might contribute to stabilize and complete the long 
term events involving gene transcription. Otherwise, the cascade is rapidly shut 
down to restore the basal conditions, getting the cell ready for a new burst of 
activation.  
The long term ERK nuclear accumulation I observed after FGF is compatible with 
the instauration of positive feed back mechanisms; ERK has been reported to 
phosphorylate already active Raf, increasing its activity 4-fold (Balan et al., 2006), 
even if hyperphosphorylation prevents Raf interaction with the Ras GTPase and 
promotes its dephosphorylation by PP2A (Dougherty et al., 2005). In addition, 
ERK has been demonstrated also to phosphorylate MPK-3 at two serine 
residues, targeting the phosphatase for degradation in the proteosome (Marchetti 
et al., 2005), thus reducing the level of ERK inactivation. 
Conversely, I can hypothesize that negative feedback loops predominate in the 
transient response to a brief exposure of FGF and/or in the rapid ERK efflux from 
the nucleus after U0126, contributing to restore the ERK cytoplasmic localization. 
It has been reported that MEK can be inhibited by ERK phosphorylation at Thr 
292 (Eblen et al., 2004) and Thr 212 (Sundberg-Smith et al., 2005) preventing 
further enhancement of its catalytical activity by PAK1 (Slack-Davis et al., 2003). 
In addition, ERK can phosphorylate also Sos, inhibiting its interaction with Grb2, 
thus preventing Sos recruitment to the membrane, thereby reducing Ras 
activation (Douville and Downward, 1997). 
I determined that ERK activation and localization are rapidly and dynamically 
regulated by concurrent processes of phosphorylation and dephosphorylation 
that also occur in the absence of extracellular stimulation. Indeed, there is a 
continuous balance between MEK and phosphatases; this push-pull mechanism 
exerts a tight control of the phosphorylation state of the protein that can be 
rapidly regulated. This fine tuning seems to be necessary to prepare the cell to 
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promptly answer to different extracellular stimuli or to the changing environmental 
conditions; all of these factors can heavily influence cell survival. 
The proteins directly involved in ERK activation/inactivation are essentially: MEK 
and phosphatases. There is a large family of dual-specificity phosphatases 
(MKP) known to dephosphorylate ERK1/2 even if their action show a high degree 
of cross-talk with other MAPK, like JNK or p38. Indeed, it is getting clear that it 
does not exist any specific phosphatase for ERK1/2 or other kinases, but rather, 
there are phosphatases which are more affine for one or more substrates respect 
to others. Anyway, it has been demonstrated that ERKs are dephosphorylated by 
3 cytoplasmatic (PP2A, MKP-X, MKP-3) and 4 nuclear (MKP-1, MKP-4, Pac-1, 
hVH3) phosphatases [reviewed in (Kondoh and Nishida, 2007)]. 
I designed a set of experiments to better elucidate the modality and the kinetic 
properties of the processes which control ERK fate, by using drugs which 
interfere with the two main regulators of ERK. While it exists a specific and potent 
MEK inhibitor (U0126), it is not available any specific substance blocking the 
activity of a specific phosphatase; in addition, as I reminded before, there are 
several phosphatases acting on ERK, so I applied a general phosphatase 
inhibitor, sodium orthovanadate, to interfere with ERK inactivation. 
By treating starved cells with sodium orthovanadate I unmasked a small level of 
basal MEK activity that caused a slow phosphorylation of ERK in absence of any 
stimulation. ERK slowly accumulated into the nucleus (Fig. 24) because the 
fraction of activated ERK cannot be dephosphorylated any more by nuclear and 
cytoplasmic phosphatases.  
In resting conditions cells do not completely stop the ERK pathway, providing for 
a more efficient reaction to extracellular stimuli. Indeed, if a residual activity is 
always present, the pathway can provide for a quicker response, skipping some 
of the start up operations.  
I demonstrated that the slow rate of ERK accumulation detected in the 
experiment of figure 24, was not influenced by the speed of permeation of the 
inhibitor inside the cell, but it reflected the real kinetics of the occurring process. 
Indeed, cells pretreated with FGF and then exposed to orthovanadate (Fig. 28) 
showed a faster ERK accumulation in the nucleus (=4 min vs. 26 min), indicating 
that ERK shows different rate of activation by MEK, depending on cellular 
conditions.  
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This last experiment gives some other important clues to the understanding of the 
complex network regulating ERK localization and activation. Indeed, while neither 
FGF nor serum stimulation provoked a maximal activation, in cells previously 
stimulated with FGF and then treated with the phosphatase inhibitor, the plateau 
of ERK nuclear concentration achieved after FGF was further lifted after 
orthovanadate administration. Therefore, the blockage of phosphatases, 
unmasked the small fraction of ERK which is continuously dephosphorylated, 
even in presence of sustained stimulation (Fig. 28). This means that the process 
of ERK recycling is continuous and a new equilibrium between activation and 
inactivation is established, in order to make the system plastic for further 
changes. 
Conversely, I unmasked phosphatases actions, blocking MEK activity with U0126 
in cells at the maximum of their stimulation (Fig. 26). I observed a fast decrease 
of ERK2 concentration in the nucleus due to ERK dephosphorylation by nuclear 
phosphatases. The two processes of ERK phosphorylation and 
dephosphorylation are dynamically controlled by feedback mechanisms acting as 
bridges which interconnect the activity of diverse proteins and make possible the 
communication between them. ERK itself intervenes in loops of auto-catalytical 
activation/inactivation; for example, it has been reported the physical and 
functional association of ERKs with PAC-1 and MPK-3, whose binding increases 
their dephosphorylative activity (Camps et al., 1998; Dickinson and Keyse, 2006; 
Muda et al., 1998; Rohan et al., 1993; Sharma et al., 2002). Furthermore, ERK 
can influence also the level of expression of phosphates such as MPK-2 
(Brondello et al., 1997) and MKP-1 (Charles et al., 1992; Keyse and Emslie, 
1992; Noguchi et al., 1993), which is rapidly induced after exposure of growth 
factors, heat shock and oxidative stress. Finally, a study has shown that hVH3 
(both in an active or inactive conformation) causes ERK translocation and 
sequestration in the nucleus (Mandl et al., 2005), suggesting that hVH3 can 
function as a nuclear anchor for ERK. 
 
ERK2 nuclear entry/exit 
The nucleus represents the end station for the action of every signaling pathway 
that controls gene expression in response to changes of the extracellular 
environment.  
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The process which mediates the entrance and exit of ERK from the nucleus has 
been object of numerous studies and several model mechanisms have been 
invoked to explain such influx/efflux. For the entrance of ERK in the nucleus, the 
following 3 mechanisms have been proposed. 
 
1. Khokhlatchev et al. studied the nuclear accumulation of ERK after activation of 
the pathway and they showed that it depends on ERK phosphorylation state 
rather than its activity. They proposed that pERK dimerizes with phosphorylated 
and unphosphorylaed ERK partners; accordingly, mutants unable to dimerize 
showed a minor capability to translocate (Khokhlatchev et al., 1998); this is in 
contrast with previous results which excluded the dependency from 
phosphorylation (Lenormand et al., 1993). However, it still remains unclear if 
dimerization is required for the rapid, agonist-induced entry of ERK into the 
nucleus, and the most recent opinions tend to consider this mechanism not really 
probable.  
2. Adachi and coworkers added that ERK can cross the nuclear barrier by 
passive diffusion (Adachi et al., 1999), concluding that there are at least two 
pathways for ERK entry in the nucleus: the passive diffusion as a monomer and 
the active transport of a dimer.  
3. Finally, Matsubayashi et al. proposed that ERK passes through the nuclear 
pore by directly interacting with the nuclear pore complex, independently from 
cytosolic factors such as the importin beta family protein and Ran (Matsubayashi 
et al., 2001). Indeed, ERK has been demonstrated to be one of the proteins 
which is not imported  by either classic or non-classic NLS systems, like -
catenin (Fagotto et al., 1998) and SMAD 2,3 and 4 (Xu et al., 2003; Xu et al., 
2000). It has been shown that ERK2 is able to interact directly with CAN/Nup214 
and Nup153 (Matsubayashi et al., 2001; Whitehurst et al., 2002). Nucleoporins 
containing FG repeat motifs are thought to be common docking sites for 
molecules that pass through the NPC [reviewed in (Peters, 2005)]. The FG 
repeats would be displaced along the internal wall of the pore channel in order to 
follow a favorable affinity gradient until reaching the end of the channel. The 
molecular and biophysical details of this process are still completely missing. 
Recently, it has been identified a 3 aminoacid domain (SPS), phosphorylated 
upon stimulation, that it has been shown to interact with the importin7, which in 
turn mediates ERK nuclear translocation (Chuderland et al., 2008). The 
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phosphorylation can occur on only one or both the serines, and these events are 
indipendent from the phosphorylation of Thr and Tyr by MEK (TEY). In 
accordance with the model proposed by Chuderland and collegues, the TEY 
phosphorylation (detected within 5 min from the stimulus) is important for the 
detachment from cytoplasmic anchors, while the subsequent SPS 
phosphorylation (detected after 15 min) should plays a role in the nuclear 
translocation. 
Interestingly, if SPS is mutated in APA (not phopshorylable) the interaction of 
ERK with the Nup153 is increased, suggesting that this specific interaction might 
be mediated by other residues and that the pSPS is required for a faster release 
of ERKs from the NUPs. This domain has been found also in other shuttling 
proteins, suggesting that it might be a general signal sequence for nuclear 
translocation.  
 
Concerning ERK exit, previous data proposed that this process uniquely 
depends on MEK. This upstream kinase acts as a nuclear export shuttle, given 
that it carries a NES and it is actively extruded by a CRM1-dependent 
mechanism (Adachi et al., 2000; Fukuda et al., 1996; Fukuda et al., 1997).  
 
I demonstrated that ERK1/2 can shuttle across the nuclear envelop (Fig. 30, 32); 
this passage of signaling molecules does not occur only at the time of activation 
but continuously, because a steady flux accounts for the biochemical 
communication between nucleus and cytoplasm. I measured the rates of shuttling 
with the FRAP imaging. The shuttling rate is determined by the steady state 
equilibrium between two simultaneous fluxes, one towards the nucleus and the 
other one towards the cytoplasm. I propose that, in addition to the mechanisms of 
entrance and exit that I have described above, ERK must be capable of diffusing 
though the nuclear pore bidirectionally. There are several evidences supporting 
this theory: first of all the very small quantity of MEK present in the nucleus, 
clearly shown in figure 44, both in starved and stimulated conditions. Indeed, 
given that the binding between ERK and MEK follow a 1:1 stoichiometry, it is 
unlikely that the few MEK molecules present in the nucleus might rapidly export 

























NIH 3T3 cells co-expressing 
MEK-CFP (cyan channel 
displayed in the first column) 
and ERK2-YFP (yellow channel 
displayed in the second 
column). While in starved 
condition ERK localization is 
overlapped to MEK, after 
stimulation ERK predominantly 
localized in the nucleus and 
MEK remained mostly in the 
cytoplasm. 
 
This might happen only if MEK would show a very fast turnover across the 
nuclear barrier, but this is really unlikely, given that it has a high MW (45 kDa) 
and it carries a NES, which would definitely not endow MEK with any special 
facilitation in entering the nucleus. Furthermore, the presence of the exclusion 
signal suggests that MEK has a more important role as ERK activator in the 
cytoplasm, rather than as ERK exporter from the nucleus.  
Consequentially, all these considerations indicate that ERK outflux should occur 
mainly by passive diffusion, while the influx is probably formed by at least two 
components: passive diffusion and an active import mediated by importin7 
(Chuderland et al., 2008). The relative size of this fluxes and the reversibility of 
the importin-mediated flux remain to be determined. This implies that 
nucleoporins must allow the bidirectional passage of ERK. In support to this 
theory, a recent paper demonstrated that nucleoporins let access molecules in 
both directions with the same probability, in permeabilized cells (Kopito and 
Elbaum, 2007). Notwithstanding this, it is usually accepted the notion that ERK 
exits from the nucleus uniquely by MEK binding; an indication that CRM1-
mediated export cannot be the only vehicle of ERK export in cells, comes from 
the experiment in which pre-treated cells with leptomycin were then sequentially 
treated with FGF and U0126 (Fig. Box 6.1). If CRM1-mediated export was the 
main vehicle of ERK export in activated cells, I should have observed an 
inhibition of the response to U0126. In contrast, I observed that the treatment with 
U0126 caused an immediate reduction of the nuclear concentration of ERK2-
GFP, indicating that efflux is still present even after the blockage of active export. 
However, since, this process was slightly slower than observed in control 
conditions ( =4.47 min vs. 3.0 min in control, Fig. Box 6.1C), it is possible that 
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there might be a small component of the efflux mediated by CRM1. I can exclude 
that the treatment with U0126 interferes with MEK export, since the 
characterization of the inhibitor interaction showed that U0126 can bind with 
identical affinity the free enzyme and the MEK-ATP complex, and this is also 
capable to bind the entire complex MEK-ERK (Favata et al., 1998). This binding 
has been reported to be noncompetitive and that it minimally perturbs the affinity 
of MEK for its binding partners. This means that MEK should be capable to bind 
CRM1 and ERK even if already bound to U0126.  
 
I can conclude that  ERK can enter as (see summary in Fig. 45):  
 
1. pERK monomer (Fig. 45 a), with an energy-independent and -dependent 
mechanism    (Costa et al., 2006; Ranganathan et al., 2006);  
2. ERK not phosphorylated (Fig. 45 b), with an energy-independent way (Adachi 
et al., 1999; Costa et al., 2006).  
3. ERK (pSPS), bound to importin7 (Chuderland et al., 2008), independently 
from the phosphorylation on TEY (Fig. 45 a/b). 
 
Concerning the exit: 
only a small fraction of ERK exits by a CRM1-mediated mechanism (Fig. 45 c), 
while the majority of the outward flux must occur though the nuclear pores, in a 
energy-independent way (Fig. 45 a/b). 
 
ERK can shuttle back and forth from the nucleus and the speed of shuttling 
determines the capability of nuclear targets to sense the extracellular 
environment, representing a possible locus for the fine tuning of the pathway 
activity. 
It is conceivable that the biological advantage of this way of communication is 
that, since the signaling elements are continuously moving between the two 












ERK import/export is regulated by the following mechanisms: 
a. Study conducted with GFP-tagged ERK2 in permeabilized cells demonstrated that 
p(TEY) ERK can be imported and exported from the nucleus in the absence of transport 
factors and energy (Ranganathan et al., 2006); but, given that it has been observed a 
dramatic increase in nuclear import of thio-pERK2 when energy was included in the 
import mixture, Ranganathan concluded that the import of pERK2 occurs predominantly 
by an energy-dependent process. 
FRAP experiments on ERK2 nuclear shuttling in stimulated cells (Fig. 30, 32) suggest a 
bidirectional passage of ERK through the nuclear pores (Costa et al., 2006).  
b. It has been reported that ERK can cross the nuclear barrier by passive diffusion 
(Adachi et al.; 1999).  
Ranganathan demonstrated that non phosphorylated ERK2 is imported in an energy-
independent way (Ranganathan et al., 2006). 
Matsubayashi et al. proposed that ERK passes through the nuclear pore by directly 
interacting with the nuclear pore complex, independently from cytosolic factors 
(Matsubayashi et al., 2001). It has been shown that ERK is able to interact with 
CAN/Nup214 and Nup153 (Whitehurst et al., 2002; Matsubayashi et al., 2002). 
Export of ERK2 occurs even with impaired MEK1 binding (Ranganathan et al., 2006). 
FRAP experiments on ERK2 nuclear shuttling in starved cells (Fig. 30, 32) and the 
dynamics of ERK change in localization following Leptomycin and U0126 administration 
(Fig. 6.1C) suggest a bidirectional passage of ERK through the nuclear pores (Costa, 
2006, JCS).  
a./b. A recent research has demonstrated that the phosphorylation of the SPS peptide (in 
the Kinase Insert Domain, KID) allows ERK nuclear translocation by importin7 
(Chuderland et al., 2008), and this mechanism is independent from the phosphorylation 
on TEY by MEK. 
c. ERK bound to MEK is actively extruded by a CRM1-dependent mechanism 




To draw a complete scheme of all the mechanisms contributing to the change of 
ERK localization I cannot ignore a further aspect: the mobility of ERK in the 
nucleus. I have reported that when the pathway is activated, ERK accumulated in 
the nucleus and concomitantly, its mobility significantly decreased (D values: 3.06 
± 0.30 µm2/s in starved cells vs. 1.57 ± 0.10 µm2/s in stimulated cells; as I 
measured by spot FRAP; Fig. Box 6.2 E,F). This suggests that pERK has an 
increased affinity for nuclear anchors and for this reason it spends more time in 
the nucleus.  
 
ERK1 and ERK2 shuttle across the nuclear membrane with different rates 
For a long time it has been believed that ERK1 and 2 were interchangeable. This 
notion was originated by their vast sequence homology (Fig. 34) and by the 
identity of the upstream activator and of the identified substrates. Only recently it 
has become clear that while ERK2 is the most active kinase form, ERK1 
contributes far less to the overall signaling output; indeed, it has been recently 
proposed that ERK1 functions as a partial agonist of ERK2 for MEK binding 
(Vantaggiato et al., 2006). However, the mechanism and the domain responsible 
for the differences between ERK1 and ERK2 have not been yet identified.  
Most of the functional domains that have been mapped on ERK sequences are 
present on both ERK1 and 2, including a consensus region for MEK (Brunet and 
Pouyssegur, 1996; Robinson et al., 2002), the catalytic domain (Tanoue et al., 
2000) and a region considered the interacting site for the nucleoporins 
(Matsubayashi et al., 2001; Whitehurst et al., 2002). Surprisingly, notwithstanding 
all these similarities, I found that ERK1 shuttles about three times more slowly 
than ERK2, although the turnover acceleration after stimulation is preserved (Fig. 
32).  I observed that translocation after stimulation followed a similar temporal 
pattern for both ERK1 and 2 (Fig. 29B). This is not surprising given that the time 
constants of nucleo-cytoplasmic shuttling of ERK1 and 2 in stimulated conditions 
are both smaller than the time constants of ERK translocation (respectively, 170 s 
ERK1, 84 s ERK2 and about 180 s for the translocation of both ERK1 and 2).   
Conversely, the time constant of the net efflux following acute inactivation of MEK 
(Fig. 29D) is much slower and it can be effectively limited by the far slower 
shuttling rate of ERKs in starved conditions.   
After U0126 administration MEK is inhibited and so the cell returns to the 
condition preceding the stimulation. As dephosphorylation proceeds, the rate of 
ERK shuttling drops: ERK1 in the dephosphorylated form moves very slowly, 
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strongly affecting the speed by which ERK1 distribution returns to the initial state. 
Indeed, the mean time constant of ERK1 shuttling in starved conditions (=10.9 
min) is very similar to the time constant of the protein redistribution after U0126 
administration (=9.3 min), like the faster efflux of ERK2 (=3.1 min) reflects its 
faster turnover (= about 3 min).  
 
ERK1 N-terminus is the domain causing the slowing down ERK1 
ERK1 is slowly exchanged between the two main compartments, nucleus and 
cytoplasm; I tried to find the main cause of such phenotype comparing the 
primary aminoacidic sequences of the two kinases. Observing figure 34 it is 
evident that ERK1/2 are very similar, displaying over 85% of sequence homology 
and sharing almost all the mapped functional domains (Box 7). Thus, there are 
no clear reasons why the two proteins should shuttle as differently as they do. 
The larger sequence divergence is a region of about 39 residues, located at the 
N-terminus of ERK1, that has not been associated to any specific function to 
date. I decided to test the hypothetical involvement of this region in ERK shuttling 
behavior by either removing, transposing on ERK2, or mutating specific portions. 
For simplicity, I divided ERK1 N-terminus in three main regions (see Fig. 35): 
 
1. an alanine rich cap, in common with the two kinases except for the 
inversion of P8G9 of ERK1 in G8P9 of ERK2 (in mouse this region spans 
aa 1 to 8); 
2. a region present only in ERK1 (aa 9-29); 
3. a homologous region (aa 30-39) which differs of only three single non 
consecutive aa (Val31, Arg33 and Pro36). 
 
As I have already pointed out, ERK1 and 2 have been considered for a long time 
as isoforms and thus, most studies about functional or active domains have been 
conducted only on ERK2 (se Box 7), consequently no information are available 
about the putative role of the N-terminus of ERK1. 
First of all, I generated a series of deleted derivatives of ERK1 N-terminus, by 
removing region 1, both regions 1 and 2 and all three regions (Fig. 36A). The 
resulting proteins gave different results in terms of nuclear shuttling (Fig. 36B). 
The removal of the alanine rich cap did not affect the time constant of shuttling 
which resulted not significantly different from ERK1 wt; the same results were 
obtained also if the poly-alanine sequence was removed from ERK2 (data not 
 119 
shown). These results demonstrate that region 1 is not involved in controlling the 
shuttling. In parallel, it has been demonstrated for ERK2, that this region is not 
involved in other functional properties, such as the capability to be 
phosphorylated and the catalytic activity (Eblen et al., 2001).  
Conversely, the removal of region 2 or both 2+3 drastically reduced, to different 
extend, the value of . The removal of both regions 2+3 (E1	7-39) made ERK1 
shuttling identical to ERK2, while the removal of region 1+2 (E1	26) caused a 
partial acceleration of the shuttling (Fig. 36). This suggest that both region 2 and 
3, cooperate and are necessary to define the slower phenotype of ERK1. 
Region 2 and 3 are not only necessary for the slowing down of shuttling, but they 
are also sufficient since, fusing region 2+3 of ERK1 on the N-terminus of ERK2 
(	39E2) causes a large slowing down of the shuttling (Fig. 37). These data 
suggest that differences between ERK1 and 2 present elsewhere than on the N-
terminus are non-consequential to the shuttling differences that I observed. 
One possible explanation for this phenotype might be that this terminal region 
masks some critical sites on the ERK ternary structure, responsible of the 
interaction with nucleoporins, which are at the basis of facilitated diffusion. 
However, since the fusion of the N-terminus to GFP dramatically slows down the 
trafficking of GFP, I must conclude that this domain is able per se to slow down 
the speed of exchange across the nuclear envelope (Fig. 38 B). 
Furthermore, the direct fusion of all the three N-terminal regions 1+2+3 to GFP 
(GFP-	N1-39) decreased GFP shuttling rate to a different extent compared to the 
fusion of only region 1+2 (GFP-	N1-27). Specifically, region 1+2 (GFP-	N1-27) was 
faster than region 1+2+3 (GFP-	N1-39), but it is significantly different from the 
GFP and from the random sequence. Putting together these data, I can conclude 
that the slow phenotype observed is due to the combination of at least two 
factors, one connected with region 2 (aa 9-29) and the other one related to region 
3 (aa 30-39).  
The slowing down effect that the N-terminus induced on GFP trafficking is 
surprising since it cannot be due to the higher molecular weight of this fusion 
protein (32 kDa). It is widely acknowledged that globular molecules smaller than 
about 40 kDa can freely permeate thought the nucleoporin [reviewed in (Patel et 
al., 2007)], thence, the GFP monomer (27 kDa) can equilibrate between nucleus 
and cytoplasm by simple passive diffusion. It seems unlikely that the addition of 
only 39 residues might cause any change in passive diffusion. Furthermore the 
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observation that a scrambled sequence of the size of region 2+3 has not effect 
whatever of GFP trafficking, suggests that the slow permeation is caused not by 
steric hindrance but rather by specific binding with other components. It is 
probable that an interaction might occur between ERK1 N-terminus and some 
binding partner, yet to be identified, that slowed down the permeation of the 
protein. This interaction, would be directly responsible for the differences in 
trafficking that have been observed between ERK1 and 2. The analysis of the 
sequence of the N-terminal region, suggests 2 possible candidates involved in 
the interaction: A) a putative SH3 recognition domain in region 2 and B) three 
aminoacids in region 3 which differ between ERK1 and 2. 
A) The presence of a putative SH3 domain in region 2 (residues 23-26 PVVP; 
Fig. 39) was assed by the probabilistic calculation generated with a web server 
(Ferraro et al., 2007) specialized in the recognition of SH3 interaction sites.  
It is possible that PVVP site might specifically interact with a SH3 binding partner 
and that this interaction might be somehow responsible for the slower 
permeation. However, the experiments clearly showed that any kind of 
manipulation on the PVVP site (mutations targeted to one or both the prolines or 
the deletion of the whole region PVVP) did not confer any acceleration to the 
protein. Therefore, even if I cannot conclude that there are no SH3 interactions 
occurring at this site, I can exclude that this putative interactions are not involved 
in nuclear trafficking.  
B) Comparing the region 3 of ERK1 and the respective homologous of ERK2, it is 
evident that there are only three differing aminoacids (Val31, Arg33 and Pro36; Fig. 
39). Therefore, I expected that one or all of them were crucial determinants, even 
if not uniquely responsible, for the different trafficking.  
Indeed, the results obtained by converting both Val31 and Arg33 in Ala, either in 
the N-terminus alone or in the entire sequence of ERK1 (Fig. 36 and 39), 
demonstrated that these two aminoacids are heavily involved in controlling 
nuclear trafficking. 
At this point a question arises: what could be the mechanism that links the 
presence of a putative binding site to the slowing down of the facilitated diffusion 
process? I can hypothesize that this domain might interact with specific 
consensus regions of nucleoporins, influencing ERK1 rate of passage through 
the pore channel. More specifically, I expect that this interaction increases the 
residency time of the protein inside the channel, thus decreasing the overall flux.  
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ERK2 is known to directly interact with some nucleoporins [reviewed in (Xu and 
Massague, 2004)], so it is likely that also ERK1 establishes similar interactions. In 
addition, it can be hypothesized that its N-terminus affects the binding, 
presumably inducing a longer residence time in the pore channel. Interestingly, 
although GFP can cross the nuclear barrier without any need of the facilitated 
diffusion mechanisms, it slowed down when tagged with ERK1 N-terminus. One 
possible explanation could be that GFP becomes more sticky to the pore walls 
increasing its residence time inside the nuclear pore (Fig. 38 B).  
Interestingly, the N-terminal peptide shows a high degree of hydrophobicity that 
can favor and increse the affinity for certain domains of the pore wall, for 
example, the repetitive stretches of Phe-Gly residues (Rout and Wente, 1994) 
which are thought directly to interact with ERK2. An alternative explanation is that 
the N-terminus binds to a yet unidentified partner not belonging to the 
nucleoporin, that increases the size of the protein with a corresponding 
decreased permeation. Regardless of the details of the molecular interactions 
involved, these results are in accordance with the idea that the N-terminus per se 
interferes with nuclear shuttling, because of direct molecular interactions, rather 
than by masking specific sites on the ternary structure of ERK.  
The striking difference obtained by targeting region 3 with the conversion of the 
two aminoacids in alanine is surprising given that they share the same chemical 
properties, respectively Val31 in ERK1 versus Met in ERK2 are both hydrophobic, 
and Arg33 in ERK1 versus Lys in ERK2 are both positively charged. This 
observation strongly suggests that these residues (one of them or both) represent 
the site of an interaction which requires their specific chemical structures and 
cannot be supported by similar aminoacids. 
I did not mutate also the third aminoacid (Pro36 of ERK1 vs. Val of ERK2) 
because the neutralization of the first two aminoacids was sufficient to obtain a 
strong difference in shuttling rate. Given that, I demonstrated that also region 2 is 
necessary to completely revert ERK1 phenotype into ERK2, I expect that the 
additional neutralization of the Pro36 would not dramatically change the effect. 
 
Phosphorylation levels of ERK1 and 2 in the nucleus and consequent 
functional outputs 
Since MEK is mainly localized in the cytoplasm (Adachi et al., 2000), the 
maintenance of a functional level of activated ERK in the nucleus depends 
 122 
crucially on the inflow of phosphorylated ERK. I speculated that the different 
efficacies of ERK1 and ERK2 might be due, at least in part, to some differences 
in their nuclear trafficking.  
ERK1 permeates the nuclear membrane far more slowly than ERK2 and this 
causes a longer permanence of ERK1 in the nucleus, as exemplified by the slow 
loss of nuclear accumulation following MEK1 blockage (Fig. 42). What are the 
consequences of the slower trafficking? Computational simulations predicted that 
the longer residency time of ERK1 in the nucleus, where inactivation 
predominates over activation, causes a pronounced dephosphorylation of ERK1 
compared to ERK2. The available evidences therefore suggest that ERK1 and 2 
differ in the capability of maintaining their phosphorylation state in the nucleus. 
Indeed, if phosphatases are inhibited in presence of serum (Fig. 43 B) I observed 
a further increase of ERK phosphorylation, that is larger for ERK1 respect to 
ERK2, indicating that the activation state of ERK1 is more affected by de-
phosphorylation than ERK2.  
 
In conclusion, I found  the following: 
 
1. ERK1 turnover is slower than ERK2, and this is due to its N-terminus, 
which probably impairs ERK1 facilitated diffusion mechanism; 
2. ERK1 slower trafficking causes a longer residence time of ERK1 in the 
nucleus, which makes the kinase more vulnerable to the phosphatase 
action. Consequently, in  the nucleus ERK1 is more dephosphorylated 
than ERK2; 
3. the minor percentage of phosphorylated ERK1 (active form) makes ERK1 
less capable of activating nuclear substrates and of inducing the cell cycle 
progression (Fig. Box 8.1). 
 
I can conclude that ERK1 results to be less competent in activating nuclear 
targets respect to ERK2. This is caused by its N-terminus, which, by impairing the 
passage through the nuclear envelop, increases its residence time in the nucleus 
decreasing its state of activation. 
 
 123 
CONCLUSIONS and FUTURE DIRECTIONS 
 
I have studied the mechanisms at the basis of ERK regulation, focusing on the 
spatio-temporal patterns of ERK trafficking in living cells, by live imaging of 
fluorescently tagged proteins. I have then measured the nucleo-cytoplasmic 
shuttling of ERK1 and 2 finding out that ERK1 and 2 drastically differ in their 
capability of crossing the nuclear envelope and that this difference is caused by a 
short domain located at the N-terminus of ERK1. Since the nucleus is a site of 
inactivation for signaling originating at the cell membrane, the speed of 
permeation through the nuclear envelope is a critical determinant of the efficiency 
of the communication between cytoplasm and nucleus.  
I have provided computational, biochemical and functional evidence that ERK1 
and 2 have different signaling capabilities and I have showed that the rate of 
nucleo-cytoplasmic shuttling and its possible modulations are crucial regulators of 
signaling to the nucleus and represent a novel possible target for the molecular 
control of this pathway. 
Furthermore, I have demonstrated that the N-terminus of ERK1 is necessary and 
sufficient to cause the differences of permeation and functional properties 
between ERK1 and 2. By directed mutagenesis I have identified some crucial 
residues responsible of the slow permeation of ERK1.  
My data suggest that the N-terminus of ERK1 might represent a domain 
interacting with some not yet identified partner; it is probable that it could bind 
specific sites present on subunits of the nucleoporins, increasing the residence 
time inside the pore channel and slowing down ERK1 in respect to ERK2. 
The next steps will be directed to identify the putative binding partners of ERK1 
N-terminus, by using a combination of techniques of structural biology and 
biochemistry. 
Computational methods, based on structural informations like crystallography and  
molecular dynamics, will be helpful to study the conformation of this terminal 
region in terms of stability, folding and steric hindrance. To date, only ERK2 has 
been crystallized (Zhang et al., 1994) and given that part of ERK1 N-terminus is 
completely absent in ERK2, I can only speculate with in silico models about the 
real configuration of this region. These studies will guide the future experiments, 
permitting to select specific targets restricting the enormous variety of possible 
interactions which could occur on this domain. 
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MATERIAL and METHODS 
Plasmid preparation 
 
GFP-ERK2  and YFP-ERK2 
cDNA was obtained by one-step reverse transcription-polymerase chain reaction 
(RT-PCR), performed with a template on 100 ng of total RNA extract from rat 
brain.  
Forward primer: 5’-ACGTCTCGAGATGCTGTGCAGCCAACATGG-3’,  
incorporating XhoI site (underlined) and the ERK2 ATG start codon (in bold); 
Reverse primer: 5’-ACGTGGATCCTTTAAGATCTGTATCCTGGC-3’  
incorporating BamHI site (underlined) and the ERK2 stop codon (in bold).  
The amplification product was purified and cleaved with XhoI/BamHI, then it was 
ligated into the corresponding restriction sites in the Clontech vectors pEGFP-C2 
and pEYFP-C1 to fuse the fluorescent reporter to the N-terminus of ERK2 (N-
ERK).  
A similar N-terminus fusion of mouse ERK2 with YFP (ATCC cat. N°9830384) 
was purchased  from ATCC (American Type Culture Collection).  
Verification of correct sequence and framing of all the engineered constructs 




The C-terminal fusion protein was obtained by digesting with XhoI and PstI the 
plasmid pECFP-C1 (Clontech) carrying the fusion rat ERK2-EYFP in frame at the 
C-terminal of the ECFP. The fragment containing ERK2 was then ligated to the 
pEYFP-N1 vector (Clontech). Most experiments were performed with the N-
terminal fusion with either GFP or YFP with identical results. Selected 
experiments were performed with the C-ERK fusion with identical results. 
 
GFP-ERK1   
cDNA was obtained by one step RT-PCR performed with a template on 100 ng of 
total RNA extract from rat brain.  
Forward primer: 5’-ACGTCTCGAGCGCAGTGGAGATGG-3’, incorporating XhoI 
site (underlined) and the ERK1 ATG start codon (in bold).   
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 Reverse primer: 5’-ACGTGGATCCTGCTTAGGGGGCCTCTGGTGC-3’  
incorporating BamHI site (underlined) and the ERK1 stop codon (in bold).  
The amplification product was purified and cleaved with XhoI/BamHI, then it was 
ligated to the corresponding restriction sites in the vector pEGFP-C2 (Clonetech) 
to produce the fusion of GFP at the N-terminus of rat ERK1.  
A similar N-terminus fusion of mouse ERK1 with YFP (ATCC cat. N° 9891061) 
was purchased  from ATCC (American Type Culture Collection).  
 
ERK1-GFP 
We produced a ERK1-GFP fusion at the C-terminus of ERK1 by amplifying ERK1 
from the ATCC plasmid with following primers: 
Forward primer: 5’-CCGCTCGAGAGCCAACATGGCGGCGGCG-3’,  
incorporating XhoI site (underlined) and the ERK1 ATG start codon;  
Reverse primer: 5’-CGGGATCCGGGGCCCTCTGGCGCCC-3’ incorporating 
BamHI site (underlined) and not carrying ERK1 stop codon.  
The amplification product was purified, cleaved and ligated to the corresponding 
restriction site in the vector pEGFP-N3 (Clonetech). All crucial experiments were 
repeated using both the N- and C-terminal fusion proteins with identical results. 
 
Swapped ERK clones 
 
GFP-	39E2 
ERK2 mouse cDNA was amplified by PCR introducing an ApaI restriction site in 
the forward primer (underlined), upstream the kinase domain (aa 19-25): 
Forward primer: 5’-AAGGGCCCGCGCTACACCACCCTCTC-3’ 
Reverse primer: 5’-CGGGATCCTTAAGATCTGTATCCTGGCTG-3’   
BamHI site is underlined, the stop codon is displayed in bold. The amplified 
fragment was cloned in ApaI/BamHI of rat ERK2/EGFP-C2. 
 
GFP-E1	39 
obtained by digesting ApaI/BamHI rat ERK1 cDNA and cloning it in pEGFP-C2  
 
YFP-E1	7-39   
obtained by digesting ApaI/BamHI rat ERK1 cDNA and cloning it in pEYFP-C1   
maintaining the aa 1-7 common to ERK1 and 2. 
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YFP-E1	27  
obtained by digesting SmaI/BamHI rat ERK1 cDNA and cloning it in pEYFP-C1. 
 
YFP-E2	7   





GFP-	N1-39 and GFP-	N1-27  
obtained by digesting pEGFP-C2- rat ERK1 with HindIII/BamHI and cloning the 
extracted fragment of ERK into pEGFP-C2 by using the same restriction 
enzymes. Then the resulting construct was digested with ApaI (	N1-39) or SmaI 
(	N1-27) and the plasmid were ligated to let its re-circularization.  
 
	N1-39-GFP  
obtained digesting the construct carrying ERK1 fused to the N-terminal of GFP 
(ERK1-GFP) with XhoI/BamHI and cloning the fragment of ERK N-terminus in 




Mutagenesis have been performed on the template the N-terminus of ERK1 
E1	7-39 and ERK1-GFP by using the Quick Change Site-directed Mutagenesis Kit 
(n. cat. 200518, Stratagene) accordingly with the manufacture procedures. Pfu 
Turbo amplified the cDNA templates with the following primers (mutagenized 
bases are shown in bold): 
 
	23-26           
Forward primer:  5’-CTGCTGGGGTCGTC…GGGGAGGTGGAGG-3’ 
Reverse primer: 5’-CCTCCACCTCCCCG…GGGACCCCAGCAG-3’ 
It has been deleted 12 pb codifying for the aminoacid 23-26 (PVVP). 
 
P23A             
Forward primer:  5’-CTGCTGGGGTCGTCGCGGTGGTCCCCGG-3’ 
Reverse primer:  5’-CCGGGGACCACCGCGACGGGAGCAG-3’ 
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P23A-P26A   
Forward primer:  5’-GCTGGGGTCGTCGCGGTGGTCGCCGGGGAGGTG-3’    
Reverse primer:  5’-CACCTCCCCGGCGACCACCGCGACGACCCCAGC-3’ 
 
V31A-K33A  
Forward primer: 5’-CGGGGAGGTGGAGGCGGTGGCGGGGCAGCCATTC-3’  
Reverse primer:5’-CGAATGGATGCCCCGCCACCGCCTCCACCTCCCCG-3’   
 
Cell culture and transfection 
NIH 3T3 cell line were cultured in Dulbecco modified medium supplemented with 
10% FBS and antibiotics (100 units/ml penicillin/streptomycin). Cells were plated 
on glass disks or on glass-bottomed dishes (Willco) at 60-70% confluence and 
transfected using Lipofectamin 2000 (Invitrogen), according to the manufacture 
procedures. After transfection cells were left undisturbed for 24 hrs before any 
further experimental manipulation. Starvation was obtained by keeping the cells 
for 24 hrs in 1% FBS.  
 
Immunoblotting  
Cultures of NIH 3T3 cell lines were growth to 90% confluence in Dulbecco 
modified medium supplemented with 10% FBS and antibiotics (100 units/ml 
penicillin/streptomycin) in 60 mm Petri dishes. Before treatments the cultures 
were starved for 24 h in 1% serum. In some experiments cells were treated with 
two mixtures of phosphatases inhibitors (P2850 and P5726, Sigma Aldrich). Cells 
were washed in cold PBS and lysed with 300 µl of RIPA buffer (1% Triton X-100, 
0,5% Na deoxicolate, 0,1% SDS, 10% glycerol, 20 mM TrisHCL pH 8, 150 mM 
NaCl, 1mM EDTA, 1mM PMSF). Then, the samples were sonicated 3 times for 
10 sec (Microsonics, ultrasonic cell disruptor) and boiled for 5 min in sample 
buffer. The same amount (around 10 µg) of cellular proteins were then subjected 
to SDS-PAGE in 10% gels and transferred to nitrocellulose membranes. 
Membranes were incubated 1 hour in TBS-Tween 20, containing 5% of non-fat 
dry milk and then exposed to a 1:1000 dilution of rabbit polyclonal antiserum anti-
pERK (M-8159 Sigma) or anti-GFP (A1112, Invitrogen) at 4 C° over night. 
Membranes were washed and incubated with 1:3000 anti-mouse IgG (H+L) or 
anti-rabbit conjugated to horseradish peroxidase (Bio-Rad 170-6516) for 1 hour 
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at room temperature and finally revealed following the standard method for the 
chemiluminescence system (Bio-Rad). Gels have been exposed with the 
ChemiDoc analyzer and the output files were analyzed with Image J to obtain the 
density profiles of the bands. Quantification was performed by computing a 
Gaussian fit for the profiles after background subtraction. Linearity was checked 
by using calibration samples at known concentration of protein (Costa et al., 
2006). 
 
Immunoprecipitation, pMBP reaction and immunoblotting  
NIH 3T3 cell line were cultured in 6 cm diameter petri dish at 80% of confluency 
and they were transfected with the vectors described in the paragraph “Plasmid 
preparation”, by using Lipofectamine 2000 (11668-027, Invitrogen). The next day, 
cells were stimulated with 10% serum for 10 minutes, then they were washed in 
cold PBS and lysed with 0.5 ml of Triton lysis buffer (10 mM phosphate buffer, pH 
7.4; 100 mM NaCl; 1% Triton X-100; 5mM EDTA) containing 1mM PMSF and 
1mM of phosphatase inhibitor 1 and 2 (P2850 and P5726, Sigma Aldrich). The 
samples were sonicated three times for 10 sec (Microsonics, ultrasonic cell 
disruptor) and then they were centrifuged at 4°C 10000 rpm. The supernatant 
were incubated 1 hour at 4°C with 50 µl of protein A-Sepharose 4B conjugate 
(10-1041 Zymed Laboratories, Invitogen) for a pre-clear step. The samples were 
then centrifuged 1 minute at 700 rpm, 4°C and the supernatants were incubated  
with 1 µg of antibody anti-GFP (A1112, Invitrogen) on a rotating wheel at 4 °C 
O/N. The next day 50 µl protein A-Sepharose were added to each sample on a 
rotating wheel 1 hour at 4°C and afterwards, the samples were washed three 
times in 10% lysis buffer in PBS 1x. 
The protein A-Sepharose conjugated with our fusion proteins were splitted in two 
aliquots for each sample, used respectively to assay the ERK1/2 phosphorylation 
and MBP activation. 
 
ERK1/2 phosphorylation 
Samples were assayed by western blot, following the standard procedures, and 
probed with anti p-ERK1/2 (M-8159 Sigma). These nitrocellulose filters were then 
stripped and re-probed with the anti-ERK1/2 (sc-153, Santa Cruz) to check for 




Samples were assayed to measure the phospho-transferase activity of our fusion 
proteins on Myelin Binding Protein (MBP), by using the pMBP assay (17-191, 
Upstate). The reactions were worked out accordingly to the manufacture 
procedures; In brief, the immunoprecipitated samples of active ERK preparations 
were mixed with Mg2+/ATP cocktail, the Assay Diluition Buffer I (ADBI, n. cat. 20-
108, Upstate) and the MAPK substrate cocktail II (n. cat. 20-166, Upstate); then, 
the reaction mixtures were incubated for 20-30 min in a 30°C shaking incubator.  
Samples were then analyzed by immunoblot probed using 1 µg/ml anti-phospho-
MBP, clone p12 (n. cat. 20-113, Upstate). 
 
Immunofluorescence  
Mouse fibroblasts NIH3T3 were fixed in Tris buffer containing 4% formaldehyde, 
1 mM orthovanadate and 30% saccarose, at room temperature for 10 minutes, 
then they were washed three times and kept in blocking solution (0.4% Triton X-
100, 10% bovine serum albumin (BSA), 10 Mm Tris and 1 mM sodium 
orthovanadate) 30’ at RT.  
Cells transfected with ERK constructs were incubated overnight with a phospho-
specific ERK1/2 antibody (dilution 1:1000, Sigma M-8159) in blocking solution at 
4°C. The reaction was completed by incubation for 2 hrs in secondary antibody 
(Alexa Fluor 546, Molecular Probes). Hoechst 33258 was used to visualize the 
nucleus localization. 
 
Calibration of protein concentration  
I estimated the concentration of ERK-GFP by comparing the fluorescence of the 
cells with artificial cells loaded with known concentrations of EGFP. Recombinant 
EGFP was diluted at decreasing concentrations in saline solution. The micelles 
were prepared by dispersing the solution in mineral oil. Imaging was performed 
on the confocal microscope in controlled conditions to ensure applicability of the 
calibration to the experiments in living cells. Figure Met.1A shows three images of 
micelles at three different concentrations; quantification has been performed in 
the central part of the micelles to avoid spurious effects because of microlensing. 

































A) Images of three GFP-including micelles at different concentration. 
Bar, 10 m. 
B) Calibration at 6 different GFP concentration (cumulative data); fitted 
by a linear function. 
 
 
Calibration data has been done for six different concentrations (Fig. Met.1.B). 
Each point is the average of at least ten measures (30 at the three lower 
concentrations). These measures are relative to the FV 300 microscope. Each 
microscope used in the study required a specific calibration curve. 
 
Fluorescence-based recordings 
Imaging experiments were performed on an Olympus Fluoview 300 or on a Leica 
SL confocal scanning microscope equipped with high numerical aperture 
objectives (Olympus water immersion 60x, 0.9 NA; Leica oil immersion HCX PL 
Apo 63x, 1.4 NA). In all experiments GFP fluorescence was excited at 488 nm 
with an Ar/K laser. In average, the laser power employed during imaging was 
about 30 µW. Coverslips were placed in a recording chamber that were firmly 
locked on the microscope stage and kept at 37°C.  
All data plotting and statistical testing (one- or two-way t-test) have been 
performed with Origin 7 package. Other statistical tests were used where 




Acquisition of pERK immunohistochemistry 
Acquisitions were performed on randomly chosen fields by blind operators. 
Images were acquired on the Olympus Fluoview 300 microscope; this unit was 
equipped with visible light and with an infrared laser for 2-photon excitation 
(Verdi-Mira; Coherent). Combined imaging of pERK immunofluorescence and 
ERK2-GFP fluorescence was performed separately for the two channels to 
minimize cross talk. Quantification of fluorescence was performed either on the 
Fluoview platform or with custom software. Cells were carefully selected by 
measuring the fluorescence of ERK2-GFP; cells characterized by medium-high 
levels of expression were avoided. Given the weak fluorescence and the need to 
contain photobleaching, we optimized detection sensitivity by fully opening the 
confocal aperture and using a wide-emission bandpass. These conditions caused 
the frequent presence of fluorescent debris over imposed on the cells. During 
quantification of fluorescence these points were avoided. Average fluorescence 
background was evaluated on non transfected cells and was subtracted from all 
measurements. To evaluate the degree of nuclear localization we measured the 
average fluorescence of the nucleus (FNuc) and of a surrounding ring of thickness 
approximately equal to the nucleus radius (FRing). The CI was computed as: 
 
 
)()( BGFBGFCI RingNuc −−=  
 
 
where BG was the average background. All images shown in the study have 
been subjected only to linear adjustments.  
 
FRAP experiments: nucleus-cytoplasm shuttling  
Photobleaching was preceded by the acquisition of a pre-bleach image that was 
used to estimate the loss of fluorescence due to bleaching and for data 
normalization. 
The nucleus of the cell was photobleached by repeated scans along a line 
centred on the nucleus at high laser power. Bleaching was applied for 
approximately 5 s, which was sufficient to quench most of the nuclear 
fluorescence. Bleaching was followed by time-lapse acquisition to measure the 
recovery (60 frames at 5 s intervals for ERK2 and 60 frames at 20 s intervals for 
ERK1).  
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where FPB indicates the fluorescence (corrected for background) measured 
before bleach in the nucleus (Nuc) or on the entire cell (Tot). This normalization 
corrects for bleaching caused by imaging (Phair and Misteli, 2000). In the 
absence of an immobile fraction, the formula has an asymptotic value of 1. The 
recovery of all imaged cells was accurately fitted with a single exponential 
defined by the time constant (τ) of shuttling and by the Immobile Fraction (IF=1-
asymptotic value). 
 
FRAP experiments: spot photobleaching  
Spot photobleaching was attained by flashing a diffraction-limited spot (1µm) in a 
fixed central position in the nucleus for 250 ms. Recovery was measured in a 
time-lapse sequence imaged immediately afterwards on a Leica TCS NT 
microscope. Owing to the technical limitations of the scanning-head, the shortest 
interval elapsing from the end of bleaching until the beginning of recovery was 
0.71 seconds, as determined by direct measurements with a photodiode. This 
delay prevented a meaningful measurement of the recovery of freely diffusible 
GFP in the nuclear compartment. The spatial profile of the bleached area was 
measured on fixed cells bleached in the same conditions as in the in vivo 
experiments. Normalized fluorescence was fitted by the equation provided by 










where K defines the depth of the photobleaching and w its width. The mean 
values for these parameters were found to be K=1.63±0.10, w=2.02±0.18 µm 
(n=8). The effective diffusion coefficient Deff was computed by fitting the recovery 




















where I0 and I are the fluorescence intensity at time zero and at the asymptote. 
The time to half recovery t1/2 depends on the diffusion coefficient Deff, and on the 












where the factor  is a weak function of the beam shape and of the bleach depth 




Photobleaching was preceded by the acquisition of 64 lines necessary for data 
normalization. The total fluorescence bleached in the imaging run was estimated 
by comparing a pre-bleach image of the nucleus with an image acquired at the 
end of the line scans. Bleaching was performed by scanning the line at high 
power (about 50 times larger than during pre bleach and recovery) for 160 ms. 
Line scan was performed at a frequency of 200 Hz and the recovery was 
evaluated for 2 min. Fluorescence is corrected for background and normalized for 
the corresponding pre-bleached regions. 
Recovery curves were fitted by a double exponential function. The immobile 
fraction was computed by the asymptotic value of the recovery corrected for the 
total amount of fluorescence loss, as estimated by the comparison of the pre-
bleach and post-bleach images.  
 
Modelling 
To understand how the speed of nucleo-cytoplasmic trafficking influence the 
equilibrium of the activation/inactivation balance of ERK we modelled the ERK 
system considering that the protein equilibrates among 4 different states 
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regulated by first order kinetics. The simulator computes the temporal evolution of 
the system starting from arbitrary initial conditions by means of a Montecarlo 
methods. In brief, the system is modelled as a collection of particles that can 
exists in any of the following states: ERKCyt, pERKCyt, ERKNuc and pERKNuc . At 
each time point of the simulation each particle can undergo the transitions 
admitted by its present state or remain in the present state. The probability of 
each transition is given by the rate (probability per second) divided by the 
temporal resolution of the sequence. A random number generator is utilized to 
decide the particle fate. The data presented have been computed on a system 
with 10000 particles simulated with a time resolution of 1 s and for a duration of 
5000 iterations. This time was sufficient to allow a complete evolution of the 
system to the equilibrium condition. Convergence to a unique solution was 
verified as the final state was independent on the values of the initial conditions. 
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